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presence and absence of both spiperone and RGS1 protein
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Abstract
Fusion proteins between the human 5-HTia receptor and wild type and 
pertussis toxin resistant forms of the Giia and Goia proteins were constructed and 
stably expressed in HEK293 cells. These constructs were assessed in terms of second 
messenger system modulation, receptor-G protein affinity and high affinity GTPase 
activity and the effects that RGS proteins had on this.
In an intact cell assay 5-HT activation of the 5-HTia receptor-G protein 
fusions concentration dependently inhibited forskolin stimulated adenylyl cyclase 
activation. Treatment with pertussis toxin abolished 5-HTia receptor mediated 
effects for the receptor alone and the wild type G protein fusions but did not have 
any effect on cells expressing either the Gly^^  ^ or Ile^^  ^ Güa and Goia 5-HTia 
receptor-G protein fusion constructs, a result that indicated a lack of coupling to the 
endogenous pool of G protein by the fusion proteins. Consistent with the results of 
Bahia et al, (1998) the concentration of 5-HT required to produce a 50% reduction in 
adenylyl cyclase activity was lowest for the Ile^^  ^ G« protein mutant followed by the 
WT Got proteins and was highest for the Gly^^  ^ G« protein mutants. Although not 
significant the results, consistent with the literature, also indicated that a lower 
concentration of 5-HT was required to produce a 50% reduction in adenylyl cyclase 
activity for the 5-HTia receptor-Gua than for the Goia fusion proteins.
The ability of GDP and suramin to prevent [^H]-8-OH-DPAT specific 
binding to membranes expressing the 5-HTia receptor and each of the Gna and Goia 
fusion proteins was assessed in radioligand binding assays. The concentrations of 
either GDP or suramin required to reduce specific binding by 50% were significantly 
lower for the Ile^^  ^ mutants than for the wild type proteins with the Gly^^  ^ mutant 
fusion proteins requiring the highest concentrations. This provided an indication of 
the affinity of the 5-HTia receptor for the various G proteins and followed the trend 
that the more hydrophobic the residue at position 351 of a Gja and Goa proteins the 
higher the affinity of the 5-HTia receptor G protein interaction. The results also 
indicated that the 5-HTia receptor had a higher affinity for Gna than Goia protein 
interactions. 8-OH-DPAT competition for [^H]-MPPF specific binding to membranes 
expressing the 5-HTiAGiiaC^^^G/I fusion proteins indicated that a significantly 
greater proportion of the Ile^^  ^ mutant G proteins exist in a 5-HT] a receptor coupled 
form than the Gly^^  ^G protein mutants.
X X lll
The high affinity GTPase activity of membranes expressing the fusion 
proteins and the effects of a range of purified RGS protein concentrations was 
examined. While agonist stimulation of GTPase activity produced an increase in V,nax 
it did not effect the K„i for GTP. The addition of either RGSl or RGS 16 proteins 
however produced concentration dependent increases in both the Vmax and the K,n due 
to their GAP activity at the Gua and Goia proteins. The effects of the two RGS 
proteins were not significantly different, but both proteins produced greater increases 
in GTPase activity in membranes expressing the Goia fusion protein than membranes 
expressing the Gna fusion protein. Neither RGS protein had any significant effect on 
basal GTPase activity for membranes expressing the Gly^^  ^ mutant fusion proteins. 
Both RGSl and RGS 16 proteins did however produce concentration dependent 
increases in basal GTPase activity in membranes expressing the Ile^^  ^ fusion 
proteins, a result that reflects the greater intrinsic constitutive GTPase activity of the
5-HT 1A receptor-Ile^^^ G protein fusion constructs.
Taking advantage of this latter result, the effects of a range of ligands on high 
affinity GTPase activity in the absence and presence of a maximal concentration of 
RGSl protein were examined. In the absence of RGSl protein WAY100635 acted as 
a weak partial agonist with spiperone, methiothepine, (+)-butaclamol, 
chlorpromazine and thioridazine acting as inverse agonists. In the presence of RGSl 
protein, the increase in basal GTPase activity for the GnaC^^^I and GoiaC^^^I fusion 
proteins of 165% and 400% respectively allowed for accurate quantification of 
ligand effects. Only haloperidol was found to be a neutral ligand at the 5-H T ia 
receptor-G protein fusions in this assay. Thus, the use of constitutively active 
receptor-G protein fusions and RGS proteins in a high affinity GTPase assay allowed 
for accurate discrimination between weak partial, neutral and inverse agonist 
activity.
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Chapter 1
Introduction
1 Introduction
1.1 Serotonin History
The discovery of serotonin was made by an Italian scientist, Dr. Vitorio 
Erspamer, working for the Institute of Comparative Anatomy and Physiology in the 
University of Pavia, Italy. His work on the smooth muscle constricting and 
contracting properties of various amine substances lead him to isolate a substance 
from the enterochromaffin cells of the rabbit gut. This substance caused smooth 
muscle contraction, especially in the rat uterus, and tests revealed that it was most 
likely an indole. He named the substance enteramine (Erspamer and Vialli, 1937) 
and published further on its properties (Erspamer, 1946, Erspamer and Ghiretti, 
1951; Erspamer, 1948; Erspamer and Boretti, 1951). It was not until 1952, when it 
was established that Dr. Erspamer had been working on the same substance that 
Irvine Page, Maurice Rapport and Arda Green had been researching since 1948, that 
enteramine became know as serotonin (Erspamer and Asero, 1952).
Irvine Page worked on the etiology and treatment of essential hypertension at the 
Cleveland Clinic in 1945. Dr. Page was looking for endogenous substances in blood 
that would lead to vessel constriction and during this research came across a 
substance which he decided must be removed from the blood before any further work 
could be done on the hypertension-producing factor. To this end he recruited 
Maurice Rapport and Arda Green who succeeded in isolating and characterising the 
substance, naming it serotonin. Arda Green is also known for the first isolation of 
luciferase in 1953 from fireflies. Isolation of 5-HT was not an easy process and 
required over seven thousand litres of blood from the Cleveland slaughterhouse 
resulting in the purification of a very small quantity of serotonin. The first 
publication describing the partial purification of serotonin was in The Journal o f 
Biological Chemistry in 1948 (Rapport et al., 1948a). Dr. Rapport continued his 
work on serotonin and completed the isolation later that year (Rapport et al., 1948b). 
Continuing his work at Colombia University Dr. Rapport published the chemical 
structure of serotonin (Rapport, 1949) and following a collaboration with Upjohn 
Pharmaceutical and Abbott Laboratories synthetic serotonin was made available for 
research.
The presence of serotonin in the brain was reported by Betty Mack Twarog in 
1953 (Twarog and Page, 1953). Dr. Twarog had previously worked on the mussel, 
Mytilus edulis and the neurotransmitters responsible for a phenomenon called 
“catch” where the molluscs’ muscles remained contracted and resisted stretch long 
after the period of excitation had passed. By 1951 Dr. Twarog had identified the 
contracting neurotransmitter as acetylcholine, but had not identified the relaxing 
neurotransmitter. Upon reading papers from Dr. Erspamer on enteramine, its 
isolation from octopus salivary glands, its excitation of mollusc heart, and the 
revelation that enteramine and serotonin were one and the same, Dr. Twarog became 
convinced, and subsequently demonstrated that the relaxant neurotransmitter was 
serotonin (Twarog, 1954). Dr. Twarog moved to the Cleveland Clinic in late 1952 
and proceeded to demonstrate for the first time, despite the doubts of Dr. Page, the 
presence of serotonin in mammalian brain (Twarog and Page, 1953).
The final person involved in establishing serotonin as one of the most important 
neurotransmitters involved in mental illness was Dilworth Wayne Woolley. Dr. 
Woolley had developed a theory in which specific substances that were structurally 
related to naturally occurring metabolites could interfere with the functioning of 
those metabolites. He refened to the synthetic compounds as “antimetabolites”. Dr. 
Woolley joined the Rockerfeller University in 1939 and despite being completely 
blind due to severe diabetes, “saw” the structure of serotonin in that of LSD. He 
demonstrated that LSD could block the effects of serotonin in the rat uterus, and 
these effects could be mimicked by bufotenine. He also believed that serotonin had a 
role in brain development and first published on his hypothesis in 1954 (Woolley and 
Shaw, 1954). Unable to get his work and hypotheses published in Lancet, Wolley 
published a book on them in 1963, The Biochemical Bases o f Psychoses or the 
Serotonin Hypothesis about Mental Illness (Wolley, 1963). Dr. Woolley was elected 
member of The National Academy of Sciences and The National Academy of Arts 
and Sciences in recognition of his work.
Following this groundbreaking work, using Falck-Hillarp histochemical 
fluorescence, 5-HT neurons and their projections were described (Dahlstrom and 
Fuxe, 1964; Fuxe, 1965). Today it is an established fact that no region of the 
mammalian CNS lacks 5-HT innervation (Dahlstrom and Fuxe, 1964; Steinbusch, 
1981, 1984; Azmitia, 1986; Jacobs and Azmitia, 1992; Azmitia-Whitaker and 
Azmitia, 1995).
1.2 Serotonin Synthesis, Metabolism and Regulation
Serotonin is synthesised in neurons from the amino acid (L)-tryptophan in two 
steps (Figure 1.1, A). Firstly, catalysed by tryptophan hydroxylase with the cofactor 
tetrahydrobiopterin, L-tryptophan is converted to L-5-hyrdroxytryptophan. This step 
is followed by aromatic L-amino acid decarboxylase catalysing conversion, in the 
presence of the cofactor pyridoxal phosphate, to 5-hydroxytryptamine (5-HT or 
serotonin). The degradation of 5-HT is also a two step process (Figure 1.1, B). 
Initially, the mitochondrial enzyme monoamine oxidase (MAO) with the cofactor 
flavin adenine dinucleotide (FAD), catalyses conversion to 5- 
hydroxyindoleacetaldehyde. This intermediate product is then rapidly converted to 5- 
hydroxyindolacetic acid (5-HI A A) by aldehyde dehydrogenase.
Neurotransmitter release from neuronal cells by exocytosis is in response to 
depolarisation. Depolarisation leads to the opening of voltage sensitive calcium 
channels resulting in calcium entry, the major signal that links depolarisation and 
exocytosis (Burgoyne and Cheek, 1995). Secretory vesicles containing 
neurotransmitters that are already docked at the plasma membrane release their 
contents into the synaptic cleft by formation of a fusion pore, a process involving a 
number of calcium sensitive proteins (Augustine et ah, 1985; Smith and Augustine, 
1988; Leveque et al., 1992). The amount of neurotransmitter released is subject to 
receptor-dependent regulation with the main autoregulator y effect of 5-HT on its 
own release being inhibitory.
Serotonin acting at the 5-HTia receptor has been shown to inhibit 5-HT release 
by reducing high threshold Ca^ "^  currents (Penington and Kelly, 1990; Penington et 
al., 1991; Penington and Fox, 1994) and increasing conductance to (Aghajanian 
and Lakoski, 1984; Yoshimura and Higashi, 1985). These experiments have been 
performed in the cell body and there is no direct electrophysiological information on 
the mechanism by which 5-HT regulates its own release. The receptor involved in 5- 
HT inhibition of its own release is dependent on the area of the neuron examined. As 
well as regulation by the 5-HTia autoreceptor in somatodendrons, release is 
controlled by terminal 5-HTib/id autoreceptors (Starke et al., 1989). The 5-HTib/id 
receptors can alter 5-HT release without effecting 5-HT neuron firing activity (Crespi 
et al., 1990). There is now evidence that at the cell body, inhibition of 5-HT release
Figure 1.1 Synthesis and metabolism of 5-hydroxytryptamine
Panel A: The synthesis of 5-hydroxytryptamine from the amino acid L-tryptophan. 
Panel B: The metabolism of 5-hydroxytryptamine to 5-hydroxyindolacetic acid.
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may not only be regulated by the 5-HTia receptor, because the non 5-HTia agonist 
mianserin blocked decreases in 5-HT release stimulated by the 5-HTi agonist RU 
24969, but WAY100135 did not (Pineyro et al., 1995, 1996). Significantly, a 
decrease in 5-HT neuron firing was also not recorded.
As well as autoregulatory mechanisms controlling the release of 5-HT there 
are mechanisms that indicate the involvement of other receptors. A decrease in 5-HT 
release is measured in the dorsal raphe nuclei by either systemic or intraraphe 
administration of GAB A or GAB A agonists (Scatton et al., 1985; Becquet et al.,
1990). It has also been found that activation of presynaptic K opioid receptors located 
on the glutamatergic fibres in midbrain slices reduces excitatory postsynaptic 
potentials due to electrically evoked release of excitatory amino acids from afferent 
fibres onto 5-HT neurons (Pinnock, 1992). GAB A and glutamate have been shown to 
modulate 5-HT release in rostral rhombencephalic raphe cells in primary culture 
(Becquet et al., 1993b). G ABA produces its negative modulation mainly via the 
GAB A A and GABAb receptors, and EAA induced 5-HT release through NMDA 
receptors (Becquet et al., 1993a). The D% dopamine receptor has been indicated also 
in the regulation of 5-HT release (Ferre and Artigas, 1993; Ferre et al., 1994).
Following its release into the synaptic cleft, 5-HT is actively removed by a 
high affinity transporter located on presynaptic neuronal membranes (Kuhar, et al., 
1972; Kanner and Schuldiner, 1987; O’Reilly and Reith, 1988). The transporter, 
SERT, functions in series with the vesicular transporter that sequesters 5-HT into 
secretory vesicles. SERT is an integral membrane protein with twelve 
transmembrane spanning domains coupling to the uptake of Na"^  and release of Cl'. 
Purified functional SERT has a molecular weight of 300,000 (Ramamoorthy et al.,
1993), and cloned SERT 70,000 (Blakely et a l, 1991; Lesch et a l, 1993; 
Ramamoorthy et a l, 1993), leading to the proposal that SERT may exist as a 
homotetramer (Ramamoorthy et a l, 1993). However, Chang and co-workers 
demonstrated that dimeric and monomeric transporter activity was similar, with 
tetrameric transporters having substantially less activity (Chang et a l,  1994).
The mechanism of 5-HT uptake by SERT has been characterised in a number 
of preparations, including platelets (Rudnick, 1977; Nelson and Rudnick, 1979, 
1982) and mouse brain plasma vesicles (O’Reilly and Reith, 1988; Reith et a l, 1989) 
and stable expression in different systems (Blakely et a l, 1991; Hoffman et a l, 
1991; Corey et a l, 1994, Gu et a l, 1994). An inward Na"^  concentration gradient has
been demonstrated to be required for 5-HT uptake. External Na'*' increases the V„iax 
and decreases K,n for 5-HT (Cool et al., 1990). Stoichiometry between 5-HT, Na"^  
and C r has been shown to have a 1: 1: 1 ratio (Cool et at., 1990; Talvenheimo et al., 
1983; Gu et ah, 1994; Nelson and Rudnick, 1982).
1.3 G protein-Coupled Receptors
For a large number of both natural and synthetic compounds, transduction of 
signals from the extracellular to the intracellular environment is via cell membrane 
bound receptors. Heterotrimeric GTP-binding protein (G protein) coupled receptors 
(GPCRs) are the largest class of membrane bound receptors and are found in 
eukaryotes and some prokaryotes. The family has an estimated 1100 members in 
Caenorhabditis elegans, comprising 5% of its genome (Bargmann, 1998), at least 
160 members in Drosophila, and is estimated to comprise at least 700 members in the 
human genome (Miklos et al., 2000). The presence of GPCRs in plants (Plakidou- 
Dymock et al., 1998), yeast (Dohlman et al., 1991), the slime mold Dictyostelium 
discoideum (Devreotes, 1994), and in protozoa and metazoa (Vernier et at., 1995; 
New and Wong, 1998) indicates that they may be one of the oldest families of 
proteins devoted to signal transduction.
The GPCR family of cell surface receptors transduces signals from a wide 
variety of extracellular stimuli, such as nucleotides, peptides, amines, odorants, Ca^^ 
ions and photons. They regulate the activity of ion channels, enzymes and transport 
vesicles by promoting the exchange of GTP for GDP, activating the various classes 
of G proteins and leading to variations in an enormous range of cell functions 
(Gilman, 1987).
GPCRs can be classified into a number of families (Figure 1.2). Families 1, 2 
and 3 contain the known human receptors, with two additional families 
encompassing the fungal pheromone and Dictyostelium GPCRs. These families are 
divided further into subclasses that are defined by sequence similarity, ligand binding 
properties and functional domains (Horn et al., 1998; Bockaert and Pin, 1999).
Family 1 contains most GPCRs, including the odorant receptors, and 
sequence alignment of receptors in this class shows approximately 2 0  conserved 
amino acids. These include two cysteine (Cys) residues in extracellular loops 1 and 
2  that form a di - sulphide bridge necessary for maintaining correct receptor
Figure 1.2 Classifîcation of GPCRs
The diverse nature of the GPCR superfamily allows only for general classification 
into five families (1-5). The first three families contain the human GPCRs with the 
vast majority fitting into family 1, a family that encompasses GPCRs for small 
ligands, e.g. p-adrenergic receptors (family la), for peptides (family lb), and for 
glycoproteins (family Ic). Family 2 have a similar morphology to family Ic, but 
share no sequence homology and family 3 contain the metabotropic glutamate and 
Ca^ "^  sensing receptors. Family 4 contains the pheromone receptors and lastly family 
5 the cAMP receptors found in Dictyostelium. A further family containing the 
“frizzled” and “smoothened” embryonic receptors has been proposed. Adapted from 
Bockaert and Pin, 1999.
. Rhodopsin
- LH-hCG
- Thrombin
- Angiotensin
- Adenosine (Aj)
- Adrenergic (P2 )
- Serotonin (5-HT^g)
- a-latrotoxin
- PTH
- Secretin 
_ VIP
- PACAP
- Glucagon
- CRF 
_ cAR4
- cAR3
- cAR2
- cARl
- mGluR4
- mGluR2
- mGluRl
-  Ca2+
-  VRi
- G0 VN2
-
- GABAb (R l)
_ VNj
- VN,
- VNg
- Smooth-Hum
- Smooth-Dro
- Frizzled-Hum
—  Frizzled-Dro
Family 1
Family 2
Family 5
Family 3
Family 4
conformation, the DRY (Asp-Arg-Tyr) motif in the proximal region of intracellular 
loop 2, an Asn-Pro-X-X Tyr motif in transmembrane domain 7 and a cysteine 
residue in the C terminal domain that can be palmitoylated generating a fourth 
intracellular loop. Family 1 is further divided into three subclasses. Class la  includes 
the receptors for small ligands such as photons and biogenic amines, and includes the 
rhodopsin, P-adrenergic receptors and serotonin receptors. This subclass of GPCRs 
has a ligand-binding site located within the transmembrane spanning domains. Class 
lb includes receptors that bind peptides such as chemokines to the N terminal region, 
the extracellular loops and the upper sections of the transmembrane domains. Class 
Ic contains receptors for glycoprotein hormones such as luteinizing hormone, follicle 
stimulating hormone and thyroid stimulating hormone and is characterised by large 
extracellular N termini involved in ligand binding that must also include binding to at 
least one of extracellular loops 1 or 3 (Bockaert and Pin, 1999).
Family 2 GPCRs have a similar morphology to the family Ic receptors but do 
not share any sequence homology and represent the second largest group of GPCRs. 
High molecular weight peptides such as glucagon, secretin, VIP-PACAP and 
calcitonin bind to this family of receptors, as does the black widow spider toxin a- 
latrotoxin (Krasnoperov et al., 1997; Davletov et al., 1998). The receptors have long 
N-terminal regions (>100 amino acids) that are involved in ligand binding and 
contain six conserved Cys residues. They also have two conserved Cys residues in 
extracellular loops 1 and 2  and approximately 15 other residues that are conserved in 
all members of this class.
The third and smallest family of GPCRs contains the metabotropic glutamate 
receptors and the Ca^ '*' sensitive receptors (CaR) (Pin and Bockaert, 1995). This 
family also contains the GABAb receptors (Kaupmann et al., 1997) and a group of 
putative pheromone receptors coupled to the Go protein, termed VRs and Gq-VN 
(Bargmann, 1997). They all possess extremely long N terminal regions that are 
involved in ligand binding and several conserved Cys residues in the transmembrane 
spanning and extracellular regions.
The fourth family comprises of the pheromone receptors (VN’s) which bind 
to the Gi class of G protein (Dulac and Axel, 1995), and the fifth family the cAMP 
receptors (cAR) only found in Dictyostelium with as yet no established vertebrate 
equivalent. One final group of receptors that may constitute a family in its own right
is the “frizzled” and “smoothened” (Smo) receptors that are involved in embryonic 
development.
1.3.1 GPCR Structural Features
Alignment of the receptors from the various families of GPCRs shows little 
or no sequence homology, but all GPCRs share a common structure. They are 
predicted to contain seven transmembrane spanning domains, consisting of 20-30 
amino acids each, linked by three extracellular and three intracellular domains of 
varying lengths, an extracellular N terminal region with N-glycosylation sites and an 
intracellular C terminal region that generally contains phosphorylation sites and may 
contain palmitoylation sites (Ji et ah, 1998; Henderson et ah, 1990; Dixon et ah, 
1986). Variability in the sequence and size of these domains results in the individual 
ligand binding and G protein coupling characteristics of various GPCRs.
The N terminal region of GPCRs is an extracellular domain that varies in size 
from less than 10 amino acids for the A2A (Furlong et ah, 1992) and A2B (Pierce et 
ah, 1992) adenosine receptors to between 340 and 450 amino acids for mature 
glycoprotein hormone receptors (Dias et ah, 1992). This region plays a role in the 
trafficking of the receptor to the plasma membrane and contains asparagine residues 
within motifs for N-glycosylation (Petaja-Repo et ah, 2000; George et ah, 1986; 
Hughes et ah, 1997), and cysteine residues involved in protein folding (Green et ah,
1994). Work on N-glycosylation of the d-opioid receptor demonstrated that this 
process is initiated co-translationally in the endoplasmic reticulum and completed in 
the trans-golgi network (Petaja-Repo et ah, 2000). It was suggested that less than 
50% of synthesised receptors are fully processed and of these only a fraction make it 
to the surface. A rate limiting step in this process was the exit of a fully processed 
GPCR from the endoplasmic reticulum indicating that in part at least, N- 
glycosylation is a key event in the control of GPCR expression. As was indicated in 
the classification of GPCRs the N terminal region of all families apart from the la  
class of GPCR is involved in ligand binding. In the calcium sensing receptor (CaR), 
the Lys^^^Asp mutation was found to result in hypocalcemia by preventing ligand 
binding (Okazaki et ah, 1999).
The next common structural feature for GPCRs is the seven transmembrane 
spanning domain regions, linked by three extracellular and three intracellular loops
(Henderson et al., 1990; Dixon et al., 1986). The seven helices are thought to be 
arranged as a tight ring shaped core (Baldwin, 1993; Ji et al., 1998) with the 
hydrophobic amino acid residues facing the lipid bilayer and the more hydrophilic
residues the core. A low resolution (9Â) electron diffraction structure of rhodopsin
revealed the orientation of the transmembrane a-helices (Unger et al., 1997). A high
resolution (2 . 8  Â) electron diffraction structure of rhodopsin has been published
(Palczewski et al., 2000) that indicated the importance of clusters of residues in 
maximum wavelength absorption, colour discrimination and interactions between the 
membrane helices and cytoplasmic surface where G protein activation occurs.
The transmembrane domains contain several highly conserved Pro residues 
important for receptor folding and expression. A mutagenesis study in the muscarinic 
Ms receptor in which three conserved Pro residues (Pro^ "^  ^ of TM5, Pro^^  ^ of TM6  
and Pro '^^  ^ of TM7) were changed to Ala demonstrated a 35 to 100 fold lower 
expression level compared to WT receptor (Wess et al., 1993). Another study on the 
vasopressin V2 receptor mutated Lys"^ of TM l to Pro, leading to a lack of 
glycosylation and retention in the pre-golgi compartment. The introduction of Pro 
was essential as mutation to Phe led to correct processing of the receptor, although 
ligand binding was affected (Tsukaguchi et al., 1995).
Using site directed mutagenesis of the melanocoitinl receptor, a number of 
important acidic residues in TM2 and TM3 in the transmembrane spanning domains 
involved in ligand binding have been established (Yang et al., 1997). There are also a 
number of aromatic residues in TM’s 4, 5, and 6  whose involvement has been 
indicated in the formation of a hydrophobic pocket for ligand binding. A naturally 
occurring mutation in the dopamine D4 receptor, Val^^^^Gly in TM4, that is one 
position removed from a Ser residue important in dopamine binding, results in a 2 
fold decrease in binding of dopamine, clozapine and olanzapine over the WT 
receptor (Liu et al., 1996).
Studies on GPCRs such as the rhodopsin receptor revealed that a change in 
the relative orientation of TM3 and TM6 , with a rotation of TM6  and a separation 
from TM3, is associated with the switch from the inactive to active conformation and 
the unmasking of the G protein binding site (Barrens et al., 1996; Bourne et a l, 1997; 
Javitch et al., 1997). This change in conformation effects the orientation of 
intracellular loops 2 and 3 (directly linked to TM3 and TM6  respectively) effecting
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what constitutes one of the key sites involved in G protein recognition and activation 
(Spengler et a l, 1993; Pin and Bockaert, 1995; Wess, 1997).
The N and C terminal regions of the third intracellular loop have been 
implicated in specificity for and coupling of G proteins (Cotecchia et al., 1992; 
D ’Angelo et al., 1996; Chung et ah, 1999), with roles also established for 
intracellular loops 1 and 2 (Wess, 1998). The intracellular loops are involved with 
interactions with other cellular proteins such as the p-arrestins (Mukherjee et al., 
1999) and contain phosphorylation sequences for G protein receptor kinases (Tsuga 
et al., 1998) and second messenger kinases (Yuan et al., 1994; Hipkin et al., 2000), 
all of which are involved in receptor desensitisation.
Contrary to previous beliefs that GPCRs required agonist binding to generate 
a second messenger response, it is now well established that GPCRs can signal in the 
absence of ligand. This intrinsic constitutive activity was described initially for the ô- 
opioid receptor endogenously expressed in NG108-15 cells (Costa and Herz, 1989), 
but only accepted widely after reports of intrinsic constitutive activity in 
overexpressed mutant 0(ib and P2 receptors (Lefkowitz et al., 1993). Studies using 
CAM (Constitutively Active Mutant), WT and inactive aiB receptors have indicated 
that Arg^ '^  ^ in the highly conserved DRY motif at the cytosolic end of TM3 plays a 
significant role in determining GPCR activation state (Scheer et al., 1996). Mutation 
to Ala or He resulted in a complete loss of receptor mediated response but mutation 
to Lys conferred constitutive activity. It was suggested that hydrogen bonds between 
various residues form a hydrophobic pocket for Arg^ '^  ^resulting in several residues in 
the second and third intracellular loops not being exposed to the cytosol. Following 
agonist binding or in the CAM structures Arg^ "^  ^ moves out of this hydrophobic 
pocket and exposes the hidden residues. In an oversimplified model, a GPCR is in a 
state of equilibrium between an inactive R form and an active R* form. In the 
absence of agonist or CAM mutations the equilibrium favours the R form, but 
following agonist binding or CAM mutation of the GPCR, the equilibrium favours 
the R* form.
The Asp^ "^  ^ in the DRY motif of the ocib adrenoceptor also has an indicated 
role in the interaction with GRKs and (3-arrestins (Mhaouty-Kodja et al., 1999). It 
was speculated that the residue either is directly involved in the binding of these
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proteins or that its mutation results in conformational changes in intracellular loops 2  
and 3 so that they can no longer interact with the regulatory proteins.
CAM GPCRs can be generated by mutations in areas other than the DRY 
motif. Mutation of Thr^^  ^ (e.g. to either Cys or Lys) in the C terminal portion of the 
third intracellular loop of the az adrenergic receptor generates basal levels of activity 
approaching those of agonist stimulated levels in WT receptors (Ren et al., 1993). 
Also, more simply, constitutive levels of activity can be generated by overexpression 
of WT receptors (Chidiac et al., 1994; MacEwan and Milligan, 1996; Smit et al.,
1996). This leads to an increase in the absolute amount of R* present.
On the extracellular loops, the single most important conserved amino acids 
are two Cys residues, one in extracellular loop 1 and one in loop 2, which form a 
di sulphide bond and play a role in the receptor conformation (Green et al., 1994). An 
additional disulphide bridge has been found between a Cys in extracellular loop 3 
and the N terminal domain in, for example, the angiotensin receptor.
The transmembrane spanning domains, which play a significant role in ligand 
binding and receptor activity, are linked finally to the GPCR’s C terminal tail. The C 
terminal tails of GPCRs contain Ser and/or Thr residues that are targeted for 
phosphorylation by G protein receptor kinases (GRKs) and are involved in receptor 
desensitisation (Bouvier et al., 1988; Seibold et al., 1998). Following 
phosphorylation, GPCRs interact with a class of proteins called arrestins (Pippig et 
al., 1993; Freedman et al., 1995). These proteins target GPCRs for internalisation via 
clathrin coated vesicles but also have been shown to couple GPCRs to the activation 
of Src-like kinases and facilitate formation of complexes including components of 
the MAPK and JNK pathways (McDonald et al., 2000; van Biesen et al., 1996).
A number of GPCRs contain a Cys residue in the C terminal domain which 
serves as a site for palmitoylation (O’Dowd, 1989; Ovchinnikov et al., 1998), that in 
many cases forms a fourth intracellular loop when the palmitate inserts into the 
plasma membrane and has been shown to affect G protein interaction (Milligan et al.,
1995). Palmitoylation at these Cys residues may also have a role in receptor turnover, 
expression and localisation (Kennedy and Limbird, 1993; Eason et al., 1994). The 
tail may contain domains that allow interaction with a variety of other proteins which 
can mediate GPCR signalling, such as Homer/Vesl proteins (Brakeman et al., 1997), 
and calc yon (Lezcano et al., 2000). The (32-adrenergic receptor has been shown to 
interact via a PDZ domain in its C terminal tail with the Na'^ ’/HT*' exchanger regulatory
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factor (NHERF) in an agonist dependent fashion (Hall et al., 1998). The rhodopsin 
receptor has been shown to interact with InaD (Chevesich et al., 1997; Xu et al.,
1998), a multi PDZ domain containing scaffolding protein which interacts with 
signalling proteins such as phospholipase cp , protein kinase C and the TRP ion 
channel (Huber et al., 1996; Shieh and Zhu, 1996; Chevesich et al., 1997; Tsunoda et 
al., 1997; Xu et al., 1998).
1.3.2 GPCR Activation States
The activation state of a GPCR is affected by a large number of factors, 
including the level of G protein expression and most obviously by agonists, the 
binding of which can be inhibited by antagonists. Antagonists may bind to the 
receptor at the same site as agonists, but do not effect the activation state. Agonists 
can be divided into three classes, full, that bind to receptors and initiate maximal 
effector modulation, paitial, that bind and initiate only a limited effector response, 
and inverse, that bind to a receptor and decrease the basal level of receptor 
modulation of effectors.
A mathematical model of receptor-G protein interactions will be defined once 
the factors involved and their effects have been discussed. Put simply, in the absence 
of agonist, receptors exist in two affinity states, G protein uncoupled (low affinity) 
for agonist, and G protein coupled (high affinity) for agonist. The existence of these 
two different states can be demonstrated using agonist and antagonist radioligand 
binding studies. Antagonists bind to the two different receptor activity states with 
equal high affinity, but agonists only bind to the G protein coupled form with high 
affinity and bind the uncoupled form with low affinity (Kobilka 1992). Two different 
assays demonstrate this. Firstly, saturation binding analysis of receptor populations 
using agonists reveals a much lower B,nax than saturation analysis with an antagonist 
(Sleight et al., 1996; Chen et al., 1997). Secondly, agonist displacement of antagonist 
radioligand binding often results in a biphasic competition curve (Waldhoer et al.,
1999). The first phase represents the displacement of antagonist following binding of 
the agonist to the high affinity, or G protein coupled, state of the receptor and the 
second phase, at higher agonist concentrations, the displacement of antagonist 
binding following binding of the agonist to the low affinity, or G protein uncoupled, 
state of the receptor.
13
The proportion of receptor that is in the high and low affinity states can be 
influenced by the relative expression levels of the receptor and G protein (Chidiac et 
al., 1994; MacEwan and Milligan, 1996; Smit et al., 1996). If there is an increase in 
the levels of G protein expression, there is a resultant increase in the incidence of the 
G protein coupled, or high affinity, state of the receptor.
Following agonist activation of a receptor, there is a conformational change 
in the transmembrane domains and intracellular loops, resulting in an increase in 
affinity of the receptor for its cognate G protein (Barrens et al., 1996; Bourne et al., 
1997; Javitch et al., 1997; Spengler et al., 1993; Pin and Bockaert, 1995; Wess,
1997). This results in an increase in the binding of inactive G protein, i.e. GDP 
bound, to the receptor, and causes a conformational change in the G protein that 
decreases the affinity of the Ga subunit for GDP and increases its affinity for GTP. 
The binding of GTP to the G« subunit has two effects. Firstly, it results in a decrease 
in the affinity of the G protein for the receptor and leads to the dissociation of the 
complex, and secondly it results in a decrease in the affinity of the Ga for the Gpy 
subunits and leads to their dissociation into Ga-oTP and Gpy. They subsequently 
become available to regulate second messenger systems (Hamm, 1998).
This process is short lived due to the intrinsic GTPase activity of the G« 
subunit. The GTP is rapidly hydrolysed to GDP (Bimbaumer and Bimbaumer, 1995; 
Helmreich and Hofmann, 1996; Hamm, 1998), leading to a reversal of the activation 
process, i.e. an increase in affinity of the Ga for the Gpy subunits and their 
reassociation, and also a return to basal affinity of the G protein for the receptor.
The affinity of a receptor for a G protein can be altered by site directed 
mutagenesis. As mentioned in the previous section, mutations within the DRY motif 
at the cytosolic end of TM3 often results in a constitutively active mutant receptor 
(Ren et al., 1993). It is hypothesised that these mutations lead to the exposure of 
residues in the intracellular loops of the GPCR that are normally only exposed 
following agonist binding and are involved in the binding of G proteins (Scheer et 
al., 1996). Their exposure would lead to an increase in the binding of G protein and 
an increase in the proportion of GPCR in the high affinity, or G protein 
coupled, state. A second method for increasing the proportion of receptor in the 
high affinity state is to fuse the N terminal end of a G protein oc subunit to the C 
terminal end of the GPCR (Kellett et al., 1999). This does not alter the affinity of
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Figure 1.3 Ternary complex model of receptor-G protein
interaction
The ternary complex model is shown in blue, with the effects of GTP and GDP 
bound states of G protein shown in red. In the figure, the GPCR is represented as R, 
the G protein as G, the guanyl nucleotide as GxP (either GDP or GTP), and the 
agonist as H. The symbols K, J and M are affinity constants. Uncoupled receptors 
have low affinities for both agonist and G protein (K and M respectively). Agonist 
increases the affinity of receptor for G protein (from M to ocM) and vice versa (the 
allosteric factor a  is >1). Guanine nucleotides inhibit the binding of agonists: ayK is 
lower than aK  so y must be lower than 1. The affinity of GxP for HRG (pyJ) is 
therefore lower than the affinity of GxP for RG (PJ): agonists inhibit the recognition 
of nucleotides by receptor-coupled G proteins. Adapted from Waelbroeck (1999).
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the receptor for the G protein or vice versa, but the close proximity of the G protein 
to the receptor increases the probability of receptor -  G protein coupling. Site 
directed mutagenesis of Cys^^\ a residue involved in binding to the intracellular 
loops of a receptor, can result in a G protein with altered affinity for a GPCR (Bahia 
et al., 1998). The mutation Cys^^^Ile results in a G protein with an increased affinity 
for receptor binding, but the mutation Cys^^^Gly leads to a decrease in affinity. Bahia 
et al, (1998) mutated the residue at this site to each of the 19 other natural amino 
acids in Gna and found that the more hydrophobic the residue at position 351, the 
higher the affinity of the G protein for the receptor.
For the majority of simple binding assays in the presence of agonists and 
antagonists, the simple ternary complex model of activity would apply (Figure 1.3 
blue). This model considers only three G protein species, G protein alone, G protein 
bound to receptor and G protein bound to ligand activated receptor (De Lean et al., 
1980; Costa et al., 1991; Lefkowitz et al., 1993; Weiss et al., 1996a; Weiss et al., 
1996b; Colquhoun, 1998). In the absence of GTP, it predicts the existence of 2 
agonist binding states, HRG (G protein coupled), and HR (G protein uncoupled), 
with dissociation constants of KH=l/otK and Kl=1/K respectively, where K is an 
affinity constant and a , an allosteric factor. Extension of this model includes the 
effects of guanyl nucleotides in G protein-receptor interactions (Figure 1.3 
red)(Ehlert and Rathbun, 1990; Onaran et al., 1992). As GTP inhibits agonist binding 
(De Lean et al., 1980; Waelbroeck et al., 1982; Mahle et al., 1992), agonists must 
decrease the affinity of GTP for RG because allosteric interactions are reciprocal at 
equilibrium. Waelbroeck (1999) discussed in great detail the effects of guanyl 
nucleotides, and the limitations of models proposed by Ehlert and Rathbun (1990) 
and Onaran et al., (1992). Waelbroeck points out although the models are compatible 
with G protein activation through low-affinity binding sites, they cannot explain 
catalytic G protein activation because the activated G protein density would have to 
be lower than the receptor density. The indications are that for each GPCR, the 
factors that affect the activation state are not only the G protein coupling state of the 
receptor and the GDP/GTP state of the receptor, but also the ligand that has bound. 
Each ligand can produce slight differences in the receptor conformation state that 
will influence affinity for G protein binding.
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1.3.3 GPCR-G protein Fusions
The strategy of linking the intracellular C terminal end of a GPCR to the N 
terminal end of a G protein a  subunit has been used to great effect in the study of 
GPCR-G protein interactions. These constructs ensure a 1: 1 stoichiometry between 
the receptor and G protein and in the case of pertussis toxin resistant G« subunit 
fusions allows for the accurate determination of GTPase activity.
After a slow start where a period of two years passed between the 
construction of the first GPCR-G protein construct between the pg-adrenoceptor and 
Gsa (Bertin et a l, 1994), this approach has been used to great effect in the study of 
both a wide variety of GPCRs and G proteins (Milligan 2000; Seifert et aL, 1999; 
Milligan and Rees 1999). The fixed stoichiometry of receptor to G protein allows for 
the measurement of GTP turnover in a cell expression system (Seifert et al., 1998; 
Wise et al., 1997; Carr et al., 1998) and the B,nax from receptor radioligand saturation 
binding studies can be used to calculate the exact expression of fused G protein a  
subunits. This information is of particular use when pertussis toxin has been used to 
ADP ribosylate and uncouple the endogenous pool of inhibitory G proteins, in the 
presence of a pertussis toxin resistant G protein fusion. Previously the addition of 
purified proteins in a reconstituted lipid vesicle system was the only method where 
such accurate measurements could be made (Brandt and Ross 1986; Cerione et al., 
1985).
Using both GTPase activity (Seifert et a l, 1998, 1999; Wise et a l, 1997) and 
GTPyS binding (Seifert et al., 1998; Wise et a l, 1997; Dupuis et a l, 1997) the 
efficacy of partial agonists and inverse agonists have been determined.
The generation of constitutively active receptors has also been used to great 
advantage in the GTPase assay. These mutants may be generated either by 
modification of the G protein, where the Cys^^^Ile mutation in Gii« has been shown 
to generate constitutive activation (Kellett et a l,  1999), or by modification of the 
receptor (Ren et a l, 1993). The expression of these proteins in a mammalian cell line 
and subsequent assay of GTPase activity is a robust system for screening ligands to 
measure potential inverse agonist activity (Kellett et a l, 1999).
The constructs can also be utilised in traditional radioligand binding studies 
where the effects of alteration of guanine nucleotide content in a reaction can be
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measure in terms of agonist binding (Wenzel-Seifert et al,, 1998; Seifert et aL, 1999; 
Waldhoer et al., 1999) providing accurate kinetics for ligand interaction.
1.4 5-HT Receptors
The advent of molecular biological techniques has had a major impact on the 
discovery and classification of 5-HT receptors. To date, mammalian 5-HT receptors 
have been divided into seven families, 5 -HT1.7 , containing 14 receptor subtypes with 
distinct structural and pharmacological profiles (Hoyer et al., 1994) (Figure 1.4). Of 
these fourteen members all are predicted to belong to the supeifamily of seven 
transmembrane spanning G protein-coupled receptors with the exception of the 5- 
HT3 receptor, which is a ligand gated ion channel. 5-HT has been implicated in the 
aetiology of many disease states, particularly mental illnesses, such as depression, 
anxiety, schizophrenia, eating disorders, obsessive compulsive disorder and 
migraine. Many drugs used to treat these illnesses act by modulating 5-HT 
signalling. For example, partial 5-HTia agonists, such as buspirone and gepirone, are 
effective as anxiolytic (antianxiety) agents (Tunnicliff, 1991; Banet, and Vanover,
1993) and 5-HTia antagonists enhance the anti depress ant effects of selective 
serotonin uptake inhibitors (S.S.R.I.s) such as fluoxetine (Prozac) (Artigas et al., 
1994; Artigas et al., 1996). The development of more selective ligands would 
hopefully lead to more effective treatments with fewer side effects.
1.4.1 The 5-HTi Receptor Family
The 5-HTi receptor family consists of five receptor subtypes initially 
characterised as a [^H]-5-HT binding site in rat cortex with low affinity for spiperone 
(Peroukta and Snyder, 1979). Subsequent studies of this [^H]-5-HT binding site 
characterised the 5-H T ia and 5-HTig receptors (Pedigo et ah, 1981; Middlemiss and 
Fozard, 1983), the 5-HTic receptor, that has now been reclassified as the 5 -HT2c 
receptor (Pazos et al., 1984), the 5-H Tjd receptor (now recognised as a species 
variant of the 5-H T ib and the closely related 5-HTio receptors)(Hoyer et al., 1985 
a,b; Heuring and Peroukta, 1987), 5-H T ie receptor (Leonhardt et al., 1989), and 5- 
HTif receptor (Amlaiky et al., 1992; Adham et al., 1993a,b). These receptors have 
high sequence homology (>40%) and all couple negatively to adenylyl cyclase via G 
proteins.
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Figure 1.4 Dendrogram illustration of the evolutionary
relationship between various 5-HT receptor 
protein sequences
The relationship is as defined in Barnes and Sharp (1999), where the multiple 
sequence alignments were created using a simplification of the progressive alignment 
method of Feng and Doolittle (1987).
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1.4.1.1 The 5-HTia Receptor
The rapid characterisation of this receptor following its identification (Pedigo 
et al., 1981; Middlemiss and Fozard, 1983) was due in part to the early development 
of the 5-HT 1A selective agonist 8 -OH-DPAT (Hjorth et a l,  1982). This ligand is now 
known to bind at relatively high concentrations to the 5 -HT7 receptor (Plassat et al., 
1993; Tsou et al., 1994; Nelson et al., 1995). The 5-HTia receptor was the first 5-HT 
receptor to be fully sequenced and was identified as a sequence homologous to the 
^2-adrenoceptor (Kobilka et al., 1987; Fargin et al., 1988; Albert et al., 1990). It has 
been established that Asn^^  ^in TM7 confers the high affinity of the receptor for some 
P-adrenergic ligands (Guan et al., 1992). The original sequence of the human 5-HTia 
receptor (Kobilka et al., 1987) contained a sequencing error near the junction of the 
second intracellular loop and TM4, and was modified (Chanda et al., 1993). The 
encoded human protein has 422 amino acids with a relative molecular weight of 
approximately 46,000. The human receptor is located on chromosome 5 (5qll.2- 
ql3) and the gene is intronless with a predicted typical GPCR structure.
[^H]-8 -OH-DPAT was synthesised in 1983 (Gozlan et al., 1983) and allowed 
the 5-HTiA receptor distribution to be mapped and binding pharmacologically 
characterised. Autoradiography using a range of radioligands, [^H]-5-HT, [^H]-8 - 
OH-DPAT, [^H]-WAY100635, [^^^I]-MPPI has mapped brain 5-HTia distribution 
extensively (Pazos and Palacios, 1985; Hoyer et al., 1986; Khawaja 1995; Kung et 
at., 1995). More recently in living human brain, PET studies using [^^C]- 
WAY100635 have been used to map 5-HTia receptors (Pike et al., 1995). These 
studies have shown high density of 5-HTia sites in the hippocampus, lateral septum, 
cortical areas, and in both dorsal and median raphe nuclei and low levels of 5-HTia 
binding sites in the basal ganglia and cerebellum. This pattern of radioligand binding 
is almost identical to the distribution of 5-HTia mRNA (Chalmers and Watson 1991; 
Miquel et al., 1991; Pompeiano et al., 1993; Burnet et a l,  1995). The 5-HTia 
receptor is located both pre- (in the mesencephalic and medullary raphe nuclei) and 
post-synaptically (in forebrain regions) (Miquel et a l, 1991, 1992; Radja et a l,
1991).
The 5-HTiA receptor is clearly set apart from the 5-HTi and other 5-HT 
receptors by its selectivity for a number of ligands (Hoyer et a l,  1994). The receptor 
selectively binds the agonists 8 -OH-DPAT, gespirone and dipropyl-5-CT and a
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number of antagonists, (S)-UH-301, WAY100135, WAY100635 (most potent) 
(Hillver et aL, 1990; Bjork et al., 1991; Fletcher et al., 1993a,b and 1996) and 
recently NAD-299 which appears to be the most selective (Johansson et aL, 1997). 
WAY100135 has been shown to have some partial agonist activity in some systems 
(Davidson et aL, 1997; Schoeffter et at., 1997). Another highly efficacious agonist at 
the 5-H T ia receptor, S 14506 (Colpaert et at., 1992), has some interesting properties. 
It is structurally related to the inverse agonist spiperone (Barr and Manning, 1997; 
Newman-Tancredi et aL, 1997a,b; Kellett et aL, 1999; Mcloughlin and Strange,
2 0 0 0 ) and behaves as one of the most potent agonists both in vitro and in vivo, but 
has binding characteristics more akin to an antagonist (Milligan et aL, 2001). It was 
proposed that S 14506 interacted with the 5-H T ia receptor not only at the 5-HT 
binding site, but also at the DRY motif that is involved in G protein coupling.
The 5-HTiA receptor is negatively coupled to adenylyl cyclase through 
activation of inhibitory G proteins as demonstrated in both rat and guinea pig tissue 
and cell lines stably expressing the cloned receptor (Boess and Martin 1994; Saudou 
and Hen, 1994; Albert et aL, 1996). Despite its high expression in dorsal raphe, the 
5-HTiA receptor does not appear to inhibit cAMP production there (Clarke et aL,
1996). There have also been reports of positive coupling to adenylyl cyclase of the 5- 
HTia receptor (Shenker et aL, 1983; Markstein et aL, 1986), but given the 
similarities between the 5-HTia and 5-HT? receptors, these results may simply have 
been misinterpreted.
The mechanism of 5-H T ia mediated inhibition of adenylyl cyclase is still 
unclear. The adenylyl cyclase family consists of at least nine members that are 
regulated by a number of different mechanisms (Hurley, 1999; Mons et aL, 1998; 
Taussig and Zimmerman, 1998), reflected in the ability of Gia proteins to bind and 
inhibit types 5 and 6  adenylyl cyclase, Gpy subunits stimulating type 2 adenylyl 
cyclase when activated Gga is present, elevations in intracellular Ca^ "^  inhibiting types 
5 and 6  adenylyl cyclase, Ca^Vcalmodulin stimulating types 1, 3 and 8  adenylyl 
cyclases, whereas Ca^Vcalmodulin-dependent protein kinase II inhibits type 3  
adenylyl cyclase, and finally, protein kinase C stimulating types 2 and 7.
The activation of PI-PLC by 5-HTia receptors was first demonstrated in 
HeLa cells (Fargin et aL, 1989) and was shown to be as effective as coupling via 
endogenous Hi receptors (Raymond et at., 1990). Activation was also shown in
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human Jurkat cells (Aune et aL, 1993) and the mechanism was demonstrated in Lkf 
fibroblasts to be by 5-HT increased phosphoinositide and intracellular levels of Ca^ '*' 
(Liu and Albert 1991) and that in both Lkf and BALB/c-3T3 cells, the increase in 
intracellular Ca^ '*' was from release from intracellular stores (Abdel-Baset 1992).
The 5-HTiA receptor is coupled to protein kinase C activation (Middleton et 
aL, 1990; Raymond et aL, 1989) in HeLa cells where it is dependent on PLC 
activation (Fargin et aL, 1989). The effect is probably mediated via Gpy and is 
dependent on the expression of Gpy regulatable PKC (Raymond et aL, 1999). 5-HTia 
mediated activation of PLA? has been demonstrated in HeLa cells (Harrington et aL,
1994), as has augmentation of Ca^ "^  induced arachidonic acid metabolism in CHO 
cells (Raymond etaL, 1992).
The 5-HTiA receptor has demonstrated coupling to a number of ion channels, 
including the G protein coupled inwardly rectifying channel (Andrade and Nicoll 
1986; Colino and Halliwell 1987; Zgombick et aL, 1987), via interaction with Gpy 
subunits released on receptor activation (Doupnik et aL, 1996). In native systems, 
inactivation of 5-HTia stimulated GIRK channel opening is 20-40 times faster than 
in systems where the cloned receptor and channel have been co-expressed (Andrade 
and Nicoll 1986; Colino and Halliwell 1987; Zgombick et aL, 1987; Dascal et aL, 
1993; Kai'schin et aL, 1991). It was suggested that additional components, in this 
case, regulators of G protein signalling (RGS) proteins, may be involved in the native 
pathway (Doupnik et aL, 1997). It was demonstrated that kinetics similar to those of 
the native systems could be restored following co-expression of the 5-HTia receptor, 
GIRKl, and one of RGSl, RGS3, and RGS4 proteins, but that co-expression with 
RGS2 protein did not restore the rapid native kinetics (Doupnik et aL, 1997).
Regulation of a number of other channels by 5-HTia receptor activation has 
been demonstrated. The 5-HTia receptor can stimulate an oscillatory Ca^ "^  activated 
Cl" current in Xenopus oocytes (Ni et aL, 1997) as well as augment the activation of 
CFTR Cr channels induced by p2-adrenergic receptors (Uezono et aL, 1993). 
Inhibition of Bay K8644-mediated Ca^ **" influx in GH4C1 cells by rat 5-HTia receptor 
activation has also been demonstrated and this requires co-expression of Goa (Liu 
and Albert, 1991; Liu et aL, 1994).
The coupling of the 5-HTia receptor to the different types of inhibitory G 
proteins has been examined in many systems. The 5-HTia receptor has been co­
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expressed with mammalian G proteins in Spodoptera frugiperda (Sf9) cells (Barr et 
aL, 1997; Butkerait et aL, 1995), where co-expression of Gia proteins and various 
combinations of Pi and y subunits increased the affinity for agonists. When the 5- 
HTia receptor was co-expressed with Pi and y%, relatively equivalent coupling to ocu, 
0Ci2 , 0Ci3 , and was seen with no coupling to % and aq (Barr et aL, 1997; 
Butkerait et aL, 1995). Co-expression of the 5-HTia with pi and On and various y 
subunits revealed an order of preference for coupling to y2^3^5>Yi (Barr et aL, 
1997; Butkerait et aL, 1995).
Expression of the 5-HTia receptor in E.coli showed a rank order of affinity 
for reconstituted purified mammalian G protein a  subunits of G#%> G%#> G u a »  
G o a »  Gsa (Bertin et aL, 1992). In HeLa and CHO cells, agonist induced coupling of 
the 5-HTiA receptor and G proteins revealed an apparent rank order of G,3a > Gi2a = 
Giia= Goa > Gza » G s a  (Gamovskaya et aL, 1997; Raymond et aL, 1993).
Linkage of 5-HTia signalling through specific G« proteins to a number of 
second messenger systems has been demonstrated. The 5-HTia receptor in HeLa 
cells was shown to inhibit adenylate cyclase and activate PI-PLC via Gi3a (Fargin et 
aL, 1991) and also in CHO and HeLa cells, 5-HTia mediated inhibition of adenylyl 
cyclase was demonstrated by Gna, Gi2a and Gisa (Raymond et aL, 1993), findings 
that are unsurprising as inhibition of cAMP accumulation in mammalian cells 
following 5-HTiA receptor activation was demonstrated via Gna, Gi2a, G^a and G%a 
(Wong et aL, 1992). These, among other studies, have suggested different 
effectiveness for various Gia proteins in either CHO or HeLa cells (Raymond et aL, 
1993; Wong et aL, 1992; Gettys et aL, 1994), but these results may have been 
affected by differences in the endogenous pools of G protein. In HeLa cells, Gi3a is 
more highly expressed than Gi2a, and in CHO cells, Gi2a is expressed at levels 
approximately nine fold of those of Gi3a (Raymond et aL, 1993). A number of studies 
suggest that the 5-HTia receptor is linked to inhibition of adenylate cyclase and 
activation of PLC through Gna or Gisa and to the inhibition of Ca^ "*" channels via Goa 
(Liu et aL, 1994; Albert et aL, 1996; Langlois et aL, 1996).
The 5-HTiA receptor has been implicated in growth stimulation (Ishizuka et 
aL, 1992). It has been reported to induce the secretion of a growth factor (protein S- 
100) from primary astrocyte cultures (Azmitia et aL, 1996) and increase markers of
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growth in neuronal cultures (Riad et aL, 1994), findings that raise the possibility of 
the 5-HTia receptor having a neurotrophic role in developing and adult brain (Riad et 
aL, 1994; Azmitia et aL, 1996; Yan et aL, 1997). The 5-HTia receptor has also been 
linked to the activation of ERK (extracellular signal-regulated kinase) and NF-kB 
(nuclear factor-KB) (Cowen et aL, 1996, 1997; Luttrell et aL, 1997; Marshall 1995; 
Gamovskaya et aL, 1996, 1998).
A number of important structural features have been identified in the 5-HTia 
receptor. The high affinity of the 5-HTia receptor for p-adrenoceptor blockers such 
as pindolol (Guan et aL, 1992) has been attributed to a single amino acid residue, 
Asn^ *^^  in TM7, which is uniquely conserved in the 5-HTia receptor and all P- 
adrenoceptors. The mutation Asn^^^Val decreased the affinity for binding of pindolol 
and similar ligands but did not effect the binding of 5-HTia receptor ligands. Other 
mutations in the TM domains have resulted in decreased affinity for 5-HT (Ho et aL,
1992). The mutations Asp^^Asn, Asp^^^Asn and Ser^^^Ala decreased the affinity for 
5-HT binding by 60-100 fold but did not effect pindolol binding. Binding of 5-HT to 
the Thr^^^Ala mutant was undetectable.
The use of synthetic peptides from the second and third intracellular loops of 
the 5-HTiA receptor suggested sites of G protein interaction (Varrault et aL, 1994). A 
peptide consisting of the entire second intracellular loop (Asp^^^-Arg^^^) and a region 
of the third intracellular loop (Ala^^ -^Leu^"^ )^, but not the (Ala^^^-Val^"^) peptide, 
inhibited forskolin stimulated cAMP production in membranes from NIH-3T3 cells, 
Sf9 cells and rat hippocampus and increased GTPyS binding to purified bovine Gj/oa 
proteins, indicating the importance of these site in G protein coupling. A role for 
Thr^ "^  ^ in the second intracellular loop has also been demonstrated in mediating Gp? 
specific responses (Albert et aL, 1998).
A number of serine and threonine sites in the second and third intracellular 
loops of the 5-HTia receptor have been identified as putative PKC phosphorylation 
sites and play a role in signalling specificity and receptor desensitisation (Lembo et 
aL, 1995, 1997). Single mutants of the 5-HTia receptor, Thr^^^Ala, Ser^^^Gly and 
Thr^^^^Ala had no effect on PKC mediated desensitisation of Ca^ "^  mobilisation in Ltk" 
fibroblasts, but the double (Thr^^^Ala and Ser^^^Gly) and triple mutant (Thr^^^Ala, 
Ser^^^Gly and Thr '^^^Ala) were progressively more resistant to PKC mediated 
desensitisation. Lembo et aL (1997) also found that the Thr^^^^Ala mutant inhibited
24
elevation of Ca^ '*’ in Ltk' cells and was unable to inhibit opening of BayK8644 
sensitive Ca^ "*" channels in GH4C1 cells while only partially uncoupling the 5-HTia 
receptor from inhibition of cAMP production. This work suggests that residues 
Thr^^ ,^ Ser^^  ^ and Thr^ "^  ^ in the third intracellular loop mediate the desensitisation of 
the rat 5-HTia receptor, that Thr^^  ^is important for coupling to inhibition of adenylyl 
cyclase and elevations in intracellular Ca^ "*" and that Thr^ "^  ^in the second intracellular 
loop has a role in elevation of intracellular Ca^^ and inhibition of adenylyl cyclase.
A technique that has been used to investigate the function of a specific gene 
in vivo is the generation of “knockout” animal models. Two groups have used this 
technique to generate mouse lines that lack 5-HTia receptors and have assessed the 
effects this had in terms of behavioural models of anxiety and stress, disease states in 
which particularly the presynaptic 5-HTia receptor has been implicated (Ramboz et 
aL, 1998; Heisler et aL, 1998). Neither group found any difference in the serotonin 
content of knockout versus WT mice or in the amount of serotonin released 
following electrical stimulation of slices from the hippocampus or mesencephalic 
regions. In WT mice, 8 -OH-DPAT produced a 30-40% reduction in this release but 
had no effect in the knockout mice (Ramboz et aL, 1998). These findings could 
either indicate that 5-HTia receptor does not play a significant role in the regulation 
of serotonin release or that in its absence another receptor is fulfilling the role.
A possible candidate for 5-HTia functional substitution is the 5-HTib 
receptor. As with the 5-HTia receptor it is negatively coupled to adenylyl cyclase 
and is also expressed presynaptically at the axon terminal (Martin et aL, 1998; 
Hammon 1997). Ramboz et al. (1998) suggested that the 5-HTib receptor may be 
upregulated in 5-HTia knockouts and demonstrated that both in WT and knockouts, 
5-HTib agonists were able to attenuate electrically evoked serotonin release.
Both groups examined the behaviour of the mice in terms of anxiety, with an 
increased level of anxiety shown as a decreased level of exploratory behaviour and 
vice versa. In both studies, the 5-HTia knockout mice showed a decreased level of 
exploration when compared to WT mice with the Ramboz study indicating that only 
male knockout mice showed a significantly decreased level of exploration. Levels of 
depression were also measured using two similar models, the forced swim test and 
the tail suspension test, both of which record increased immobility as an indicator of 
increased depression. Again the results from the two groups were the same, with the
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knockout mice recording shorter periods of immobility compared to WT mice 
indicating that a lack of functional 5-HTia receptor favours a less depressed state.
These models are helpful in furthering understanding of 5-HTia receptor 
function but more stringent studies were suggested by both groups. Heisler et al. 
(1998) suggested both microdialysis and electrophysiological studies, whereas 
Ramboz et al. (1998) suggested using a tissue specific knockout approach (Kuhn et 
a l, 1995).
1.4.1.2 The 5-HTib Receptor
The 5-HTib serotonin receptor was identified at the same time as the 5-HTia 
receptor as a [^H]-5-HT binding site in rodent brain with low affinity for spiperone 
(Pedigo et al., 1981). However, its low affinity for 8-OH-DPAT, the selective 5- 
HTia receptor agonist, set it apart pharmacologically (Middlemiss and Fozard 1983). 
The gene encoding the human 5-HTib receptor is located on chromosome 6 (6ql3) 
(Saudou and Hen, 1994) and the receptor is expressed highly in the rat basal ganglia 
and other regions (Pazos et al., 1985; Verge et al., 1986; Bruinvels et al., 1993). 
There are a large number of ligands available to study the 5-HT]b receptor, but few 
of these show any selectivity (Hoyer et al., 1994). The most potent agonists include 
5-CT and RU 24969, with methiothepin being a potent antagonist. However, these 
ligands have affinity for other 5-HT receptors, particularly the 5-HTia receptor. 
Some selectivity has been provided by the antagonist GR 127935 (Skingle et ah,
1995) which has shown high selectivity for the 5-HTib/id over other 5-HT receptors 
and the antagonists SB-224289 and SB-216641 which show selectivity 5-HTib over 
5-HTid (Price et a l, 1997; Roberts et al., 1997).
The 5-HTiB receptor couples negatively to forskolin stimulated adenylyl 
cyclase (Adham et al., 1992; Levy et a l, 1992a; Weinshank et al., 1992). A number 
of compounds, including methiothepine, ketanserin and SB-224289 have shown 
inverse agonist activity at the 5-HTib receptor using [^^S]-GTPyS binding (Pauwels 
et al., 1997; Roberts et al., 1997). There is also evidence supporting the role of 5- 
HTib receptors as autoreceptors on 5-HT nerve terminals (Middlemiss and Huston, 
1990; Buhlen e ta l ,  1996).
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1.4.1.3 The 5-HTid Receptor
The classification of the 5-HTid receptor was a long process that involved 
confusion with the 5-HTib receptor and definition as 5-HTiDo/p isoforms (Hamblin 
and Metcalf 1991; Levy et ah, 1992a,b; Weinshank et ah, 1992). However, the 5- 
HTidp was redefined as a species homologue of the 5-HTib receptor and with the 
discovery of a rat gene homologous to the 5-HTiDa receptor with a 5-HTid binding 
site profile (Hamblin et ah, 1992), the 5-HTioa receptor was renamed the 5-HTid 
receptor (Hartig et ah, 1996). Due to a lack of 5-HTid selective radioligands the 
distribution of the receptor is poorly defined. In situ hybridisation studies have 
detected 5-HTid mRNA in various rat regions including caudate putamen, olfactory 
cortex and dorsal raphe nucleus (Hamblin et ah, 1992; Bruinvels et ah, 1994a,b). 
Available data indicate on the whole that the 5~HTid receptor is present mainly on 
axon terminals of both 5-HT and non 5-HT neurones.
The 5-HTiD receptor has a binding profile that is almost indistinguishable 
from the 5-HTib receptor (Weinshank et ah, 1992; Boess and Martin, 1994). Only a 
few compounds show any selectivity for the 5-HTid receptor over the 5-HTib 
receptor, ketanserin and ritanserin being only 15-30 fold selective (Kaumann et ah, 
1994; Pauwels et ah, 1996) and BRL-15572 only 60 fold selective 5-HTm over 5- 
HTib (Price et ah, 1997). The 5-HTm couples negatively to adenylyl cyclase 
activation (Hamblin and Metcalf 1991; Weinshank et ah, 1992).
1.4.1.4 The 5-HTie Receptor
The 5-HTiE receptor was identified as a novel 5-HT receptor in radioligand 
bindings using selective ligands to block the 5-H Tia, 5-HTib and 5-HTic (now the 5- 
HT2c) receptors and distinguishable from the 5-HTid receptor by having a low 
affinity for 5-CT (Waeber et ah, 1988; Leonhardt et ah, 1989). It was subsequently 
isolated (McAllister et ah, 1992; Zgombick et ah, 1992). The 5-H T ie receptor gene 
is intronless, encodes a protein of 365 amino acids (McAllister et ah, 1992; 
Zgombick et ah, 1992; Gudermann et ah, 1993), and is located on chromosome 
6ql4-ql5 (Levy et ah, 1992b). There are currently no selective ligands for the 5- 
HTie receptor, but it is characterised by its high affinity for 5-HT and lower affinity 
for 5-CT, as well as low affinity for p-adrenergic ligands (Adham et ah, 1994). The 
receptor has shown modest inhibition of adenylyl cyclase activity, with methiothepin
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acting as a weak antagonist and 5-CT as a weak agonist (McAllister et al., 1992; 
Zgombick et al., 1992; Levy et al,, 1992a).
1.4.1.5 The 5-HTif Receptor
The 5-HTif receptor was initially detected in mouse (Amlaiky et al., 1992) 
and later in human (Adham et al., 1993b) having initially been described as a 5- 
HTiEp receptor (Amlaiky et al., 1992). The receptor shows a similar low affinity to 
the 5-HTie receptor for 5-CT, but markedly different mRNA distribution in the brain. 
As with the other members of the 5-HTi family it is intronless with the gene located 
on chromosome 3 q ll (Saudou and Hen 1994). As with the 5-HTie, the 5-HTif 
receptor has a high affinity for 5-HT and a low affinity for 5-CT but shows a high 
affinity for sumatriptan whereas the 5-HTm receptor does not (Amlaiky et al., 1992; 
Adham et al., 1993a,b; Lovenberg et al., 1993a,b). There are two selective 5-HTip 
agonists available, LY 344864 and LY 334370 (Overshiner et a l ,  1996; Johnson et 
a t ,  1997; Phebus et al., 1997). The receptor is negatively coupled to forskolin 
stimulated adenylyl cyclase (Amlaiky et al., 1992; Adham et al., 1993a,b; Lovenberg 
et al., 1993a,b) with 5-HT acting as a potent agonist and methiothepine as a weak 
antagonist. The selective 5-HTip receptor ligands, LY 344864 and LY 334370 are 
potent agonists when inhibiting cAMP accumulation (Johnson et a l ,  1997; Phebus et 
a l ,  1997).
1.4.2 The 5-HT2 Receptor Family
There are currently three members of the 5 -HT2 receptor family, the 5-HT2A, 
5 -HT2B and 5 -HT2C. The 5-HT2a receptor was originally called the 5-HT D receptor 
(Gaddum and Picarelli 1957) and the 5-HT2c replaced the 5-HTic receptor 
(Humphrey et al., 1993; Hoyer et al., 1994). The amino acid sequences of the 5 -HT2 
receptors are highly homologous within the 7TM domains but are distinct from the 
other 5-HT receptors (Baxter et al., 1995). All 5 -HT2 receptor genes have two (2A 
and 2B), or three introns (2C) in the coding sequence (Yu et al., 1991; Chen et al., 
1992; Stam et al., 1992) and all couple positively to PLC and mobilise intracellular 
calcium.
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1.4.2.1 The 5-HT2A Receptor
5 -HT2A binding sites have a high affinity for spiperone, but relatively low 
affinity for 5-HT (pM) (Leysen et ah, 1978; Peroukta and Snyder, 1979). The human 
5 -HT2A receptor is located on chromosome 13ql4-q21 and has a high sequence 
homology with the 5-HT2c receptor but lower with the 5-HT2b receptor (Pritchett et 
al., 1988; Julius et al., 1990). The receptor has five possible glycosylation sites, 
approximately eleven possible phosphorylation sites and a single site for 
palmitoylation (Saltzman et a l ,  1991). The antagonist MDL 100907 is selective for 
and potent at the 5-HT2a receptor, with lower affinity for the 5-HT2c and other 
receptors (Sorenson et a l ,  1993; Kehne et a l ,  1996). The 5-HT2a receptor couples 
positively to PLC leading to increased accumulation of inositol phosphates and 
intracellular Ca^^ (Boess and Martin 1994). It has also been linked to altered 
expression of a number of genes including the brain-derived neurotrophic factor 
(BDNF) (Vaidya et a l ,  1997).
1.4.2.2 The 5 HT2B Receptor
This receptor was originally classed as 5-HTi like (Bradley et a l ,  1986) and 
was responsible for the contraction of the rat stomach fundus (Vane 1959). Schmuck 
et a l  (1994) isolated what was originally termed the 5-HT2f receptor (Kursar et al ,
1992) but this was later reclassified as the 5-HT2b receptor (Humphreys et a l ,  1993). 
It has 481 amino acids, two introns that are present at positions corresponding to 
those of the 5-HT2a and 5-HT2c receptor genes and is located on chromosome 
2q36.3-2q37.1 (Foguet et a l ,  1992). The novel antagonist SB 204741 is 20-60 fold 
selective for the 5 -HT2B receptor over the 5-HT2a, 5-HT2c and other receptors 
(Baxter et a l ,  1995; Bonhaus et a l ,  1995; Baxter 1996). The cloned 5-HT2b receptor 
stimulates phosphoinositol hydrolysis (Wainscott et a l ,  1993; Kursar et a l ,  1994; 
Schmock et a l ,  1994). The receptor may also have a role in neural development 
indicated by severe neural abnormalities in knockout 5-HT2b mice (Choi et a l ,  1997; 
Nebigil e t a l ,  1998).
1.4.2.3 The 5-HT2C Receptor
This receptor was originally termed the 5-HTic due to its high affinity for 
[^H]-5-HT (Razos et a l ,  1984) but once it was cloned and further characterised it
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was reclassified as the 5-HT2c receptor (Humphreys et al., 1993), A splice variant of 
the 5 -HT2C receptor has been found in rat, mouse and human (Canton et al., 1996), 
but a functional role is unclear as it lacks a 5-HT binding site. The receptor is X- 
linked (human chromosome Xq24) and has three introns and may produce a GPCR 
with 8TM domains, however this has yet to be demonstrated (Yu et al., 1991). The 
antagonists SB 242084 and RS-102221 are at least 10-100 fold selective for the 5- 
HT2C receptor over the 5-HT2A, 5-HT2B and other receptors (Bonhaus et a l ,  1997; 
Kennett et ah, 1997a,b). The 5-HT2c receptor increases PLC activity in the choroid 
plexus and stably transfected cell lines via a G protein coupled mechanism (Boess 
and Martin 1994).
1.4.3 The 5-HT3 Receptor
The 5 -HT3 receptor is the exception of the 5-HT receptor family as it is a 
ligand gated ion channel (Derkach et al., 1989; Maricq et al., 1991). It is a multiple 
subunit channel with genes encoding the 5 -HT3A subunit (Maricq et al., 1991) and 
the 5 -HT3B subunit (Davies et al., 1999) having been identified. A spliced variant of 
the 3A subunit has been identified (5-HT3as or short) (Hope et al., 1993) mRNA for 
which is 4-6 times more abundant in mouse neuronal tissue (Werner et al., 1994). 
The ion channel is cation selective (K^ = Na"*") and is prone to rapid desensitisation 
(Jackson and Yakel 1995). The receptor has a selective antagonist, MDL 72222, 
which shows varying interspecies affinity (Kilpatrick and Tyers 1992) and is 
associated with fast synaptic transmission in the brain (Sugita et al., 1992).
1.4.4 The 5-HT4 Receptor
The 5 -HT4 receptor was identified in cultured mouse colliculi neurones and 
guinea pig brain (Dumuis et at., 1988; Bockaert et al., 1990). There are four isoforms 
of the receptor, 5 -HT4S (short) and 5 -HT4L (long) (Gerald et al., 1995), renamed 5- 
HT4(a) and 5-HT4(b) respectively by the recommendations of lUPHAR (Hoyer and 
Martin 1997), and 5-HT4(c> and 5-HT4(d) (Blondel et al., 1998: Bockaert et a l ,  1998). 
A number of highly selective antagonists are available for the 5 -HT4 receptors, with 
GR 113808 and SB 204070 among them. The receptors all couple positively to 
adenylyl cyclase (Gerald et al., 1995; Claysen et al., 1996), with as yet no 
distinguishable differences between the various isoforms.
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1.4.5 The 5-hts Receptor Family
There are two 5-hts receptors, the 5-htsa and 5-htsb, both of which were 
identified from a mouse brain cDNA library (Plassat et al., 1992a,b; Hen 1992). The 
human 5-htsa receptor has also been isolated (Rees et al., 1994). In accordance with 
lUPHAR nomenclature, lower case lettering is used as functional activity has yet to 
be demonstrated for the 5-ht5 receptors. Both genes contain an intron in a position 
corresponding to the middle of the third intracellular loop (Matthes et al., 1993). 
Both receptors have relatively high affinity for 5-CT, LSD, methiothepin and 
sumatriptan (Erlander et al., 1993; Matthes et al., 1993). Using multiple expression 
systems, neither the 5-htsa or 5-htsb receptors have demonstrated coupling to either 
adenylyl cyclase or inositol phosphates (Plassat et al., 1992a,b; Erlander et al., 1993; 
Metthes et al., 1993; Wisden et al., 1993), although in HEK293 cells at levels of 
expression exceeding 25pmol/mg protein there was a report of inhibition of forskolin 
stimulated adenylyl cyclase activity (Fracken et al., 1998).
1.4.5.1 The 5-htsa Receptor
The receptor is predicted to have 357 amino acids (Plassat et al., 1992a,b; 
Rees et al., 1994; Erlander et al., 1993) and contains consensus sequences for both 
N-linked glycosylation in the N terminal tail and PKC sensitive phosphorylation sites 
in the intracellular loops. The 5-htsa gene is located on human chromosome 7q36 
(Matthes et al., 1993).
1.4.5.2 The 5-htsb Receptor
The 5-ht5b receptor is predicted to contain 370-371 amino acids in mouse or 
rat (Erlander et al., 1993; Mathes et al., 1993; Wisden et al., 1993) and has 
consensus sequences for N-linked glycosylation in the N terminus and for PKC 
sensitive phosphorylation on the intracellular domains. The 5-htsb receptor gene is 
located on human chromosome 2qll-13 (Metthes et al., 1993).
1.4.6 The 5-htg Receptor
Following some differences in original sequences of the 5-hte receptor 
cDNAs, the reports were reconciled (Kohen et al., 1996; Boess et al., 1997). The 
human S-htg receptor comprises 440 amino acids and is predicted to be a member of
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the GPCR superfamily (Kohen et al., 1996). It has a consensus sequence for N- 
linked glycosylation on the N terminus and a number of predicted phosphorylation 
sites on the third intracellular loop and C terminal tail (Kohen et al., 1996). It 
undergoes agonist-induced desensitisation following phosphorylation catalysed by 
cAMP dependent protein kinase (Sleight et al., 1997) with studies indicating that the 
5-ht6 receptor is positively coupled to adenylyl cyclase (Sebben et ah, 1994; 
Schoeffter and Waeber 1994). The human 5-htô receptor gene is located on 
chromosome lp35-36. Two 5-htô selective antagonists are available, Ro 04-6790 and 
Ro 63-0563 (Sleight et al., 1998).
1.4.7 The 5-HT7 Receptor
Despite it being the most recently cloned 5-HT receptor, functional responses 
corresponding to the 5 -HT7 receptor were recorded prior to its cloning (Eglen et al., 
1997). It has been identified in a large number of species including mouse, rat, 
guinea pig and human (Bard et al., 1993; Lovenberg et al., 1993a,b; Meyerhof et al., 
1993; Plasat et al., 1993; Ruat et al., 1993; Shen et al., 1993; Tsou et al., 1994; 
Nelson et al., 1995). The full length receptor is predicted to be between 445 and 448 
amino acids, is located is located on chromosome 10q21-q24 (Gelemter et al., 1995) 
and contains two introns (Ruat et at., 1993; Erdmann et a l ,  1996; Heidmann et al., 
1997). There are at least four splice variants of the 5 -HT7 receptor in humans, 5- 
HT7(a)-(d), but as yet expression of the 5-HT7(c> has not been detected (Heidmann et 
al., 1997). They are predicted to be members of the GPCR superfamily and have 
consensus sequences for two N-linked glycosylation sites in the N terminus (Bard et 
al., 1993; Lovenberg et al., 1993a,b; Meyerhof et al., 1993; Plasat et ai ,  1993; Ruat 
et al., 1993; Shen et al., 1993; Tsou et al., 1994), and a number of predicated protein 
kinase A and C phosphorylation sites in the third intracellular loop and C terminus 
(Bard et al., 1993; Lovenberg et al., 1993a,b; Meyerhof et al., 1993; Plasat et al., 
1993; Ruat et al., 1993; Shen et al., 1993; Tsou et al., 1994; Nelson et al., 1995; 
Heidmann et al., 1997). To date no pharmacological differences have been detected 
between the 5-HT? isoforms. The receptor is positively linked to adenylate cyclase 
via Gsa (Obosi et al., 1997).
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1.5 Therapeutic Roles for the 5-HTia Receptor
The 5-HTia receptor has been indicated in a wide variety of therapeutic roles, 
the vast majority of which are due to its CNS expression. It has been indicated in 
thermoregulation (Balcells-Olivero et al., 1998; Seletti et al., 1995), aggression 
(Miczek et at., 1998; Hen 1996), depression (Blier et al., 1997; Shiah et al., 1998), 
anxiety (Parks et al., 1998; Ramboz et al., 1998) and neurogenesis (Gould 1999). It 
also plays a role in immune responses (Mossner and Lesch 1998).
Administration of the 5-HTia selective agonist 8-OH-DPAT decreases the 
core body temperature of rats (Balcells-Olivero et a l, 1998; Torup et al., 2000). In 
the latter study, Torup et al. found that 8-OH-DPAT had a neuroprotective role 
following a 2-vessel occlusive ischaemic event. Core body temperature of 8-OH- 
DPAT treated and control rats was monitored for 24 hours post ischaemia and after 
seven days the number of viable CAl neurons were counted. In the 8-OH-DPAT 
treated rats more than twice as many viable cells were found and it was proposed that 
this was due to the significantly lowered core body temperature induced by the 5- 
HTia agonist (Torup et al., 2000).
In patients suffering from depression, treatment with 5-HTia agonists is 
accompanied by a decreased hypothermic response when compared to non depressed 
controls (Cowen et al., 1994; Lesch et al., 1990), indicating that an abnormality in 
the 5-HTiA receptor or its signalling is involved. This has been widely known for 
many years and a number of treatments for depression are aimed at 5-HT and the 5- 
HTia receptor where depression is associated with an increase in the firing activity of 
5-HT neurons of the dorsal raphe nucleus (Pineyro and Blier, 1999). The use of both 
SSRIs (selective serotonin uptake inhibitors) and MOAIs (monoamine oxidase 
inhibitors) for the treatment of depression are both aimed at altering the levels of 5- 
HT in the synaptic cleft following 5-HT neuron activation. This leads to an increased 
activation of the somatodendritic 5-HTia autoreceptor and the activation of a 
negative feedback loop that decreases the firing of the 5-HT neuron (Pineyro and 
Blier, 1999). The drawback to these therapeutic approaches is that following their 
sustained administration, the somatodendritic 5-HTia receptor desensitises and the 
effectiveness of the drugs decreases. This may be due to downregulation of the 
presynaptic 5-HTia receptor. Following 14-21 days of treatment the pre-treatment 
firing frequency of the 5-HT neurons returns (Dong et a l, 1997,1998; Pineyro and
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Blier, 1999). Interestingly, there does not appear to be any effect on the postsynaptic 
CA3 5-HTia mediated responses over this time (Blier and Monigny 1994). If these 
contrasting effects are due to receptor reserve postsynaptic ally and a lack of reserve 
presynaptically or another mechanism remains unclear (Pineyro and Blier, 1999).
The presynaptic 5-HTia autoreceptor has also been indicated as having a role 
in stress and anxiety (Chaouloff et al., 1999). Increases in both the firing activity of 
5-HT neurons and in the levels of 5-HT in the synaptic cleft of the dorsal raphe 
nucleus are associated with stress. A decrease in the sensitivity of somatodendritic 5- 
HTia autoreceptors to 5-HT is recorded following the chronic exposure to stressors, 
but not to acute exposure (Laaris et a l, 1997) that may indicate the down-regulation 
of the receptor. These characteristics of stress/anxiety and depression are supported 
by the results of behavioural studies on 5-HTia knockout mice (Ramboz et al., 1998; 
Heisler et al., 1998). Both research groups found that homozygous 5-HTia knockout 
mice showed increased levels of anxiety coupled with decreased levels of depression 
indicating that the 5-HTia receptor plays a pivotal role in the pathophysiology of 
these two disease states.
It has been demonstrated that serotonin has a role in the growth of developing 
and adult brain (Manzer et al., 1997; Yan et al., 1997). Specifically, the neurogenesis 
in adult mammalian brain dentate gyrus, an area that is rich in 5-HTia receptors, is 
enhanced by 5-HT receptor activation (Jacobs et al., 1998). Growth in the majority 
of brain regions is restricted to gestation, but continues in the granule cell layer of the 
dentate gyrus into adulthood where the majority of new cells differentiate into 
mature neurons (Gould et al., 1997,1998,1999a). It was suggested that these cells 
could be involved in growth and learning (Gould et al., 1999). Conditions such as 
stress (Gould et al., 1997), ageing (Gould et al., 1999a), and NMDA receptor 
activation (Cameron et al., 1995), that inhibit granule cell genesis also decrease the 
density of 5-HT fibres or 5-HTia receptors, or inhibit 5-HT release in the dentate 
gyrus (Gould et al., 1999b). Activation of 5-HTia receptors with 8 -OH-DPAT 
increases the rate of proliferation of granule cell precursors, the majority of which 
differentiate into granule neurons (Gould et a l, 1999b) suggesting that the 5-HTia 
receptor is directly involved in the stimulation of adult dentate gyrus neuronal 
growth.
The 5-HTiA receptor may also have roles in aggression (Hen 1996), where 5- 
HT ia agonists decreased aggressive behaviour in mice, in Tourette’s syndrome (Lam
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et al., 1996; Robertson 2000), where a number of mutant 5-HTia receptors have been 
detected in patients, in immune function (Mossner and Lesch 1998), where 5-HTia 
receptor antagonists inhibit the production of Tni-type cytokines by memory T cells 
and agonists abrogate monocyte induced suppression of NK cell functions, and also 
in schizophrenia (Millan 2000) where D? receptor antagonists that have partial 
agonist activity at 5-HTia receptors may provide improved treatment of the disease.
1.6 G proteins
Heterotrimeric GTP binding proteins (G proteins) transduce extracellular 
signals that activate transmembrane spanning G protein coupled receptors to the 
intracellular environment via second messenger systems. Heterotrimeric G proteins 
consist of a , P, and y subunits and transduce signals from GPCRs activated by such 
diverse ligands as photons, neurotransmitters and hormones to second messenger 
regulating systems ranging from adenylyl cyclase to ion channels and the MAP 
kinase signalling cascade (Figure 1.5). Currently more than 20 a  subunits have been 
classified and have been assigned to five different families (Simon et al., 1991). 
There are five different G protein p subunits and at least 12 different y subunits. 
Initially, signalling was thought to progress through the a  subunits with the Py dimer 
having a membrane anchorage role. However, it has been shown that the latter is also 
involved in effector signalling (Clapham and Neer 1997).
1.6.1 G protein Structural Features
The structure of Gtaand Gii« have been solved in several conformation states 
including the GDP bound form (Lambright et ah, 1994; Coleman et al., 1994; Mixon 
et al., 1995), the GTPyS form (Coleman et al., 1994; Noel et al., 1993), the apy 
oligomer and the Py dimer (Wall et al., 1995; Lambright et al., 1996; Sondek et al., 
1996) as well as the complex between G^a and RGS4 protein (Tesmer et al., 1997). 
These studies have revealed a considerable amount about the structures of the a, P 
and Y subunits and their interactions with one another.
The a  subunit has a p2F^Liike domain and an a  helical domain separated by 
the guanine nucleotide binding site. The confomation of the a  subunit with GDP 
bound is different to that when GTP is bound by movements in three discontiguous
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Figure 1.5 GPCR -  G protein signalling cascade
Following agonist activation of a GPCR, a conformational change takes place in the 
receptor leading to G protein binding. This interaction results in an exchange of GDP 
for GTP and the subsequent dissociation of the G protein from the receptor and the G 
protein a  and Py subunits from one another. The free G protein subunits modulate 
the activity of effectors generating a signal within the cell. The hydrolysis of GTP to 
GDP leads to the re-association of the G« and Py subunits and termination of activity.
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loops, switch I that connects the helix cxF and strand |32, switch II that connects %  
and P4 , and switch III that connects « 3  and P4 . The switch II region interacts with the 
Py dimer (Faurobert et al., 1993; Thomas et al., 1993; Conklin and Bourne 1993), 
with switch II and switch III participating in the formation of effector binding sites I 
and II which suggests that dissociation of the py dimer is a prerequisite for effector 
binding at these sites. A third effector binding site is formed by helix 0(4 and Pô-
The Py subunits provide a more rigid structure, with the P subunit consisting 
of a rigid propeller like core composed of seven WD40 repeats and the y subunit 
composed of an extended a  helical conformation. The amino termini of the p and y 
subunits form a coiled coil which is famesylated or geranylgeranylated and is 
oriented towards the amino terminal a  helix of the a  subunit (Wall et at., 1995; 
Lambright et al., 1996). The Py dimer does not significantly change structurally 
following a  subunit dissociation (Wall et al., 1995; Lambright et al., 1996), 
indicating an important role as a scaffold protein for the a  subunit, the reassociation 
of which results in its deactivation.
In a simplified form the mechanism of signalling through G proteins has been 
well understood for a number of years (Hepler and Gilman 1992). In the basal state 
the G protein exists as the (%Py heterotrimer with GDP bound to the a  subunit, with 
the slow rate of GDP release (^ off is 10-100 times slower than A:cat of GTP) 
maintaining the G protein in the “o ff’ state and leading to py binding with high 
affinity. Agonist binding to a receptor leads to a conformational change in the GPCR 
and reveals sites on the intracellular loops of the receptor where an appropriate G 
protein may bind. Receptor binding leads to a structural change in the G protein a  
subunit and a decrease in affinity for GDP and the subsequent binding almost 
instantaneously of GTP. The a  subunit and Py dimer dissociate and interact with 
second messenger systems modulating their activity. The intrinsic GTPase activity of 
the a  subunit cleaves the terminal phosphate group from GTP, then the a  subunit 
returns to the inactive conformation and reassociates with and deactivates the Py 
dimer.
This simple system of G protein activation and deactivation is subject to 
many modulations. The GTPase activity of the a  subunit can be accelerated by the 
effector (Bernstein et ah, 1992) or by the RGS family of proteins (Dohlmann and
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Thomer 1997; Berman and Gilman 1998) which may also modulate the signalling of 
the Py dimer. Signalling is also affected by intrinsic levels of basal activity within 
receptors (Schütz and Freissmuth 1992; Lefkowitz et al., 1993) that in the absence of 
agonist can result in the activation of G proteins. It is also becoming apparent that 
receptors and G proteins do not have to dissociate to terminate signalling and exist as 
a complex prior to signalling (Chidiac 1998; Rebois et al., 1997). The simple “on or 
o ff’ model of signalling is also unlikely, with evidence pointing towards multiple 
activation states of GPCRs where agonists may regulate the levels of interaction with 
different classes of G protein and thus effectors (Krumins and Barber, 1997; Perez et 
al., 1996; Kenakin, 1995; Berg et al., 1998).
1.6.2 G protein a  Subunits
Over twenty a  subunits of the G protein heterotrimer are known to exist and 
can be divided into a number of groups based on structure and function; the Gsa 
group stimulates adenylyl cyclase, the Gia group which inhibits adenylyl cyclase, the 
Gi/ga group or the transducins and gustducins which stimulate retinal cGMP 
phosphodiesterases and presumably a related gustatory effector, the Gq« group that 
activates PLCp and non receptor tyrosine kinases, and finally the Gn/isa group that 
regulates low molecular weight G proteins of the rho family. The a  subunit in the 
inactive form has GDP bound and is complexed with the Py dimer. Activation of the 
G protein results in the exchange of GDP for GTP and the dissociation of the a  
subunit from the py dimer and the subsequent modulation of effector activity. The 
intrinsic GTPase activity of the a  subunit hydrolyses GTP to GDP and inactivates 
the a  subunit which reassociates with the py dimer and in turn deactivates its 
signalling. The wide variety of a, p and y subunits allows for specific modulation of 
a large number of effectors.
16.2.1 Gia proteins
There are six subtypes of “inhibitory” G protein, Güa, Gi2a, Gi3„, Goia, Go2a 
and Gz that range in size from 39-41 kDa. All are negatively coupled to adenylyl 
cyclase (Gilman 1987) and with the exception of G%, can also be characterised by 
their sensitivity to pertussis toxin (Katada et al., 1984). Pertussis toxin catalyses the
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ADP ribosylation of Cys^^\ a feature that Gz lacks, at the C terminal end of the Ga 
protein, a modification that prevents receptor mediated exchange of GDP for GTP 
and thus maintains the G protein in the inactive state. The G\ protein was first 
purified from rabbit liver (Bokoch et al., 1983, 1984) and human erythrocytes 
(Godina et a l ,  1983, 1984), and Goa, which has been estimated to make up 0,5% of 
brain membrane proteins (Offermans 2001), from brain tissue (Stemweis and 
Robishaw 1984; Neer et at., 1984). This group of G proteins also couple to inhibition 
of neuronal Ca '^  ^channels and stimulation of channels through release of the Py 
dimer. Members of this family are targets for N-myristoylation, the attachment of 
myristate through an amide bond to a glycine residue at a protein N terminus, a 
reaction catalysed by N-myristol coA-transferase (NMT) (Johnson et al., 1994). This 
requires a Gly^ and usually Ser^Thr^ motif. Although insufficient for stable 
membrane attachment (Peitzsch and McLaughlin 1993), this modification was found 
to be a pre-requisite for palmitoylation (Mumby et al., 1994; Hallak et al., 1994; 
Galbiati et al., 1994). The attachment of palmitate by a thioester bond to a cysteine 
residue near the N terminus of the G« protein is reversible and no clear consensus 
sequence or catalysing enzyme have been identified (Chen and Manning 2001). The 
modification can occur at the plasma membrane, an area established as having the 
capacity for palmitoylation (Dunphy et al., 1996), following weak attachment of the 
protein by myristoylation. It alone is sufficient to stably anchor the Ga subunit to the 
membrane (Shahinian and Silvius 1995). Interaction of the Ga subunit with the Py 
dimer also enhances palmitoylation in vitro (Dunphy et a l ,  1996).
The myristate and palmitate modifications have been shown to considerably 
increase the affinity of G;a subunits for the Py dimer (Jones et a l ,  1990; Linder et a l ,  
1991), with the interaction between Goa and py dimers being unstable and the Py 
dimer being unable to suppress GDP dissociation. The effects on Gia proteins are not 
as pronounced, but pertussis toxin catalysed ADP ribosylation of the a  subunit is 
reduced seven fold in the absence of myristoylation (Jones et a l ,  1990; Linder et a l ,  
1991).
Myristoylation has been shown to be a pre-requisite for Gia inhibition of 
adenylyl cyclase in vitro (Taussig et a l ,  1993). In Sf9 membranes, a myristoylated 
Gia protein from E.coli inhibited adenylyl cyclase, but a deficient protein did not. In
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rat la  cells, a similar lack of adenylyl cyclase inhibition has been recorded, but the 
effect of lack of palmitoylation was not investigated (Gallego et ah, 1992).
The 5-HTia receptor has been shown to promote palmitate exchange on 
endogenous Gia proteins in CHO cells (Chen and Manning 2000). Pulse chase 
experiments with [^H]-palmitate demonstrated that agonist activation by 8-OH- 
DPAT resulted in agonist concentration and time dependent increase in Gi« protein 
[^H]-palmitate radiolabelling. These effects were inhibited by the antagonist MPPI 
and pertussis toxin treatment, demonstrating the requirement for receptor activation.
The Gza protein was shown to be rapidly phosphorylated following the 
incubation of human platelets with a PKC-activating phorbol ester (Carlson et ah, 
1989) and this was suggested to occur at either Ser^  ^ or Ser^^ (Lounsbury et ah, 
1991). Subsequent studies identified Seri^ as a preferred site of phosphorylation with 
Se/^ also being targeted (Lounsbury et ah, 1993), It is unclear if the activation state 
of the Gza subunit affects phosphorylation, but it is clear that the interaction of the Py 
dimer inhibits phosphorylation (Fields and Casey, 1995; Kozasa and Gilmann 1996; 
Wang et ah, 1999). The converse is also true, with phosphorylation inhibiting the 
binding of Gza with the Py dimer (Fields and Casey, 1995; Kozasa and Gilmann 
1996; Wang et ah, 1999). Data for the other members of this family are not yet 
consistent with some indicating PKC or PMA induced phosphorylation (Daniel- 
Issakani et ah, 1989; Strassheim and Malbon, 1994) and others indicating a lack of 
phosphorylation (Kozasa and Gilmann 1996).
The intrinsic GTPase activity of this family of Ga subunits can be increased 
by a family of proteins know as Regulators of G proteins Signalling (RGS) proteins 
(Dohlmann and Thomer 1997; Berman and Gilman 1998). These proteins bind to the 
GTP bound form of G« subunits and stabilise the transition state resulting in an 
increase in kc&\ for GTP hydrolysis. This family of proteins will be discussed further 
in section 1.5.
A large number of G protein a  subunit knockout mice have been generated to 
analyse G protein function in the intact organism. Knockout mice for the Gia, Goa 
and Gza have been generated (Valenzuela et ah, 1997; Jiang et ah, 1998; Yang et ah, 
2000; Hendry et ah, 2000;Rudolph et ah, 1995). Goa (-/-) mice showed no gross 
morphological abnormalities and neural pathfinding and growth cone collapse was 
normal (Valenzuela et al., 1997). However, they were smaller and weaker than their
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littermates and had greatly reduced postnatal survival rates (Valenzuela et al., 1997; 
Jiang et al., 1998). These mice suffered from tremors, had occasional seizures and 
showed elevated motor activity and extreme turning behaviour. Inhibition of Ca^ "^  
channel currents in dorsal root ganglia following opioid receptor activation was 
reduced by about 30% (Jiang et al., 1998). Gza (-/-) mice in some cases showed more 
pronounced increases in motor activity compared to WT following cocaine 
administration (Yang et al., 2000) but no alteration in the acute effects of morphine 
in a different strain (Hendry et al., 2000). The effects of catecholamine re-uptake 
inhibitors on behaviour were abolished (Yang et al., 2000). G,2a deficient mice 
develop a diffuse inflammatory bowel disease and many show colonic 
adrenocarcinomas (Rudolph et ah, 1995).
1.6.2.2 Gsa proteins
There are four splice variant from the same gene encoding the Gsa protein of 
which two major isoforms are expressed, one of 45 kDa and another of 52kDa 
(Northrup et al., 1980; Stemweis et al., 1981; Hildebrandt et a l, 1984). The protein 
is characterised by is ability to stimulate adenylyl cyclase activity and also by cholera 
toxin catalysed ADP ribosylation that results in the inactivation of its GTPase 
activity resulting in persistent activation (Bourne et al., 1991). The Gsa protein is not 
myristoylated but is palmitoylated at a single site near the N terminus. It was shown 
in Gia proteins that myristoylation is a pre-requisite for palmitoylation but no 
equivalent lipid modification has been identified for the Gsa protein. Circumstantial 
evidence that a postranslational, as yet unidentified modification, does occur (not 
palmitoylation) comes from effects of Gsa to activate adenylyl cyclase (Kleuss and 
Gilman, 1997). The EC50 of Gsa purified from rabbit liver for activation of adenylyl 
cyclase was about O.lnM but for Gsa expressed and purified from E.coli it was 50nM 
(Kleuss and Gilmann, 1997). This difference was lost following removal of 30 amino 
acids from the N terminus of the Gsa protein and partitioning experiments suggested 
that the modification was hydrophobic (Kleuss and Gilman, 1997).
In pulse chase experiments with the P2 adrenergic receptor, an increase in 
[^H]-palmitate incorporation to the Gsa protein was measured (Wedegaertner and 
Bourne 1994; Mumby et al., 1994). The degree of incorporation to receptor -  Gga 
fusion proteins correlated with the intrinsic efficacy of agonists to stimulate adenylyl
41
cyclase (Loisel et al., 1999). Phosphorylation of the Gsa protein in response to PKC 
stimulation (Lounsbury et al., 1993) or PKA (Wang et al., 1999) has not been 
recorded.
Homozygous knockout mice embryos for the Gsa protein do not survive 
beyond day 10 (Yu et al., 1998). Heterozygous mice do survive and show increased 
birth weight with subcutaneous oedema, later exhibiting delayed development of 
thymus, kidney and cerebellum and ataxia and tremors (Yu et al., 1998). Most 
animals die during the early postnatal weeks and are resistant to parathyroid hormone 
(PTH).
1.6.2.3 Gt/ga proteins
Activation of the light sensitive GPCR rhodopsin results in interaction with 
Gt protein, transducin (Gilman, 1987). There are two forms of this protein, Gtia and 
Gt2a, one which is present exclusively in cone photoreceptor outer segments, Gt2a 
(Lerea et al., 1986) and one which is present in the rod outer segments, Gtia 
(Grunwald et al., 1986). These proteins activate cGMP phosphodiesterases. 
Gustducin, or Ggusta protein is thought to be responsible for the mediation of “bitter” 
taste and is assumed to modulate phosphodiesterase activity in a similar manner to 
transducin (Kolesnikov and Margolskee 1995; Mclaughlin et al., 1992; Ming et al., 
1998; Ruiz-Avila et al., 1995; Spielman 1998; Wong et al., 1996; Y an et al., 2001). 
It was suggested that the y subunit that interacts with Ggusta is Y13 as it has been 
shown to colocalise with the G^ subunit (Huang et al., 1999). The Ggusta protein has 
also been shown to colocalise with the novel family of 7TM bitter taste receptors 
(Adler et al., 2000; Chandrashekar et al., 2000).
Heterozygous knockout mice for the Gtia protein appear to be largely normal, 
with homozygotes demonstrating defective light responses and developing mild 
retinal degeneration with age (Clavert et al., 2000). Ggusta knockout mice show 
decreased electrophysiological and behavioural responses to bitter and sweet agents, 
indicating a role for Ggusta in the perception of “sweet” stimuli also, but responses to 
sour and salty stimuli were identical to those of WT mice (Lindemann 1996; 
Kinnamon and Margolski 1996).
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1.6.2.4 Gqa proteins
There are five members of the Gqa family of a  subunits, Gqa itself, Gna, 
Gwa, Gisa and Giea (Pang and Stemweis 1990). These proteins are pertussis toxin 
insensitive, lacking the Cys residue that the toxin targets for ADP ribosylation. They 
are positively coupled to PLC-p and have lower rates of GTPase activity that those 
of the Gia and Gga proteins (Fields and Casey 1997). Gqa and Gna are fairly 
ubiquitously expressed (Fields and Casey 1997), with Gwa expressed predominantly 
in spleen, lung, kidney and testis (Wilkie et a l, 1991) and Gi5« and Gi^a expressed in 
cells of myeloid and lymphoid lineage (Wilkie et al., 1991; Amatruda et al., 1991). 
The members of this family are not myristoylated but are palmitoylated (Chen and 
Manning 2001), and similar to Gga, lipid modifications other than palmitoylation is 
suspected (Hepler et al., 1996). It has also been suggested that interaction with the Py 
dimer is a pre-requisite for palmitoylation, as mutants unable to bind Gpy were not 
palmitoylated (Evanko et al., 2000). A modification that allowed myristoylation 
restored palmitoylation, but not Gpy interaction and it was suggested that Gpy acted 
for Gqa in the same way as myristoylation does for Gia (Evanko et al., 2000). The 
incorporation of palmitate into Gq« proteins increases in response to receptor 
activation, both with serotonin receptors and a-adrenergic receptors in vitro (Bhamre 
et al., 1998; Gurdal et al., 1997), as does tyrosine phosphorylation following 
carbachol activation of the Mi muscarinic receptor (Umemori et al., 1997).
Gq/ 11 a knockout mice die at embryonic day 11 due to severe thinning of the 
myocardial layer of the heart (Offermans et a l, 1998), with both the trabecular 
ventricular myocardium and the subepicardial layer being underdeveloped. The 
receptors involved in the activation of Gq/ua during embryonic development are 
unknown. Knockout mice of Gi5a, the murine equivalent of Gi6a, showed no cellular 
defects apart from a reduced effect of C5a in macrophages (Davignon et a l, 2000), 
showing normal hematopoiesis and normal morphology and function of major 
immunological tissues. This may be surprising as the Gisa, and the human Giea, are 
exclusively expressed in hemapoietic cells (Amatruda et a l, 1991; Wilkie et a l, 
1991).
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1.6.2.5 Gi2/i3ot proteins
This family of G protein a  subunits are involved in the activation of the rho 
family of low molecular weight G proteins that affect cytoskeletal structure (Prasad 
et ah, 1995; Buhl et a l, 1995). Mutationally activated Gi2a and Gisa proteins have 
been implicated in the induction of mitogenesis and neoplastic transformation in 
N1H3T3 and Rat-1 cells (Xu et a l, 1993; Voyno-Yasenetskaya et a l, 1994). In 
contrast to this is their involvement in the induction of apoptosis and INK mediated 
by two MAPKK kinases, MEKKl and ASKl (Berestetskaya et a l,  1998). This 
apoptosis could be inhibited by Bcl-2 (Berestetskaya et a l, 1998). Neither Gi2a nor 
Gi3a are myristoylated but they are palmitoylated, with G ^a having one potential site 
and Gi3a having two (Chen and Manning, 2001). Both Gi2a and Gisa are 
phosphorylated, a process that can be induced for Gi2a following exposure of 
N1H3T3 cells to the PKC activator, PMA, most likely at Ser^ ,^ a site that strongly 
resembles Ser^  ^ in G%a (Kazasa and Gilmann 1996). The situation for Gisa is less 
clear. It also appears to be a substrate for PKC mediated phosphorylation but 
possibly requires different conditions (Kozasa and Gilmann, 1996; Offermanns et a l, 
1996).
Gisa knockout mice terminate about midgestation and show defects in the 
vascular system, most prominently in the yolk sac and the head mesenchym 
(Offermanns et a l, 1997) with angiogenesis including remodelling of existing 
endothelial cells being severely disrupted even in the presence of Gi2a expression. 
Gi2a knockout mice showed no obvious defects.
1.6.3 G protein Py Subunits
The other members of the G protein heterotrimer are the P and y subunits. 
Initially seen as only a docking protein for Ga subunits it has been known for some 
time that release of the Gpy dimer following receptor activation results in the 
modulation of a variety of effector proteins (Clapham and Neer 1997). There are 
known to be 5 G protein P subunits and at least 12 y subunits (Holler et a l, 1999) 
making for a very large number of possible G protein apy trimer combinations. The 
Gpy dimer functionally acts as a monomer as the two subunits cannot be separated 
under nondenaturing conditions (Holler et a l, 1999). The Py dimer has been shown.
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in the presence of activated Gsa, to increase the activity of type II adenylyl cyclase 
isoforms (Taussig et ah, 1993; Sunahara et ah, 1996) and inhibit type 1-like adenylyl 
cyclase as well as stimulate PLC-p (Camps et ah, 1992, 1993; Smrcka and Stemweis
1993). The Gpy dimer can also activate G protein regulated inward rectifying 
(GIRK) channels (Wickman et ah, 1994) and inhibit neuronal Ca^ "^  channels 
(Herlitze et ah, 1996, 1997; Zamponi et ah, 1997). In a less defined mechanism they 
can also activate MAP kinase (Crespo et ah, 1994; Van Biesen et ah, 1995; Lopez- 
llasaca et ah, 1997). The Gpy dimer has a role in the regulation of receptor 
desensitisation, binding and redistributing G protein receptor kinases (GRKs) at the 
membrane (Premont et al., 1995; Lohse 1993) and activating dynamin 1, a GTPase 
protein involved in the pinching off of clathrin coated vesicles from the plasma 
membrane (Lin and Gilmann 1996). The dimer has also been shown to activate the 
nonreceptor tyrosine kinases Btk and Tsk (Langhans-Rajasekaran et ah, 1995).
The association of the G protein a  subunit and the Py dimer has two 
functions. The Py dimer maintains the G« subunit in a conformation that slows the 
kon rate for GDP release and maintains the protein in an inactive state (Holler et ah, 
1999). The G« subunit has the same effect on the py dimer. Following GTP 
hydrolysis, the Ga subunit returns to a stmctural confomation that favours Gpy 
binding and thus deactivates Gpy modulation of effector proteins (Holler et ah, 1999).
The Gp subunits are approximately 340 amino acids in length with predicted 
molecular weights between 35 and 39 kDa and share a high degree of homology with 
each other (Clapham and Neer 1997). Not all Gp and Gy protein combinations appear 
to be possible. While Gpi can combine with all of the known Gy subunits, the Gp% 
protein cannot combine with Gyi (Clapham and Neer 1997).
The G protein py dimer is modified post-translationally. The Gy^ subunit is a 
substrate for PKC both in vitro and in intact cells (Morishita et ah, 1995; Yasuda et 
ah, 1998). The Gyn subunit is the only member of the y subunit family to contain a 
SSK motif near its N terminus, the first serine of which is the proposed site of 
phosphorylation, that is phosphorylated by both PKCa and p, less well by ô and e, 
and not at all by Ç in vitro (Morishita et ah, 1995; Yasuda et ah, 1998). This 
modification was found to increase the affinity of the Gpyi2 dimer for Goa and also 
Gia (Morishita et ah, 1995), that lead to an increase in high affinity receptor binding
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(Yasuda et al., 1998). It was also found that this phosphorylation lead to a decrease 
in stimulation of adenylyl cyclase type II but had no effect on the activity of PLC-P 
(Yasuda oZ., 1998).
Other modifications that have been reported include prénylation. Gy subunits 
contain a CAAX motif near the C terminus that directs this modification, but the 
form of prénylation varies, with Gyi being famesylated and Gy% being 
geranylgeranlyated (Clapham and Neer, 1997). Removal of the Cys residue that is 
the target for modification results in mutant Gpy dimers not being properly targeted to 
the plasma membrane and being found in the cytosol (Muntz et al., 1992; Spiegel et 
al., 1991) indicating a membrane anchorage role for the prénylation.
Gpy subunits enhance the interaction between receptors and G« subunits and 
have been shown to bind directly to receptors, for example p-adrenergic receptors 
and rhodopsin (Heither et al., 1992; Philips and Cerione 1992; Philips et al., 1992; 
Higashijima et al., 1987). The composition of the Py dimer also effects the 
interaction of G« subunits with receptors. Gpi with Gyi can support the binding of Gt« 
and rhodopsin, but Gpiya cannot (Kisselev et al., 1995). So far there have been no 
reports of either Gp of Gy subunit knockout mice (Offermanns et al., 2001).
1.7 Regulators of G protein Signalling (RGS) Proteins
It was thought that stimulation of GPCRs involved agonist binding a receptor 
that bound a G protein, the activation of which resulted in the modulation of a second 
messenger system. Recently a fourth component of this signalling cascade was 
identified, the regulators of G protein signalling (RGS) proteins (Dohlman and 
Thomer 1997; Koelle 1997; Berman and Gilman 1998). These proteins add another 
level of modulation by binding to and increasing the intrinsic level of GTPase 
activity of the G protein a  subunit. Initially these proteins were recognised in lower 
eukaryotes as negative regulators of G protein signalling (Dohlman et al., 1996; Yu 
et al., 1996; Koelle and Horvitz, 1996). However, with a family of mammalian RGS 
proteins of nearly 30, these proteins have been found to fulfil roles other than as 
GTPase activating proteins (GAPs) (Hepler, 1999).
The common structural feature of all RGS proteins is an approximate 125 
amino acid RGS domain (Berman and Gilman, 1998; Hepler, 1999; De Vries et al..
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Figure 1.6 Structural Features of RGS Proteins
All RGS proteins contain an approximate 120 amino acid RGS domain and some 
members contain other structural features including: PDZ domain (PSD-95, disc- 
large and zo-1), DEP domain (dishevelled, egI-10 and pleckstrin), GGL domain (G 
protein gamma subunit like), PTB domain (phosphotyrosine binding), GRK domain 
(G protein coupled receptor kinase) and Gpy binding (G protein Py subunits).
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2000; Burchett, 2000). The domain is responsible for the GTPase activating property 
of the proteins, but within the family it has only between 45-80% sequence 
homology (Burchett, 2000). The RGS domain contains three distinct highly 
conserved GH (GAIP or GOS Homology) domains that in mammalian RGS proteins 
are nearly contiguous (DeVries et al., 1995; Druey et at., 1996; Koelle and Horvitz,
1996). The proteins can also act as G protein antagonists, inhibiting the binding of 
the Ga proteins to its effector systems (Hepler et al., 1997; Tesmer et al., 1997). In 
some cases this may actually prolong the signalling of Gpy dimers by preventing their 
reassociation with inactive Ga-oop (Bunemann and Hosey 1998).
RGS proteins bind to the activated GTP bound form of Ga (Hepler et al., 
1997; Tesmer et al., 1997; Popov et al., 1997), the structural features of which were 
investigated by determination of the crystal structure of RGS4 protein bound to Giia 
with a stable GTP substitute (GDP-A1F4 ) in the GDP/GTP binding pocket (Tesmer 
et al., 1997). The RGS domain of RGS4 was found to form nine oc-helices that fold 
into two subdomains with the hydrophobic amino acids at the core of these domains 
being involved in structural stability and GAP activity (Tesmer et al., 1997; 
Srinivasa et at., 1998). Interaction between the RGS domain and the Ga protein 
occurred at three sites necessary for GDP/GTP and effector binding (Burchett, 2000). 
The amino acids Thr^^  ^ and Gly^^  ^ on Giia are essential for high affinity Ga-RGS 
binding (Tesmer et al., 1997; Dibello et al., 1998). Thr^^  ^is conserved in the Gia and 
Gqa G protein families and not in Gsa or Gi2a which may explain why so far no 
interactions between RGS proteins and the latter two Ga protein families have been 
recorded (Burchett et al., 2000). The preference for binding to the GTP bound form 
of the Ga protein suggests that the RGS protein stabilises the Ga formation required 
for GTP hydrolysis (Berman et al., 1996; Srinivasa et al., 1998), and this interaction 
may also have a stabilising effect on the RGS protein (de Alba et al., 1999). 
Deletions of small portions of the RGS domains of RGS4, RGS 10 or GAIP abolish 
their GAP activity in vitro (Faurobert and Hurley, 1997; Popov et al., 1997; 
Srinivasa et al., 1998).
A large degree of promiscuity of RGS protein for Ga is a feature of in vitro 
studies on this interaction. For example, Gia proteins have been shown to interact 
with RGSl, RGS3, RGS4, RGS5, RGS 10, RGS 12, RGS 16, RET-RGSl and RGS- 
GAIP in vitro (Hunt et al., 1996; Watson et al,, 1996; Chen et al., 1997; Faurobert
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and Hurley, 1997; DeVries et al., 1995; Berman et al., 1996; Hepler et al., 1997; 
Snow et al., 1998). Interactions of RGS proteins and other G« families have been 
demonstrated with Gq« interacting with RGS2, RGS4 and RGS-GAIP (DeVries et 
al., 1995; Berman et al., 1996; Hepler et al., 1997; Heximer et al., 1997) and Gta 
interacting with RGS9 and RGS9S (He et al., 1998).
As well as the GAP activity of the RGS proteins modulating the effector 
signalling of the Ga subunits, effects on Gpy dimer signalling have been recorded. 
Expression of RGS proteins in mammalian cell lines attenuates ERK and p38-MAPK 
signalling by the Gpy dimer released from Gi« or Gq« activation by accelerating the 
reassociation of the G a  and Gpy subunits (Buckbinder et al., 1997; Huang et al., 
1997; Ingi et al., 1998; Zhang et al., 1999). The Gpy dimer can also modulate the 
activity of GIRK and N-type Ca^ '*' channels. The inhibition of N-type Ca^ '*' channel 
opening by Gpy is attenuated in the presence of RGS proteins (Melliti et al., 1999). In 
contrast, the effects of RGS proteins on Gpy dimer activation of GIRK channels is not 
as clear. The expression of a number of RGS proteins results in the acceleration of 
both GIRK channel activation and deactivation independent of a reduction in peak 
current (Doupnik et al., 1997; Saitoh et al., 1997, 1999; Kovoor et al., 2000). If the 
only role of the RGS protein was as a G« subunit GAP protein then both the 
activation and peak current would be diminished due to the accelerated reassociation 
of G a  and Gpy. The acceleration of the activation rate has been speculated to be either 
due to acceleration of the dissociation of activated Ga from py, or by antagonising 
the reassociation of G^ and py (Burchett et al., 2000).
The RGS domain is what groups these proteins into a family but many of the 
proteins have large N and C terminal domains that fulfil other cellular functions. A 
few RGS proteins contain little other than the RGS domain, e.g. RGSl, RGS2 and 
RGS4. Others have further functional domains, like the GRKs (G protein receptor 
kinases) that contain a kinase domain and Gpy binding domain, or RGS proteins 6,7, 
9 and 11 that contain both DEP (dishevelled, Egl-IO, pleckstrin) and GGL (G protein 
gamma like) domains (Hepler, 1999). The roles of GRK protein kinase and 
Gpy binding domains in the desensitisation of GPCR signalling have been clearly 
defined (Krupnik and Benovic, 1998) but their more recently discovered RGS 
domain, that would appear to complement their primary function, has yet to be 
characterised functionally. The role of the DEP domain that is found in a large
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number of unrelated proteins is unclear (Ponting and Bork, 1996), but is predicted to 
be involved in targeting DEP containing proteins to GPCRs. For RGS proteins that 
do not contain traditional membrane anchorage modification such as palmitoylation 
or myristoylation, the DEP domain may allow targeting to the membrane and 
specificity of interaction by binding only to specific DEP binding proteins. For 
example, both RGS7 and RGS9S, which lack membrane spanning domains or 
membrane associated modifications, complex with the G protein Ps subunit 
(Khawaja et al., 1999; Watson et al., 1994; Cowan et al., 1998).
The GGL domains of RGS proteins also appear to have a role in specificity of 
protein interactions. RGS proteins 6, 7, 9 and 11 contain GGL domains that interact 
strongly with Gp subunits (Snow et ah, 1998), particularly with Gpg. Both the RGS 
proteins 6, 7, 9 and 11 and Gpg are either exclusively or highly expressed in the brain 
and retina (Gold et al., 1997; Granneman et al., 1998; He et al., 1998; Snow et a l, 
1998; Burchett, 2000). The co-expression of Gpg and either RGS7 or RGS9 in 
Xenopous oocytes showed increased activation kinetics of GIRK channels over 
expression of either RGS protein or Gps alone (Kovoor et al., 2000), but it is unclear 
if an interaction between these proteins was involved.
Other methods of RGS protein interaction with the plasma membrane have 
been indicated. RGSl contains three motifs for possible myristoylation in its N 
terminus (Denecke et al., 1999) that could result in weak anchorage of the protein to 
the membrane, but further modification such as palmitoylation would be required for 
stable anchorage (Resh, 1999). A number of RGS proteins (RET-RGSl, GAIP and 
RGS 17) contain cysteine “rich” regions that could be targeted for palmitoylation 
(DeVries et al., 1996; Faurobert and Hurley, 1997; Wang et al., 1998; Zheng et al., 
1999). RGS-GAIP is palmitoylated in this region and it has been suggested that the 
modification may play a role in membrane anchoring of the protein to clathrin coated 
vesicles where RGS-GAIP was found to localise (DeVries et al., 1996).
Palmitoylation also occurs on Cys residues in regions rich in basic amino 
acids. RGS4, RGS5 and RGS 16 all contain such regions and two cysteine residues, 
Cys^ and Cys^^ (Burchett, 2000). RGS4 is palmitoylated at these residues and is a 
membrane anchored RGS protein, however palmitoylation deficient mutants are still 
membrane anchored and have GAP activity (Srinivasa et al., 1998). RGS 16 is also 
palmitoylated at Cys2 and Cys^^ and again this is not essential for membrane
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association (Chen et a l, 1999; Druey et ah, 1999), but palmitoylation deficient 
mutants in this case decrease the GAP activity of the protein (Druey et al., 1999).
RGS proteins have been indicated as having roles in a number of disease 
states. The inactivation of p53 is a common defect in human cancers and in colon 
carcinoma cells the expression of p53 suppressor protein is associated with an 
upregulation in RGS 16 (Buckbinder et a l, 1997). Levels of RGS2 mRNA have been 
found to be markedly upregulated in the CNS following seizures in models of 
epilepsy (Ingi et al., 1998). Other RGS proteins may also have roles, such as RGS7 
in autosomal-dominant polycystic kidney disease (Kim et al., 1999) and axin in 
familial adenomous polyposis (Kishida et a l, 1998; Behems et al., 1999). Regulation 
of GPCR -RGS protein interaction may have a significant role in many future 
therapeutic regimens.
1.8 Project Aims
As has been indicated a more complete understanding of the 5-HTia receptor 
and its regulation of the signal transduction mechanisms that it couples to could help 
in the development of new therapeutic regimes for a variety of diseases. To this end 
the aims of this project were fourfold: (1) to characterise the regulation of adenylyl 
cyclase by 5-HTia receptor-G protein fusions, (2) to determine the role of Cys^^  ^
mutations in the affinity of agonist activated 5-HTia receptor-G proteins interactions, 
(3) to examine the effects of a range of concentrations of RGSl and RGS 16 proteins 
on the high affinity GTPase activity of membranes expressing the 5-HTia receptor-G 
protein fusions, (4) to characterise the contribution of RGS proteins in the design of a 
robust high affinity GTPase assay for ligand characterisation using the 5-HTia 
receptor-G protein fusions.
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Chapter 2
Materials and Methods
Materials and Methods
2.1 Materials
The materials used were obtained from the following suppliers;
Alexis Corporation^ San Diego, CA, USA 
DTT
American Tissue Culture Collection, Rockville, USA 
Human embryonic kidney (HEK293) cells
Amersham Pharmacia Biotech UK Ltd., Buckinghamshire, UK 
[’m-WAY100635, [^H]-8 -OH-DPAT, [^H]-Adenine, Glutathione Sepharose® 4B, 
full range Rainbow™ molecular weight marker, anti rabbit Ig horseradish peroxidase 
linked antibody (from Donkey)
BDH Chemicals Ltd., Poole, UK
NaCl, MgClz, acetic acid, KOH, CaCh, MnCL
BloWhittaker Molecular Applications, Rockland, ME, USA
SeaKem® LE Agarose
Camlab Ltd., UK
Plastic binding tubes PS/T400-3A
Corning, Horseheads, NY 14831, USA
5,10 and 25ml graduated sterile tissue culture plastic pipettes, pyrex borosilicate 
glass binding tubes
Costar, Cambridge, MA, USA 
75cm^ and 150cm^ tissue cult
6,12 and 24 well tissue culture plates, cryovials
ure flasks, 60mm and 100mm tissue culture dishes.
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Eppendorf, Hamburg, Germany 
96 Well Deepwell plates
Fisher Scientific, Loughborough, Leicestershire, UK 
HEPES, EDTA, DMSO, methanol, ethanol, concentrated HCl
GIBCO BRL Life Technologies, Paisley, UK
LipofectAMINE, OptiMEM, Glutamine, BL21-SI Competent Cells
Invitrogen BV, Groningen, Netherlands 
NuPAGE® Novex high-performance pre-cast gels
Iwaki, Scitech Division, Asahi, Japan
IScvc? and 150cm^ tissue culture flasks, 60mm and 100mm tissue culture dishes,
6,12 and 24 well tissue culture plates
Konica, Tokyo, Japan
X-ray film
NEN Life Science Products Inc., Boston, USA 
pH]-MPPF, [^^P]-GTP
Novagen, Madison, WI, USA
Benzonase® Nuclease, bugbuster™ protein extraction reagent
Oxoid Ltd., Hampshire, UK
Tryptone, yeast extract
Packard Instruments BV, Netherlands
Ultima Gold XR liquid scintillation cocktail, Optiplate™ 96 well plates, 
microscint™
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Pierce, Illinois, USA
SuperSignal® Chemiluminescent Substrate, Coomassie® protein assay reagent
Premier Brands UK Ltd., Merseyside, UK 
Marvel
Promega, Southampton, UK
Wizard™ Miniprep Kit, restriction enzymes, G-418 sulphate
Qiagen, Crawley, West Sussex 
Qiagen® plasmid maxiprep kit.
Roche Molecular Biochemicals/Boehringer-Mannheim, Germany
App[NH]p, creatine phosphate, creatine kinase, GTP, tris, bovine serum albumin 
fraction V, DNA molecular weight marker X (0.07-12,2kbp), restriction enzymes, 
IPTG
Schleicher and Schuell, Dassel, Germany 
Protran® nitrocellulose transfer membrane
Sigma-Aldrich Company Ltd., Poole, Dorset, UK
DMEM, newborn calf serum, trypsin, dowex AG50 W-X4 (200-400mesh), 
imidazole, forskolin, 5-HT, WAY 100635, ampicillin, ouabain, pertussis toxin, 
DMSO, NaCL, trichloroacetic acid, coomassie blue, IB MX, activated charcoal, ATP, 
cAMP, ascorbic acid, alumina, glutathione, bicinchoinic acid, Tween20
Tocris, Bristol, UK 
8 -OH-DPAT hydrochloride
Whatman International Ltd., Maidstone, UK 
Branded GF/C Glassfibre filters
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(+) Butaclamol hydrochloride, thioridazine hydrochloride, haloperidol base, 
chlorpromazine hydrochloride, spiperone hydrochloride and methiothepine maleate 
were generous gifts from Dr. Mark Millan, Servier, Centre de Recherches de 
Croissy, Croissy-sur-Seine, France.
ONI antibody was generated against a synthetic peptide corresponding to Goa amino 
acids 1-16 of the mature peptide (Mullaney and Milligan 1989).
l i e  antibody was generated against a synthetic peptide corresponding to G^a amino 
acids 159-168 of the mature peptide (Green et ah, 1990).
2.2 Molecular Biology
2.2.1 Preparation of BL21-SI/XL1 Blue Competent Ceils
An overnight culture of BL21-SI/XL1 Blue bacteria was grown in 5ml of LB 
broth. The following day the culture was used to inoculate 100ml of LB broth that 
was grown with aeration until the optical density at 550nM reached 0.48. The culture 
was chilled on ice for 10 minutes and spun at 1200g for 10 minutes at 4°C in sterile 
2x50ml disposable plastic tubes. The supernatant was carefully removed and the 
cells gently resuspended in 20ml of buffer 1 (filter sterilised 0.03M KAc, O.IM 
RbCL, O.OIM CaCl2, 0.05M MnCL, 15% glycerol, pH 5.8 with acetic acid). The 
suspension was chilled on ice for 5 minutes and spun at 1200g for 10 minutes at 4°C. 
Following careful removal of supernatant the cell pellets were resuspended by 
pipetting in 2ml of buffer 2 (filter sterilised lOmM MOPS pH 6.5, 0.075M CaCL, 
O.OIM RbCL, 15% glycerol, pH 6.5 with concentrated HCl). Following 15 minutes 
on ice the samples were aliquoted and stored at -80°C until required.
2.2.2 Preparation of Antibiotic Agar Plates
LB agar (1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl, 
and 1.5% (w/v) agar) was autoclaved and allowed to cool before the addition of 
ampicillin (50|Lig/ml). The liquid LB agar was decanted into 90mm Petri dishes and 
allowed to solidify prior to storage at 4°C until required.
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2.2.3 Transformation of Competent BL21-SI/XL1 Blue Cells with
Plasmid DNA
To an aliquot of 50|Jl1 competent bacteria that have been allowed to thaw on 
ice, lOng of DNA was added, and incubated on ice for 15 minutes. The cells are 
incubated at 42°C for 90 seconds and returned to ice for 2 minutes. 450pl of LB 
broth was added to the reaction and incubated at 37°C for 45 minutes in a shaking 
waterbath. 2 0 0 p,l of the reaction was spread onto agar plates containing ampicillin 
that were incubated inverted overnight at 37°C and transformed colonies selected 
from the following day.
2.2.4 Preparation of Plasmid DNA
Colonies transformed using XLl Blue bacteria were picked and grown 
overnight in 5ml of LB broth containing ampicillin (50pg/ml). Plasmid DNA was 
prepared using the Promega™ Wizard Plus SV miniprep purification system as per 
manufacturers instructions. Preparation of larger quantities of DNA was 
accomplished by transferring the 5ml overnight culture into 500ml of LB broth and 
allowing a further overnight period of growth. The DNA was subsequently purified 
using the Qiagen plasmid maxi-prep kit. DNA concentration was determined by 
measuring the absorbance of a 1 : 2 0 0  dilution of the sample at 260nm where 1 
absorbency unit was equivalent to 50p.g/ml of double stranded DNA.
2.2.5 Plasmid DNA Digestion
Using the appropriate restriction enzymes (2-4 units) and buffer as per 
manufacturers instructions, lp,g of DNA was digested in a lOjitl volume. Agarose gel 
(1% w/v) electrophoresis was used to analyse the DNA. The gel contained 40|ig/ml 
ethidium bromide. Samples were diluted 1:3 with loading buffer and the gel run at 
100 volts for 20-30 minutes in IxTAE buffer (40mM Tris-acetate, ImM EDTA, 
glacial acetic acid pH 8.0).
2.2.6 TaqMan QrtPCR
TaqMan is PCR-based assay for high-throughput quantitation of nucleic acid 
sequences. It combines thermal cycling and fluorescence detection enabling cycle- 
by-cycle detection of the increase in the amount of PCR product. Forward primers.
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reverse primers and probes were designed for RGS proteins 2, 3, 4, 9 and GRK2 (see 
table 1) and supplied by Genosys in desiccated form. These were dissolved in TE 
buffer (lOmM Tris HCl, O.lmM EDTA pH 8.0). PCR conditions for the experiments 
were established using RGS protein cDNA. Three different primer ratios were 
assayed in triplicate, 50:50, 300:300 and 900:900 (nM), with the probe concentration 
remaining constant at lOOnM and lOng of cDNA used per reaction. Each reaction 
was compared to a no-template control (NTC). The assay was carried out in a 
96well-plate format using a Perkin Elmer ABI Prism™ 770 Sequence Detector 
running Sequence Detector vl.6.3 software. Each reaction contained 2x Real Time 
Taqman™ Mastermix containing dNTPs (including dUTP), Hot Goldstar DNA 
polymerase, MgCla (5mM final), Uracil-N-glycosylase, stabilisers and Rox Passive 
Reference. The thermal cycler conditions were as follows: stage 1, 2 minutes at 
50°C, stage 2, 10 minutes at 95°C, and stage 3, 15 seconds at 95°C followed by 1 
minute at 60°C repeated 40 times.
Table 2.1 Primers and Probes for Taqman QrtPCR
RGS Protein Sequence
RGS2 Forward primer : GATTGGAAGACCCGTTTGAGC 
Reverse primer : CAGGAGAAGGCTTGATGAAAGC 
Probe : CTGGGAAGCCCAAAACCGGCAA
RGS3 Forward primer : CTGGTTCACAAATACGGGTTAGC 
Reverse primer : TCACAAGCCAACCAGAACTCC 
Probe : TGTTCCAAGCCTTCCTTCGCACTGA
RGS4 Forward primer : TTCATCTCAGTCCAGGCAACC
Reverse primer ; CTTCTGGGCCTCATCAAAGC
Probe : ACCAGGGAAGAGACAAGCCGGAACAT
RGS9 Forward primer : TGATGGACTCGGAGGATGC
Reverse primer : GCATTTGGGTGACATTTGAAGA
Probe : TGTAAGGAAAGAGGCAGGCTGAGTTGGG
GRK2 Forward primer : CGATAAGTTCACACGGTTTTGC 
Reverse primer ; GTATGACATGCAGACAATGAATGG 
Probe : CCGGAAGCGTGACACAGGCAAGAT
Following establishment of PCR conditions the assay was run using DNA 
from untransfected HEK293 cells. Standard curves for the RGS proteins were run at 
seven cDNA concentrations (lOng/jxl, Ing/jil, lOOpg/^l, lOpg/p.1, lpg/p.1 and 
lOOfg/jLtl) alongside the HEK293 DNA sample. 18S ribosomal DNA expression was 
examined as a reference.
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2.3 GST Fusion Protein Preparation
2.3.1 Preparation of Protein
Colonies of transformed BL21-SI bacteria were selected and grown overnight 
in 10ml of LB broth containing ampicillin (50pg/ml). The following morning, this 
culture was added to 500ml of LB broth containing ampicillin (50 pg/ml) and grown 
with aeration until an OD600 of 0.2 was reached. 500pl of IM IPTG was added and 
the culture grown for a further 4 hours with aeration after which the sample is cooled 
on ice for 10 minutes. 1ml samples that were taken prior to IPTG addition, and after 
2 and 4 hours incubation, were spun at 20000g to pellet the cells and 100ml loading 
buffer added.
The large culture was spun for 15 minutes at 6000g to pellet the cells and the 
supernatant discarded. The pellet was resuspended in Bugbuster™ protein extraction 
reagent (5ml per gram of wet pellet), 2-4pl of Benzonase® nuclease enzyme added, 
left on ice for 1 hour and sonicated 2x30 seconds at 60kHz using a probe sonicator. 
The main sample was spun at 20000g for 30 minutes and the supernatant transferred 
to a sterile 50ml tube containing 300pl of washed (2x1 ml with sterile PBS) 
glutathione Sepharose® 4B gel. DTT was added to a final concentration of 5mM and 
the sample spun on a rotary wheel for 30 minutes at 4°C. The mixture was spun at 
500g for 5 minutes, the supernatant removed and stored at -80°C, and the glutathione 
sepharose® 4B gel washed twice with 5ml of sterile PBS. The pellet was 
resuspended in 300pl of lOmM glutathione, mixed by gentle inversion and left on ice 
for 5 minutes. The sample was spun for 3 minutes at 500g and the supernatant 
removed and kept on ice. The addition of glutathione and its removal was repeated 
five times. A IOp.1 sample from each elution was removed and 90pl of SDS-PAGE 
loading buffer added.
2.3.2 Polyacrylamide Gel Electrophoresis
Samples were boiled at IOO°C for five minutes in loading buffer (Tris 60mM, 
Glycerol 5%, DTT 50mM, SDS 80mM at pH 6 .8 ) and loaded onto precast 
NuPAGE® Bis-Tris 4-12% gradient gels alongside full range Rainbow™ molecular 
weight markers. A constant 200volts was applied to the gel in MOPS SDS running 
buffer (3-(N-morpholino)propane sulfonic acid 50mM, Tris base 50mM, SDS
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3.465mM, EDTA 1.025niM at pH 7.7) with variable AMPs until the dye front 
reached the end of the gel. The stacker was removed and the protein stained for using 
Coomassie Blue.
2 .3 .3  Coomassie® Protein Assay
Samples of purified RGS-GST protein were diluted 1:5, 1:10 and 1:20 to a 
final volume of 20pl using PBS and 480|al of Coomassie® reagent added. The 
mixture was vortexed briefly and triplicate 100p,l aliquots added to a 96 well plate 
and the OD at 595nm read. Calculation of protein concentration was by comparison 
to a BSA standard curve.
2.4 Cell Culture
2.4.1 Cell Maintenance
HEK293 cells were grown in DMEM supplemented with 10% NBCS and 1% 
L-glutamine in a 37°C humidified 5% CO2 atmosphere. DMEM for cells stably 
expressing the 5-HTia receptor and G protein fusion constructs also contained G-418 
(Img/ml). Confluent cells were passaged at 1:10 by the addition of 1ml of trypsin to 
detach the cells, 9mls of medium added and the cells pipetted gently to resuspend 
evenly.
2.4.2 LipofectAMINE Transfections
HEK293 cells were transiently transfected at approximately 80% confluency 
in lOcm^ dishes. lOjig of DNA and 30|4l of lipofect AMINE reagent were mixed 
gently with 450p,l of OptiMEM and incubated for 45minutes. During this period, cell 
monolayers were washed with OptiMEM and medium replaced with 9.5ml of 
Optimem. The DNA-LipofectAMlNE mix was added drop wise to the plates and 
returned to the incubator for 3 hours. The transfection medium was replaced with 
fresh DMEM and the cells analysed in the following 24-48 hours.
Stable transfection followed the same protocol as transient transfection with 
the exceptions, cells were transfected at 40-50% confluency, using serum free 
medium, and the cells were washed with serum free medium prior to addition of the
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DNA-lipofectAMINE mix. Following incubation, the transfection mix is replaced 
with serum free medium and incubated for 48 hours. This medium is replaced with 
DMEM containing NBCS and L-glutamine with G-418 (Img/ml) and changed daily 
until distinct colonies of cells could be observed. Colonies were picked and grown 
and selected following determination of receptor expression levels by single point 
pseudo-saturation radioligand binding.
2.5 Radioligand Binding
2.5.1 Preparation of Cell Membranes
Cells were grown to confluency in either 75cm^ or ISOcm'  ^flasks the medium 
discarded and harvested by scraping using disposable cells scrapers. The cells were 
resuspended, washed using 2x1 Omis of ice cold PBS and spun for 5 minutes at lOOOg 
in a refrigerated centrifuge. The supernatant was discarded, the pellet resuspended in 
1ml of TE buffer (lOmM Tris, 5mM EDTA pH 7.5 @ 4°C) and the mixture 
homogenised by 30 strokes of a chilled glass-on-glass Dounce homogeniser. The 
homogenate was spun for 6  minutes at 500g resulting in two fractions. The upper 
supernatant was removed and spun at llOOOOg for 30 minutes and the lower fraction 
discarded. The resultant pellet was resuspended in 300|il of TE buffer and following 
determination of protein concentration, diluted to l|4g/p.l, aliquoted and stored at -  
80°C until required. Cells were routinely treated with 25ng/ml pertussis toxin.
2.5.2 Saturation Radioligand Binding
Specific radioligand binding over a range of concentrations determined 
receptor expression levels in membrane samples. Triplicate reaction mixtures were 
set up containing 2.5|Ag of protein, radioligand ranging in concentration from 0.02nM 
to lOnM, with non-specific binding being determined by the addition of lOOfxM 5- 
HT. The samples were incubated at 30°C for 60 minutes and subsequently harvested 
through a Branded GF/C glassfibre filter using a Branded cell harvester in a TE 
buffer (75mM Tris, 5mM EDTA pH 7.5). Filter discs were removed and soaked for 
at least 1 hour in 5ml of scintillant prior to counting of radioactivity on a Packard 
1900TR Liquid Scintillation Analyser.
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specific binding was determined by the subtraction of non-specific counts 
from the total counts and the results plotted against radioligand concentration. Using 
the data analysis package Graphpad Prism total receptor expression {B„jax) and the 
equilibrium dissociation constant (Kd) were calculated. An example of this 
calculation can be found in the appendix (Section 9.1).
2.5.3 Competition Radioligand Binding
Triplicate reaction mixtures were set up containing 2.5pg of protein, 
radioligand at a concentration equivalent to its for the receptor, and a range of 
concentrations of competing “cold” ligand usually from InM to lOOpM. Non 
specific binding was determined by the addition of 5-HT (lOOpM). Samples were 
incubated for either 1 hour for [^H]-WAY100635 or 30 minutes for [^H]-8 -OH- 
DPAT or [^H]-MPPF at 30°C prior to filtration as in the saturation binding assay. 
Data were analysed using Graphpad Prism, plotted as % of radioligand binding 
against log “cold” ligand concentration and an EC50 value determined using 
nonlinear regression. The equilibrium dissociation constant for the binding of the 
competing “cold” drug (Kf) was calculated using the Cheng-Prusoff equation (Cheng 
and Prusoff 1973). See appendix for an example of the calculation (Section 9.2).
2.5.4 Prevention Bindings
Triplicate reaction mixtures were set up containing 2.5pg of protein, 
radioligand at a concentration equivalent to its Kd for the receptor, and a range of 
concentrations of either GDP from InM to lOOpM, or suramin from O.lnM to lOpM, 
Non specific binding was determined by the addition of 5-HT (lOOpM). Samples 
were incubated for 30 minutes with either [^H]-8 -OH-DPAT or [^H]-MPPF at 30°C 
prior to filtration as in the saturation binding assay. The assay buffer contained 
20mM HEPES and lOmM MgCU. Data were analysed using Graphpad Prism, 
plotted as % of radioligand binding against log GDP/suramin concentration and an 
E C 5 0  value determined using nonlinear regression.
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2.6 Intact Cell Adenylyl Cyclase Assay
Intact cell cyclase assays were performed as described by Wong (1994) and 
Merkouris et al. (1997). Cells were split into 24 well plates and incubated in medium 
containing -adenine at 0.5|LiCi/well for 16 hours prior to assay. Inhibition of 
forskolin (SOpiM) stimulated cAMP accumulation by 5-HT was measured over a 30 
minute period at 37°C in the presence of the non-selective phosphodiesterase 
inhibitor IB MX (ImM). The reaction was terminated by the removal of the 
incubation medium, the addition of stop solution (5% (w/v) TCA, ImM ATP, ImM 
cAMP) and the transfer onto ice for a further 30 minutes. Cells were scraped off the 
plate, transferred to eppendorf tubes and spun at 20000g for 2 minutes. The [^H]- 
cAMP in the supernatant was separated from the -adenine and [^H]-ATP by a 
two step column method (Taussig et al., 1994) and counted on a Packard 1900TR 
Liquid Scintillation Analyser. [^H]-cAMP (dpm) was expressed as a percentage of 
total [^H] and each 5-HT treatment subsequently expressed as a percentage of 
forskolin stimulated [^H]-cAMP production. These percentage stimulation data were 
plotted against 5-HT concentration and EC50 values estimated using nonlinear 
regression.
2,7 High affinity GTPase Assay
The high affinity GTPase assays were performed as in Hoffmann et al. 
(2001). Each reaction was performed in triplicate using 2.5p,g of protein in a lOOpl 
total volume over a 20 minute incubation period at 37°C in 96 well deep well plates 
and was terminated by the addition of 900|li1 of 5% (w/v) activated charcoal in lOmM 
orthophosphoric acid. The reaction mixture volume of lOOpl contained 20mM 
creatine phosphate, 0.1u/(il creatine kinase, 0.2mM App[NH]p, 2mM ATP, 2mM 
ouabain, 200mM NaCl, lOmM MgCL, 4mM DTT, 0.2mM EDTA, 80mM Tris/HCl 
and [^^P]-GTP for 50,000cpm per reaction. Following centrifugation at 2800g for 10 
minutes at 4°C a 300p,l sample of supernatant was counted using a Packard Topcount 
NXT™ microplate scintillation counter.
High affinity GTPase activity was determined over a range of GTP 
concentrations (25nM-3000nM) to allow calculation of Vmax for GTP hydrolysis and 
the K„i for GTP. This was measured in the absence and presence of 5-HT (lOOj^M)
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and a range of RGS protein concentrations (lnM-l|LiM (RGS16) or 5piM (RGSl)). 
The data were analysed and plotted using Graphpad Prism™ as V (pmol/mg/min) 
against [GTP] using a nonlinear regression one site binding hyperbola and also as V 
(pmol/mg/min) against V (pmol/mg/min)/S (substrate concentration) using linear 
regression. An example of these calculations can be found in the appendix.
High affinity GTPase activity over a range of concentrations for various 
ligands was also measured in the presence and absence of RGS I (l|xM) at a single 
GTP concentration (IjrM final). The effects of the ligands were assessed by plotting 
GTPase activity (% of basal) against ligand concentration using Graphpad Prism and 
an EC50 value for each calculated. An example of these calculations can be found in 
the appendix (Section 9.3).
2.8 Western Blot Analysis
Following sample separation as in section 2.1.2, the gel was immersed in 
transfer buffer (bicine 25mM, Bis-Tris 25mM, EDTA 1.025mM, chlorobutanol 
O.OSmM at pH 7.2) and the protein was transferred onto nitrocellulose by application 
of a 30volt constant current for 1 hour. The nitrocellulose was blocked in 5% 
skimmed milk overnight and washed 5 times with PBS/0.1% Tween over a 30 
minute period. Incubation with the primary antibody was in 1% skimmed milk 
prepared in PBS/0.1% Tween was for 1 hour, followed by 5 washed in PBS/0.1% 
Tween over a 30 minute period. Secondary antibody was prepared in 1% skimmed 
milk- PBS/0.1% Tween for 1 hour, again followed by 5 washes over 30 minutes with 
PBS/0.1% Tween. The nitrocellulose was incubated with a 50:50 (v/v) mixture of 
ECL reagents for 2 minutes prior to exposure to and development of X-ray film.
2.9 Statistical Analysis
Statistical analysis was calculated using Graphpad Prism™. The T-test 
calculations in chapters 1,2 and 4 comparing the results from the seven different 
stable cell lines may have produced falsely significant results. Comparisons should 
have been made using analysis of varience (ANOVA). Analysis of varience was used 
to examine the results in chapter 5. The GTPase assay 5-HT concentration response 
curves were analysed using ANOVA and the Newman-Keuls multiple comparison
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post-test. The K,n and V„iax results from the RGS protein concentration response 
curves were analysed using ANOVA and the Dunnetts post-test.
Unless otherwise stated in the results, data are mean +/- SEM from three 
similar experiments with data consisting of triplicate determinations.
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Chapter 3
Intact Cell Adenylyl Cyclase Assays
3.1 Introduction
The wide range of physiological effects that 5-hydroxytryptamine has been 
indicated in are mediated by a large family of receptors consisting of at least 14 
subtypes (Hoyer et al., 1994). All of these receptors with the exception of the S-HTs 
receptor, a ligand gated ion channel, are members of the superfamily of G protein- 
coupled receptors and can be characterised structurally by their seven membrane 
spanning domains with an extracellular N-terminus and intracellular C-terminus.
The 5-HTia receptor (Pedigo et al., 1981) is one of the most highly studied 
members of this family and can be characterised by its uniquely high affinity for the 
agonist 8-OH-DPAT (Gozlan et al., 1983; Hjorth et al., 1982) and the antagonist 
WAY100635 (Fletcher et al., 1993). The 5-HTia receptor is expressed in neurons, 
both pre- and post-synaptically, where it signals via activation of members of the 
pertussis toxin-sensitive family of Gi-like G proteins to inhibit adenylyl cyclase (De 
Vivo and Maayani, 1986; Weiss et al., 1986) and activate inwardly rectifying 
channels (Andrade and Nicoll, 1986; Colino and Halliwell, 1987; Zgombick et al., 
1989). It is present on serotonergic neurons in raphe nuclei of the brain stem 
(Hammon, 1997) where it has a role in the control of the anxiety state of a subject 
functioning as a classical “autoreceptor” with 5-HT release activating the presynaptic 
5-HTiA receptor and inhibiting further 5-HT release. Partial 5-HTia agonists, such as 
buspirone and gepirone, are effective as anxiolytic (anti-anxiety) agents (Tunnicliff, 
1991; Barret, and Vanover, 1993) and antagonists enhance the antidepressant effects 
of selective serotonin uptake inhibitors (S.S.R.I.s) such as fluoxetine (Prozac) 
(Artigas etal., 1994; Artigas etal., 1996).
Receptor-G protein fusions, where the C-terminal tail of the GPCR is linked 
directly to the N-terminal tail of the G protein, have been constructed to study in 
detail GPCR-G protein interaction (Seifert et al., 1999; Milligan, 2000). The 5-HTia 
receptor has previously been fused to wild type (Cys^^^) and pertussis toxin - 
resistant (Gly^^  ^ and Ile^^^) forms of Gna (Kellett et al., 1999). In a membrane high 
affinity GTPase assay a maximal concentration of 5-HT produced a large increase in 
GTPase activity. A level of pertussis toxin sufficient to ADP ribosylate all wild type 
Gia completely inhibited 5-HT stimulation in membranes expressing wild type 5- 
HTiA/Giia, but had no effect on membranes expressing the 5-HTiA/GiiaC^^^Gly/Ile 
mutants. This demonstrates a lack of coupling to the endogenous pool of G; of the
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fusion proteins. Pertussis toxin treatment reduced the basal GTPase activity of the 5~ 
HTia-WT Gila fusion but had no effect on basal GTPase activity of the mutant 
receptor-G protein fusions, a result that has been previously been taken to indicate a 
lack of constitutive activity (Samama et aL, 1993; Lefkowitz et al., 1993). However, 
in support of previous reports of inverse agonist activity, the ligand spiperone 
produced a decrease in basal (unstimulated) GTPase activity in membranes 
expressing 5-HTiA/Giia and 5-HTiA/GiiaC^^^Ile fusions, but not in those expressing 
5-HTiA/GiiaC^^^Gly, indicating that the Gly^^  ^ mutation did not allow constitutive 
activity. Pertussis toxin did not attenuate the effects of spiperone at the 5- 
HTiA/GiiaC^^^I fusion protein, a result that might indicate that the endogenous pool 
of Gi was not involved. Pertussis toxin treatment did attenuate the effects of 
spiperone for the S-HTiA/Gna protein.
5-HT mediated inhibition of adenylyl cyclase activation by forskolin was 
seen in HEK293 stable cell lines expressing each construct. Pertussis toxin 
abolished the inhibition mediated by the WT 5-HTiA/Giia fusion but had no effect on 
cells expressing the Gly^^  ^ and De^ ^^  mutant fusions. 50% inhibition of cAMP 
production occurred at a concentration of 5-HT approximately a molar log order 
lower with the Ile^^  ^mutant than the Gly^^  ^ mutant. The E C 5 0  of the WT Cys^^  ^ was 
between the two.
It was decided to further characterise the 5-HTiA-Gna fusion proteins in terms 
of constitutive activity and inverse agonism. With many reports indicating 
measurable differences in coupling between Gi and Go ot subunits (Clawges et al., 
1997; Berlin et al., 1992; Gamovskaya et al., 1997; Raymond et al., 1993), parallel 
studies investigating coupling to the Go class of G protein were undertaken.
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3.2 Results
Prior to this project’s initiation, along with the WT 5-HTia receptor, a 
number of 5-HTia receptor-Ga protein fusions proteins had been made. These 
consisted of the entire length of the 5-HTia receptor fused at the end of the C 
terminal tail to the N terminal tail of the G« subunit. A schematic representation of 
the 5-HTiA GPCR fused to the Giia G protein is shown in Figure 3.1. It has been 
previously demonstrated that the GPCR-G protein fusion did not prevent coupling to 
second messenger systems but may effect agonist potency (Kellett et a l, 1999).
G proteins of the inhibitory Gi class undergo ADP ribosylation at Cys^^  ^ on 
the Ga subunit, a reaction catalysed by pertussis toxin (Milligan, 1988). The 
modification prevents receptor-mediated exchange of GTP for GDP, with the Ga 
subunit remaining in the GDP bound inactive conformation thus preventing 
activation of second messenger systems. Mutation of Cys^^  ^ to, in this case, either 
Ile^^  ^ or Gly^^  ^ creates a pertussis toxin-resistant Ga subunit allowing prior pertussis 
toxin treatment of cells transfected with such constructs to inactivate the endogenous 
pool of Gi. The pharmacological advantages of this technique are vast. Previously it 
was not possible to quantitate the exact levels of G proteins being activated in a cell 
system. Now, as [^H]-ligand-binding techniques allow exact quantitation of receptor 
levels, the 1:1 stoichiometry of the receptor to pertussis toxin-resistant G protein 
means that exact measurements of G protein activation can be made.
In this case both WT and mutant Gna and Goiawere utilised. cDNA encoding 
the 5-HTiA receptor with a BamHl site at the C terminus and encoding the 
appropriate Gna or Goia protein with a BamHl site at the N terminus were digested 
and ligated into pcDNA3 (Figure 3.2). These constructs were used to set up stable 
cell lines in HEK293 cells. In the case of the 5-HTia receptor and the case of 5- 
HTiA/Giia, 5-HTiA/GiiaC^^^G/I, and the 5-HTiA/GoiaC^^^G fusions, stable cell lines 
expressing the constructs at high levels were already available (Table 3.1). Stable 
cell lines were consequently created expressing the 5-HTiA/Goia receptor and the 5- 
HTiA/GoiaC^^^I fusions.
For each construct 48 colonies were selected, membranes prepared and 
relative expression levels assayed using single point pseudo-saturation binding 
assays. As can be seen from Figures 3.3 and 3.4, the majority of clones expressed the 
constructs at sub pmol/mg levels. To allow meaningful comparison of the stable cell
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lines already available and those being generated, clones with similar expression 
levels were chosen. Two clones of each construct were selected and full saturation 
binding carried out to accurately determine expression levels. For the 5-HTiA/Goia 
construct these were termed Gol2 and Go27, and for the 5-HTiA/GoiaC^^^I construct 
these were termed GoI39 and GoI48. Figure 3.5 shows such a curve for GoI48 
where [^H]-MPPF, a highly selective 5-H T ia antagonist (Kung et ah, 1996), was 
utilised. The data analysis package Graphpad Prism™ was used to estimate the B,nax- 
This revealed expression levels of 5-6pmol/mg of protein for the Go27 and GoI48 
constructs and lower expression levels for Gol2 and GoI39 (Table 3.2). It was 
decided that the clones Go27 and GoI48 would be used in future for stable cell line 
work on these constructs.
A second method used to confirm expression of the 5-HTia receptor-G 
protein fusions was Western blotting. Although an antibody was not available for the 
5-HTiA receptor there were antibodies specific for the Go and Gi subunits. Membrane 
samples for each of the seven stable cell lines were run on two separate gels. The Gi 
protein specific antibody identified the endogenous pool of G, at approximately 
40kDa as well as a band at approximately 85-90kDa that represents the receptor-Gi 
protein fusion proteins (Figure 3.6, panel A). The Go protein fusion proteins did not 
produce a signal.
The second gel was probed using an antibody specific to Goa (ONI) in the N 
terminal region. The Go fusion proteins generated a signal at approximately 85- 
90kDa, but the Gi fusion proteins did not (Figure 3.6, panel B). Rat brain was run as 
a positive control on both gels.
After establishing expression of the constructs, the next step was to 
demonstrate functional activity. As the 5-HTia receptor is Gi-linked, its activation 
results in inhibition of adenylyl cyclase. This coupling has been observed in several 
previous studies (Banerjee et a l, 1993, Fargin et a l, 1989, Liu and Albert, 1991, 
Varrault et al., 1992, Kellett et ah, 1999). In order to look at inhibition of cAMP 
production, cells that had been labelled with [^H]-adenine for 24 hours were treated 
with forskolin that binds to and directly activates adenylyl cyclase. These elevated 
levels of cAMP production can be inhibited with the addition of 5-HT, activating the 
5-HTiA receptor and its G protein fusions.
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A decrease in cAMP production was observed following 5-HT stimulation 
using all seven stable cell lines (Figures 3.7 - 9). Following pre-treatment with 
pertussis toxin, abolition of 5-HT inhibition of cAMP production was seen in the 5- 
HTia, 5-HTiA/Gila and 5-HTiA/Goia stable cell lines. The ADP ribosylation of Cys^^  ^
of endogenous and WT fused inhibitory G proteins prevents G protein activation and 
thus inhibition of adenylyl cyclase activity. Pertussis toxin treatment did not have a 
significant effect on 5-HT inhibition of cAMP production by the four ADP 
ribosylation resistant G protein receptor fusions. This indicates that for the mutant 
fusion proteins, ligand-activated signal transduction in this assay is conferred by the 
fused G protein only. If the 5-HTia receptor -  Ile^^  ^ and Gly^^  ^ G protein fusions 
were coupling to the endogenous pool of inhibitory G proteins a difference between 
non-, and pertussis toxin-treated cells should have been apparent.
In figure 3.7, it is demonstrated that fusing the WT inhibitory G proteins to 
the 5-HTiA receptor produces a significant increase in the EC50 for inhibition of 
adenylyl cyclase (P < 0.05), with an EC50 for the 5-HTia receptor alone being 
approximately ten fold lower (3.9+/-0.7nM versus 52.4+/-17.6nM and 48.0+/- 
16.4nM) (Table 3.3). This may suggest that the ligand stimulated wild type receptor 
is capable of coupling to more than one G protein, resulting in the inhibition of a 
larger proportion of the forskolin activated adenylyl cyclase at the same level of 
receptor occupancy.
Examining the results for the Gjia fusions in isolation, in terms of signal 
transduction, 5-HT was most potent in the 5-HTiA/GiiaC^^^I cell line, with an EC50 of 
approximately 2nM (Figure 3.8). In decreasing order of potency, the WT Giia fusion 
had an EC50 of 14nM for 5-HT, followed by the Gly^^  ^ mutant with an EC50 of 
approximately 60nM. The observed Hill slopes followed a similar order, with the 
steepest being in the order of -1.7 for the Ile^^  ^ mutant and the shallowest being -0.9 
for the Gly^^  ^ mutant (Table 3.3). The WT fusion again fell between the two with a 
Hill slope of -1.2. These results will be discussed in detail later.
The results for the Goia fusions followed the same pattern, although in a less 
pronounced fashion (Figure 3.9). The 5-HTia/Go1ocC^^ I^ fusion had an EC50 of 
approximately 8nM and a Hill slope of between -1.6 and -1.9 (Table 3.4). The WT 
fusion had an EC50 of 42 nM with a slope of -1.9, and finally the Gly^^  ^ mutant had
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an EC50 of between 43 and 59nM with a Hill slope of between -0.9 and -1.5. Again 
these results will be examined in the discussion.
Comparison of the inhibition of cAMP production resulting from stimulation 
of the 5-HTiA/Gjia fusions and the 5-HTiA/Goia fusions showed a general trend 
towards greater inhibition at a lower concentration of 5-HT for the G^a fusion 
proteins.
It is not clear whether inhibition of adenylyl cyclase activity by 5-HTia 
receptor activation of the Goia protein is mediated by the Goa protein or the Gpy 
dimer. In an attempt to ascertain if Gpy subunits were involved the 5-HTiA/GoiaC^^^G 
fusion protein was co-transfected transiently into HEK293 cells with the a  subunit of 
transducin (Figure 3.10). It was hypothesised that free Gpy subunits released by 5-HT 
activation of the fusion protein would bind to transducin a  and a decrease in 
inhibition of adenylyl cyclase activity would be recorded if the Gpy dimer were 
involved. As not all cells would express the 5-HTiA/GoiaC^^^G and a  subunit of 
transducin cDNA, forskolin stimulation of adenylyl cyclase activity would mask any 
5-HTiA receptor-mediated effects. Adenylyl cyclase was stimulated by co­
transfection and activation of the p2-adrenergic receptor that is Gg linked. No 
difference was found between cells not transfected or transfeced with the a  subunit 
of transducin cDNA but no conclusion can be drawn from this as expression was not 
confirmed using western blot analysis.
Another component of the intact cell adenylyl cyclase results to take note of 
was the tendency for an increase in cAMP production at concentrations of 5-HT 
greater than 1(aM. This effect was most visible in the 5-HTiA/GiiaC^^^I results and 
those of the pertussis toxin-treated 5-HTia receptor. As pertussis toxin had no effect 
on this adenylyl cyclase stimulation it could be suggested that another 5-HT receptor 
which is Gs linked may be present endogenously in HEK293 cells at low levels.
In order to confirm this hypothesis, a whole cell cyclase assay was carried out 
on un-transfected HEK293 cells. 5-HT produced an increase in basal and forskolin- 
stimulated cAMP production at concentrations greater than lp,M (Figures 3.11 and 
3.12). These data will be interpreted fully in the Discussion.
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Figure 3.1 2D snake diagram of the human 5-HT]A receptor -
rat Gila protein fusion
The human 5-HT |a receptor was fused to both wild type and mutant inhibitory G 
proteins. The point o f fusion was at the C terminal end of the 5-HT]A receptor and 
the N terminal end o f the G protein. Both Giia and Goia proteins were utilised and 
Cys^^* mutated to Gly^^' and Ile^^'. Shown in the diagram is the human 5-HTia 
receptor joined at the C terminal to the N terminal o f Gna, using G and S amino acids 
as a linker. A 341 amino acid section o f the G^a protein has been removed to allow 
presentation.
5-HTlA Receptor 
Gila G-protein 
ADP ribosylation site 
Linking amino acids
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Figure 3.2 Strategy for construction of plasmids expressing
human 5-HTiA/rat Ga fusion proteins
The 5-H T ia receptor and the appropriate G protein were digested out of the pcDNA3 
vector using Hindlll and BamHl. Following gel purification, the appropriate cDNA 
segments were ligated into pcDNA3 forming the receptor-G protein fusion. The 
BamHl site produces a 6-substrate element that encodes the GS amino acid linker 
sequence. The stop codon from the 5-HTia cDNA and the start codon from the Ga 
protein cDNA were removed.
72
X
3
9O
oC/)
OnHr1X1
U) +
LAI
X
H
P
Ho' - tnU)LAd:zi
T
O
O
O
OQft)t/3
r
OQ%n>
ar-fo
13o
§>w
H
1
Î
COp
[/)373
rop
1
3
>H
C/Db
LAI
XH
S P
HoMnOJLAoi s

Table 3.1 Expression of the 5-HTia receptor and its G
protein fusions in HEK293 stable cell lines
Saturation binding assays were used to determine B^ax for the 5-HTia receptor and 
its inhibitory G protein fusions following stable expression in HEK293 cells. 
Membranes were prepared from harvested cells and [^H]-MPPF saturation binding 
carried out and data analysed using Graphpad Prism as described in Methods 
(Section 2.5.2). Data are mean+/-SEM for three separate experiments.
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Construct m a xExpressed (pm ol/m g)
5-HT,A 6.3+/-0.5
5 - H T ,/0 „ . 4.4+/-0.2
5-HT,VG„„C” 'G 8.6+/-0.9
5-H T ,/G „,C :!iO  ptox 9.5+/-0.5
5 -H T ,/G „ .C ':'[ 8.6+/-0.4
5-HT„/G,,„C«'I ptox 9.4+/-0.7
5-H T ,/G .,.C »:'G 7.4+/-0.2
5-H T ,V G „.C ’S'G ptox 8.6+/-0.2

Figure 3.3 Single point pseudo saturation analysis of [^ H]-
MPPF binding to membranes expressing 5- 
HTiA/Goia fusion proteins
HEK293 colonies growing in DMEM containing 0.5mg/ml genetecin were picked, 
split into two 60mm dishes and grown to confluency. One dish was harvested, 
membranes prepared and single point pseudo saturation binding carried out using the 
5-HTlA receptor selective antagonist [^H]-MPPF. Non-specific binding was 
determined using lOpM 5-HT. An example of the calculation of expression in 
pmol/mg can be found in the appendix (Section 9.1). Data are from a single 
experiment.
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Figure 3.4 Single point pseudo saturation analysis of [^ H]-
MPPF binding to membranes expressing the 5- 
HTiA/GoiaC^^ I^ fusion protein
HEK293 colonies growing in DMEM containing 0.5mg/ml genetecin were picked, 
split into two 60mm dishes and grown to confluency. One dish was harvested, 
membranes prepared and single point pseudo saturation binding carried out using the 
5-H T ia receptor selective antagonist [^H]-MPPF. Non-specific binding was 
determined using lOpM 5-HT. An example of the calculation of expression in 
pmol/mg can be found in the appendix (Section 9.1), Data are from a single 
experiment.
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Figure 3.5 Saturation analysis of |^H]-MPPF binding to the
5-HTiA/Goi(%C  ^ I stable clone GoI48.
Membranes were prepared from the GoI48 clone stably expressing the 5- 
HTiA/G,iaC^^'l fusion and a saturation-binding assay carried out using the 5-H Tia  
receptor selective antagonist [^H]-MPPF. Non-specific was determined using lOpM 
5-HT. Using the data analysis package Graphpad Prism, nonlinear regression 
analysis of the data fitted a single binding site, determining total number o f binding 
sites {Bmax) and the equilibrium dissociation constant (Ky). Data are means of 
triplicate determinations and are representative o f at least three similar experiments.
5-HTiA/GoiaC” 'l 
5-HTlA/GoiaG^  ^ I ptox
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Table 3.2 Expression of 5-HTiA/Goia fusion proteins as
determined by [^H]-MPPF saturation binding 
analysis.
Following single point pseudo saturation analysis of clones expressing the 5- 
HTia/Gou fusions, two clones expressing either construct were selected, and full 
[^H]-MPPF saturation analysis carried out on prepared membranes (see Fig. 3.5). 
Nonlinear regression analysis was used to determine B„iax (pmoFmg) and the 
equilibrium dissociation constant (Kd) in Graphpad Prism. Data are Mean +/- SEM 
from three separate experiments.
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Figure 3.6 Western blot analysis of G protein expression in
cells stably expressing the 5-HTia receptor and its 
G protein fusions
Membranes from rat brain cortex (1), and cells stably expressing the 5-HTia receptor 
(2), the 5-HTiA/Giia fusion (3), the 5-HTiA/GiiaC’^'G fusion (4), the 5- 
HTiA/Gii„C” 'l  fusion (5), the 5-HTia/G„u  fusion (6), the 5-HTiA/GoiaC^^'G fusion 
(7), the 5-HTiA/GoiaC^^'l fusion (8) and mock transfected HEK293 cells (9) were
resolved by SDS page.
Panel A: Immunoblot detection of the S-HTia/Gü» fusion constructs and endogenous 
Gila with antiserum IlC  (Green et a l,  1990), which identifies amino acids 159 to 168 
of Gila. Top, detection of the fusion proteins. Bottom, detection of endogenous Gna.
Panel B: Immunoblot detection of the 5-HTiA/Goia fusion constructs and endogenous 
Goa with antiserum ONI, which identifies amino acids 1 to 16 of Go». Top, detection 
of the fusion proteins. Bottom, detection of endogenous Goia-
Equal amounts of protein were added for each sample. Blots are representative of 
three such experiments carried out on different membrane samples.
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Figure 3.7 Adenylyl cyclase regulation in intact cells
expressing the 5-HTia receptor and WT Gna and 
Goia fusions
Concentration dependent 5-HT inhibition o f 50pM forskolin stimulated adenylyl 
cyclase activity in HEK293 cells stably expressing the 5-HTia receptor, or WT 
inhibitory G protein fusions. 100% is defined as maximal incorporation of [^H]- 
adenine into cAMP following forskolin mediated stimulation o f adenylyl cyclase. 
Data were fitted using nonlinear regression analysis (Graphpad Prism). Data are 
means of triplicate determinations and are representative of at least three similar 
experiments.
■ 5-HT,A
▲ 5-HT ia ptox
T 5-HT,A/Gna
♦ 5-HTiA/G,ia ptox
O 5-HT ia/GoIq
o 5-HT ia/GqIo ptox
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Figure 3.8 Adenylyl cyclase regulation in intact cells
expressing the 5-HTiA/Gii„C^^*G/I fusions
Concentration dependent 5-HT inhibition of 50pM forskolin stimulated adenylyl 
cyclase activity in HEK293 cells stably expressing the 5-HTiA/GüaC^^’G/I fusions. 
100% is defined as maximal incorporation o f [^H]-adenine into cAMP following 
direct stimulation of adenylyl cyclase with 50pM forskolin. Data were fitted using 
nonlinear regression analysis (Graphpad Prism). Data are means of triplicate 
determinations and are representative of at least three similar experiments.
5-H T,A /G i,„C” 'G  
5-HT lA/GjiaC^^'G ptox
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Figure 3.9 Adenylyl cyclase regulation in intact cells
expressing the 5-HTiA/GoiaC^^^G/I fusions
Concentration dependent 5-HT inhibition of 50pM forskolin stimulated adenylyl 
cyclase activity in HEK293 cells stably expressing the 5-HTiA/GoiaC^^^G/I fusions. 
100% is defined as maximal incorporation of [^H]-adenine into cAMP following 
direct stimulation of adenylyl cyclase with 50pM forskolin. Data were fitted using 
nonlinear regression analysis (Graphpad Prism). Data are means of triplicate 
determinations and are representative of at least three similar experiments.
□  5-HT,A/GoiaC''G 
A  5-HTiA/GoiaC^ '^Gptox 
V  5-H T |A /G qi«C ""l 
O  5-HTia/Goi„C^^^I ptox
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Table 3.3 EC50 and Hill slope determinations from whole
cell adenylyl cyclase assay of the 5-HTia receptor 
and Gila protein fusions
5>Hydroxytryptamine EC50 values for inhibition o f forskolin (50pM) stimulated 
adenylyl cyclase activity in cells stably expressing the 5-H T ia receptor and W T and 
mutant Gna protein fusions. Data were analysed by nonlinear regression using the 
Graphpad Prism data analysis package. Average EC50 and Hill slope values 
following either three or four replications.
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Table 3.4 ECgo and Hill slope determinations from whole
cell adenylyl cyclase assay of the 5-HTia receptor 
and Goia protein fusions
5-Hydroxytryptamine EC50 values of inhibition of forskolin (50juM) stimulated 
adenylyl cyclase activity in cells stably expressing the 5-HT ia receptor and WT and 
mutant Goia protein fusions. Data were analysed by nonlinear regression using the 
Graphpad Prism data analysis package. Average E C 5 0  and Hill slope values 
following three replications.
83
w n
u>
00
Ot—‘ 00P  b
O n U)
c» c> c> c> c>
1/1 Lo Üj  4^
w

Figure 3.10 Inhibition of isoprenaline stimulated adenylyl 
cyclase activity by agonist activation of the 5- 
HTiA/GoiaC^^*G fusion protein in the absence and 
presence of transducin a
The 5-HTiA/GoiaC^^’G fusion protein was transiently transfected into HEK293 cells 
with the p2 adrenoceptor in the presence and absence o f transducin a  transfection. 
The ability of 5-HT activation of the 5-HTiA/GoiaC^^’G fusion protein to inhibit P2 
activation of adenylyl cyclase activity following isoprenaline stimulation was then 
studied. Data points are mean values o f triplicate replications and are representative 
of at least three individual experiments.
5-HT,A/GoiaC” 'G
5-HTiA/GoiaC '^'G + Transducin a
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Figure 3.11 Adenylyi cyclase regulation in non-transfected
intact HEK293 cells
Concentration dependent 5-HT stimulation of adenylyl cyclase activity in non- 
transfected HEK293 cells. Data are expressed as the % of total [^H]-Adenine 
incorporated into cAMP and was fitted using nonlinear regression analysis 
(Graphpad Prism). Data are means of triplicate determinations and are representative 
of at least thi ee similar experiments.
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Figure 3.12 Adenylyl cyclase regulation in non-transfected
intact HEK293 cells
Concentration dependent 5-HT stimulation of adenylyl cyclase activity in non- 
transfected HEK293 cells following SOjuM forskolin activation. 100% is defined as 
maximal incorporation of [^H]-adenine into cAMP following forskolin treatment and 
data was fitted using nonlinear regression analysis (Graphpad Prism). Data are means 
of triplicate determinations and are representative of at least three similar 
experiments.
86
250-1
CO 200-
m3E
M—O
50-
1 0 ® 10®Fsk
[5-HT] (M)
3.3 Discussion
The 5-HTia receptor (Pedigo et al., 1981), which has been studied 
extensively, has been indicated as having an important role in determining the human 
emotional state. It is present both pre- and post-synaptically on serotonergic neurons 
in raphe nuclei of the brain stem (Hammon, 1997). These cells are responsible for 
the synthesis of the majority of the 5-HT within the brain and project throughout the 
C.N.S. The partial 5-HTia agonists, buspirone and gepirone, are effective 
anxiolytics (Tunnicliff, 1991; Barret, and Vanover, 1993), and the effects of the 
S.S.R.L, Prozac (fluoxetine), are enhanced and accelerated by co-administration of 5- 
HTia antagonists (Artigas et a l, 1994; Artigas et ah, 1996). The 5-HTia receptor 
has many other indicated roles, including in food intake (Gilbert et ah, 1988; 
Yamada et ah, 1998), memory (Edagawa et ah, 1998) and sexual behaviour 
(Maswood et ah, 1998).
Two groups have used the “knock out” approach in mice to examine the 
effects of the loss of 5-HT]A receptor expression on behaviour, using models of 
anxiety and depression (Ramboz et ah, 1998; Heisler et al., 1998). Knockout animals 
showed no difference in the brain levels of serotonin compared with wild types and 
Ramboz et al. measured the amount of serotonin released following electrical 
stimulation in brain slices and in both wild type and knockout animals, 8-OH-DPAT 
was able to reduce serotonin release by 30-40%. This could suggest that either the 5- 
HTia receptor does not play a large part in modulating serotonin release or that its 
role has been taken over by another receptor subtype. In terms of behavioural 
differences, tests designed to measure the anxiety levels of mice showed that the 
homozygous mutant mice were more “anxious” than the wild type mice. Further tests 
used to examine the levels of depression in mice showed that the knockout mice 
were less “depressed” than the WT mice, supporting the idea that a lack of functional 
5-HT]A receptor favours a less depressed state. It is hoped that a more complete 
understanding of the 5-HTia receptor-G protein interaction gained from these studies 
may lead to advances in therapeutic treatments for a wide range of mental illness, 
such as depression, anxiety and eating disorders.
This work explored the interaction of the human 5-HT]A G protein coupled 
receptor and various inhibitory Ga subunits through which the receptor has been 
demonstrated previously to couple to inhibition of adenylyl cyclase (Banerjee et ah.
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1993; Fargin et al., 1989; Liu and Albert, 1991; Varrault et al., 1992; Kellett et al.,
1999). The C terminal tail of the 5-HTia receptor was fused to the N terminal tail of 
the Ga subunit forming a single construct (Figure 3.2). Both wild type Giia/Goia and 
mutant (Gly^^  ^ and Ile^^^) forms of these Ga subunits were utilised. These mutations 
have been previously characterised (Wise et a l,  1997; Bahia et al., 1998; Jackson et 
al., 1999) and are resistant to pertussis toxin-catalysed ADP-ribosylation, a 
modification which prevents the activation of these G proteins by receptors.
The isolated 5-HTia receptor and the six fusion proteins were stably 
expressed in HBK293 cells prior to functional analysis. Five of these cell lines were 
already available with only the 5-HTiA/Goia and the 5-HTiA/GoiaC^^^I constructs 
requiring stable expression. The expression levels in membranes of 48 clones of each 
construct were assessed by single point [^H]-MPPF binding (Figures 3.3 and 3.4). 
MPPF is a selective 5-HTia receptor antagonist (Thielen et al., 1996; Thielen and 
Frazer, 1995). With pseudo saturation receptor expression levels similar to the stable 
cell lines currently available, two clones expressing each construct were selected and 
complete [^H]-MPPF saturation analysis carried out (Figure 3.5). These data were 
analysed by nonlinear regression and B,nax calculated (Table 3.1). The two clones 
selected for all future signal transduction analysis were Go27 and GoI48. Table 3.3 
shows the receptor expression levels of the seven stable cell lines, indicating Bmax of 
cells that would be routinely pertussis toxin-treated.
A second method was used to identify positive expression of the fusion 
proteins. Membrane fractions of the clones selected were immunoblotted using two 
separate antisera. In panel A of figure 3.6, an antiserum with an epitope between 
amino acids 159 and 168 of G^a identified polypeptides of apparent Mr between 85 
and 90kDa in the lanes containing membranes from cells stably expressing 5-HT]a 
receptor fused to WT and mutant Güa- No protein of this size was found in the lanes 
containing membranes of the isolated receptor or the Goia fusions. In panel B of 
figure 3.6, an antiserum with an epitope between amino acids 1-16 of Goa identified 
polypeptides of apparent Mr between 85 and 90 kDa in the lanes containing 
membranes from the cells stably expressing fusions between the 5-HTia receptor and 
WT or mutant Goia- Again, no protein of this size was found in the lanes containing 
membranes of the isolated receptor or the Gna fusion proteins.
The next step was to assess the functional activity of the 5-HTia receptor G 
protein fusions. Kellett et al (1999) previously reported that 5-HTiA/Giia fusions 
produced decreases in forskolin-stimulated adenylyl cyclase activity following 
agonist activation. This effect was blocked by pre-treatment with pertussis toxin in 
cells expressing the isolated 5-HTia receptor and the WT Giia fusion, but no effect 
was observed in those expressing the Gly^^  ^ and Ile^^  ^mutants. The result of receptor 
activation by 5-HT on forskolin-stimulated cAMP production was examined in intact 
cells expressing the 5-HTiA/Güa and Goia fusions. 5-HT produced concentration 
dependent decreases in maximal forskolin-stimulated (50|LiM) adenylyl cyclase 
activity in cells expressing all constructs, but pre-treatment with pertussis toxin 
significantly inhibited this in cells containing the isolated 5-HTia receptor and both 
the WT Gila and Goia receptor -  G protein fusions. Pertussis toxin treatment had no 
effect on signal transduction in cells expressing the Gly^^  ^ and Ile^^  ^mutants. This is 
an indication that the receptor-G protein fusions do not signal through the 
endogenous pool of inhibitory G proteins, only via the G protein fused to the 
receptor’s C terminal tail. If endogenous G proteins were activated, a difference 
between vehicle and pertussis toxin pre-treated cells would be expected. The EC50 
value (4nM) observed for inhibition of forskolin-stimulated adenylyl cyclase 
activation for the 5-HTia receptor was significantly different (P < 0.05) to those of 
the two WT G protein -  receptor fusions (Gna -  48nM, Goia 52nM). This could 
indicate that the isolated receptor can activate many inhibitory G proteins and that 
fusion of a G protein a  subunit to the C terminal tail of the 5-HTiA receptor prevents 
its coupling to the endogenous pool of inhibitory G proteins.
For the 5-HTia receptor and both the 5-HTiA/Güa and the 5-HTiA/Goia fusion 
proteins, pertussis toxin treatment of the cells results in abolition of agonist mediated 
inhibition of cAMP production (Figure 3.7). Examining the E C 5 0  values of 5-HT for 
the Gila fusion proteins in greater detail (Table 3.3), the 5-HTiA/GiiaC^^^I fusion has 
the greatest potency to inhibit cAMP production (1.5 +/- O.lnM non, and 1.9 +/- 
0.4nM pertussis toxin-treated respectively). These values are significantly lower than 
the E C 5 0  values for the Gly^^  ^ Gna mutant (P < 0.05). The trend among the Gna- 
receptor fusion proteins following 5-HT stimulation is for the Gly^^  ^ mutant to have 
the weakest potency followed by the WT Cys^^\ and the most potent being the Ile^^  ^
mutant. This result is supported by the findings of Bahia et al. (1998) where Cys^^^
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in the Güa protein was mutated to the 19 other naturally occurring amino acids. They 
found that the EC50 in agonist induced GTPyS binding, following stimulation of the 
a 2A-adrenoceptor, to the Cys^^  ^ mutants correlated strongly (r = 0.92) with the 
partition coefficient between octanol/water (log P(octanolZwater)) following the 
elimination of methionine and proline. The reason for methionine being an outlier 
was suggested that it might be present as methionine sulfoxide which would severely 
affect its hydrophobicity, and proline may affect the conformation of the C terminal 
tail of the G protein. In short, they concluded that the more hydrophobic the amino 
acid at position^^^ in the a  subunit of inhibitory G proteins, the stronger the receptor- 
G protein interaction.
This trend is not as apparent in intact cell measures of regulation of adenylyl 
cyclase activity by the 5-HTia receptor-Goia proteins (Table 3.4). Although the Ile^^  ^
mutant had the lowest EC50 value, the WT Goia fusion had the highest. No firm 
conclusions can be drawn from these data as statistical analysis failed to show that 
any of the EC50 values were significantly different from one another.
Comparison of the Güa fusion protein results to those for the Gda fusions 
showed an obvious trend towards the fusion proteins between the 5-HTia receptor 
and the WT Gua protein and its mutants having a greater ability to inhibit forskolin 
stimulated adenylyl cyclase activity. The EC50 for inhibition of cAMP production by 
the 5-HTiA/GiiaC^^^I fusion protein of 2nM was significantly less than that of the 5- 
HTiA/GoiaC^^^I fusion (P < 0.05). This finding is supported by work carried out in a 
variety of expression systems. Addition of purified G protein subunits to Sf9 cell 
membranes expressing 5-HTia receptors demonstrated that the ability of G« subunits 
to shift receptors into a high affinity state for agonists in the presence of either brain, 
or retinal pi/y was greatest with otu followed by Oi2, Oa3 and finally Oo (Clawges et 
aL, 1997). 5-HT]A receptors expressed in E.Coli showed a rank order of affinity for 
reconstituted purified mammalian G protein a  subunits of Gi3a> Gi2a> G ü a »  
G o a »  Gsa (Bertin et ah, 1992). Finally, agonist promoted physical coupling of the 
5-HT]A receptor to G proteins was demonstrated in HeLa and CHO cells using high 
affinity binding and co-immunoprecipitation assays with an apparent rank order of 
Gi3a> Gi2a> Giia= Goia> G%a» Gga (Gamovskaya et a l, 1997; Raymond et al., 
1993).
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These results do not indicate if the inhibition of cAMP production is via the 
Got or GpY subunits as pertussis toxin prevents agonist mediated receptor activation of 
the G protein. One approach to investigate the mediator of the effects of the 5-HTia 
receptor on adenylyl cyclase activity was to co-express to the 5-HTiA/GoiaC^^^G 
receptor and transducin protein a  subunit in HEK293 cells (Figure 3.10). As this 
work is in transiently transfected cells where only a fraction of the cells express the 
constructs, it was not possible to use forskolin to stimulate adenylyl cyclase activity, 
so the Gs linked P% receptor is co-transfected into the cells and the P2 agonist, 
isoprenaline used to stimulate activity. In theory, the over-expression of transducin 
protein a  subunit could restrict activation of second messenger systems by Gpy 
subunits by binding to the Py subunits once they are released from the 5-HTia 
receptor-fused G protein heterotrimer following 5-HT activation of the 5- 
HTiA/GoiaC^^^G fusion protein.
No significant difference was found between the EC50 values for inhibition of 
adenylyl cyclase activity in cells either transfected with or not transfected with 
transducin a  (3.9nM and 4.3nM respectively), which may indicate that agonist 
activation of the 5-HTiA/GoiaC^^^G fusion protein results in inhibition of adenylyl 
cyclase activity via the G« proteins. However, a western blot examination of the cells 
transfected with transducin a  was not performed to confirm overexpression of the 
transducin a  protein.
Another noticeable characteristic of the whole cell cyclase inhibition curves 
for the 5-HTiA receptor Güa protein fusions is that the Hill slope gets steeper from 
the Gly^^  ^ through the Cys^^  ^ to the Ile^^\ Statistical analysis of slope values for the 
pertussis toxin treated Gly^^  ^ (-1.075+/-0.13) and lle^^  ^ (-1.791+/-0.01) mutants 
showed them to be significantly different (P < 0.05 (0.0055)). This may be related to 
the hydrophobicity of the amino acid at position^^^ discussed above and a reflection 
of the degree of intrinsic constitutive activity imparted on the receptor following G 
protein fusion. Indications of intrinsic constitutive activity in 5-H T ia receptor-mutant 
G protein fusions were suggested by Kellett et al. (1999). Spiperone, which acts as 
an inverse agonist at the 5-HTia receptor (Barr and Manning 1997; Newman- 
Tancredi et al., 1997a,b), had no effect on GTPase activity of the 5-HTiA/GüaC^^^G 
mutant, but functioned effectively in membranes expressing the Ile^^  ^ mutant. Prior 
treatment with pertussis toxin had no effect on these data, demonstrating that the
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inverse agonist effect could only be through the mutant Gjia protein fused to the 5- 
HTia receptor and not the endogenous pool of G proteins. This confirms that the 
constitutive activity was a result of interaction between the 5-HTia receptor and the 
fused mutant G protein.
The final point of discussion raised by the results was the presence of a 5-HT 
induced stimulation of cAMP production at concentrations greater than IjxM. This 
effect was most obvious in the pertussis toxin-pretreated data from the 5-HTia stable 
cell line (Figure 3.7) and from both pertussis toxin-pretreated and untreated data for 
the 5-HTiA/GiiaC^^^I (Figure 3.8) stable cell line. Malmberg and Strange (2000), 
who observed a similar effect when measuring adenylyl cyclase activity in WT and 
mutant 5-HTia receptors, attributed this to coupling of the 5-HTia receptor to Gj. As 
they only saw the effect with 5-HT and not with the 5-HTia selective agonist 8-OH- 
DPAT and partial 5-HTia agonist buspirone, it seems more likely that it could be due 
to low level expression of a Gg-linked 5-HT receptor of a different subtype. This is 
supported by the results shown in figures 3.9 and 3.10. A whole cell adenylyl cyclase 
assay was carried out on non transfected HEK293 cells. In figure 3.9 where adenylyl 
cyclase activity was not stimulated with forskolin, concentrations of 5-HT greater 
than IpiM produced elevations in cAMP production approximately three fold over 
basal. Following forskolin stimulation this effect was still recorded. At 50|uiM 
forskolin, 5-HT still more than doubles this effect (Figure 3.10). Forskolin is 
regarded as a non-specific stimulator of all forms of adenylyl cyclase. For 5-HT may 
be producing stimulation above these effects through two possible mechanisms. It 
may be that forskolin is only a partial activator of some or all forms of adenylyl 
cyclase and that 5-HT is activating a receptor that produced complete activation. This 
hypothesis could be investigated by checking if a Gsa linked receptor such as the P2- 
adrenoceptor could stimulate adenylyl cyclase activity above maximal forskolin 
activation. A second possibility is that 5-HT is activating a second messenger system 
that results in modification of adenylyl cyclase leading to a more active form of the 
enzyme. This could possibly be following PKC/PKA mediated phosphorylation of 
adenylyl cyclase, a mechanism that could be investigated using PKC/PKA inhibitors 
such as H-7 or H-9.
Taken together with the lack of stimulation of adenylyl cyclase by 8-OH- 
DPAT, the data presented suggest that this effect is not mediated through the 5-H T ia
92
receptor. The other possible candidates for the role that have previously been shown 
to be Gs linked, are 5 -HT4 (Gerald et al., 1995; Claeysen et al., 1996; Van den 
Wyngaert et al., 1997), 5 -HT5A, 5-HT6 (Monsma et a l, 1993; Ruat et a l, 1993a,b; 
Kohen et al., 1996; Boess et al., 1997; Schoeffter and Waeber, 1994; Sebben et a l, 
1994; Unsworth and Molinoff, 1993; Conner and Mansour, 1990) and 5 -HT7 (Bard et 
a l, 1993; Lovenberg et a l, 1993a,b; Plassat et a l, 1993; Ruat et a l, 1993a,b; Shen et 
a l, 1993; Tsou et a l,  1994; Hirst et a l, 1997; Heidmann et a l,  1997, 1998; Stam et 
a l, 1997). As 8-OH-DPAT is a weak agonist at the 5-HT? receptor (Wood et a l,
2000) and does not produce any cyclase stimulation in HEK293 cells (Malmberg and 
Strange, 2000), it can be excluded. Another candidate, the 5-HTsA receptor, has been 
show to couple to pertussis toxin sensitive G proteins, i.e. Gi/o, and to inhibit 
adenylyl cyclase activity in HEK293 cells (Francken et a l, 1998). Thus the most 
likely candidate is either 5 -HT4 or 5-HT6 at low levels, or possibly another 
endogenous receptor that has low affinity for 5-HT for example the p2-adrenergic 
receptor that is endogenously expressed in HEK293 cells. It is possible to uncouple 
signalling through Gs proteins by pre-treatment with cholera toxin. This would not be 
appropriate in this assay, as cholera toxin restricts the Gs protein to the GTP bound 
form, resulting in constant stimulation of second messenger systems.
Following the results of the whole cell adenylyl cyclase assays, it was 
decided that the affinity of the 5-HTia receptor - mutant Gly^^  ^ and Ile^^  ^ G protein 
fusions should be investigated further using a variety of radioligand binding assays.
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Chapter 4
Radioligand Binding Assays
4.1 Introduction
G protein - coupled receptors exist in different states that have a varied 
degree of affinity for agonists, but similar high affinity for antagonists. Existence of 
the receptor in the G protein coupled form imparts a high degree of affinity for 
agonists, but dissociation of the G protein results in free receptor with a low degree 
of affinity which can often no longer be labelled by agonists (Emerit et al., 1990). 
The binding of antagonists is independent of the G protein - coupled state of the 
receptor, as they bind either form with equivalent affinity (Kobilka, 1992). The 
difference in affinity for a compound for these affinity states can give an indication 
of a receptor’s intrinsic activity (Birdsall and Lazareno, 1997). Given the indications 
that some of the 5-HTia receptor G protein constructs introduced in chapter three 
may have constitutive activity and altered receptor -  G protein affinities, it was 
decided to investigate this further using a radioligand binding approach.
GPCR signalling is initiated by the formation of a ternary complex between a 
ligand, receptor and a G protein (Hepler and Gilman, 1992; Neubig et al., 1988). 
Once a receptor binds an agonist, it shifts into an activated state and associates with 
its cognate G protein. In this activated complex, the agonist is bound with high 
affinity. Binding of an activated receptor to a G protein causes a conformational 
change in the Ga subunit, reducing the affinity of the G protein for GDP, resulting in 
the release of GDP and the binding of GTP (Brandt and Ross, 1986). Conversely, an 
excess of GDP lowers the affinity of the G protein for the receptor (Hepler and 
Gilman, 1992). In a radioligand binding assay, increasing concentrations of GDP 
result in the dissociation of receptor and G protein, indicated by a decrease in 
specific binding of the agonist to the receptor (Waldhoer et al., 1999). Waldhoer et al 
(1999) showed a decrease in high affinity agonist binding to adenosine A] receptor 
Ga subunit fusions. Unlike previous studies using a 2A-adrenoreceptor -  G protein 
fusions where mutation of Cys^^  ^ in the a  subunit of the G protein resulted in 
decreased affinity of the G protein for the receptor with Gly^^  ^ and increased affinity 
with Ile^^  ^ (Bahia et al., 1998), Waldhoer et al (1999) found that both Gly and He 
substitutions at Cys^^  ^ decreased the affinity of the G protein for the receptor.
In order to investigate any changes in affinity of mutated G; and Go a  
subunits for the 5-HTia receptor, two main approaches were used. Firstly, the 
affinity of the agonist [^H]~8-OH-DPAT for the 5-HTia receptor and the Güa and
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Goia fusion proteins was assessed using GDP prevention bindings. Secondly, the 
ability of suramin to inhibit the binding of [^H]-8-OH-DPAT was examined. Suramin 
binds directly to G protein a  subunits and can be used to estimate the affinity of G 
protein for receptor by competing with the activated receptor for G protein binding 
(Waldhoer et al., 1998; Freissmuth et al., 1996).
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4.2 Results
The affinity of the 5-HTia selective agonist [^H]-8 -OH-DPAT for the 5-HTia 
receptor and 5-HT]A receptor -  G protein fusions was examined in GDP prevention 
binding assays. Increasing concentrations of GDP from lOnM to ImM displaced the 
binding of [^H]-8 -OH-DPAT in a concentration dependent manner (Figures 4.1 -  
4.3). Pertussis toxin treatment of cells prior to membrane production and assaying for 
binding abolished any high affinity binding of the agonist radioligand to the 5-HTia 
receptor or 5-HTia receptor fused to the WT Güa and Goia G proteins (Figure 4.1). 
The EC50 for GDP prevention of binding to membranes expressing the 5-HTia 
receptor was 13.7 +/- 2.4|liM (Table 4.1) and the values for membranes expressing 
the 5-HTiA/Giia and 5-HTiA/Goia fusion proteins were 2.2 +/- 0.5 and 5.9 +!- 3.8|iM 
respectively (Tables 4.1 and 4.2). The E C 5 0  for the 5-HTia receptor was not 
significantly different to that of the 5-HTiA/Goia fusion, but was significantly 
different to the 5-HTiA/Güa fusion (P < 0.05). The lower E C 5 0  values for the 5- 
HTiA/Gila and 5-HTiA/Goia fusion proteins may reflect the lack of coupling to the 
endogenous G protein pool, restricting coupling to its fused G protein. The higher 
E C 5 0  value of the 5-HTia receptor in this assay may reflect the effects of a greater 
number of instances of coupling of endogenous G proteins to the receptor, putting it 
in the high affinity binding state for a greater period of time.
GDP prevented specific binding of [^H]-8 -OH-DPAT to membranes 
expressing the 5-HT % A/GüaC^^^G/I fusions in a concentration dependent manner 
(Figure 4.2). Pertussis toxin treatment of the cells prior to harvesting and membrane 
production abolished any potential binding of the fusions with the endogenous pool 
of Gi proteins as ADP-ribosylation of Cys^^  ^ prevents receptor coupling. This pre­
treatment did not have any effect on the E C 5 0  values of GDP prevention for either 
construct (P > 0.05) (Table 4.1). A lack of coupling of the pertussis toxin-resistant 
receptor - G protein fusions to endogenous G proteins was also indicated in the 
adenylyl cyclase results in Chapter 3. The E C 5 0  values of either the non - pertussis 
toxin treated 5-HTiA/GüaC^^^G and 5-HTiA/GüaC^^^I fusions (0.30 +/- 0.05 and 10.0 
+/- 3.1p.M respectively), or the pertussis toxin pretreated fusions (0.10 +/- 0.05 and 
6.9 +/- 2.9p,M respectively) were not statistically different from each other (p = 
0.0593) (Table 4.1). A rank order of E C 5 0  values for the constructs of the Ile^^  ^
(approx. 7-lOjLiM) construct, followed by the WT Cys^^  ^ Güa fusion (2.2pM) and
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lastly by the Gly^^  ^ mutant (approx. 0.15-0.25pM), indicates that the receptor has 
highest affinity for the G protein with He at position^^^ followed by WT Cys and has 
poorest affinity for the G protein with Gly at position^^\
GDP prevented [^H]-8 -OH-DPAT binding to the 5-HTiA/GoiaC^^^G/I fusions 
in a concentration-dependent manner and, as with the Gna mutants, pertussis toxin 
pre-treatment did not have any effect on agonist binding (Figure 4.3). Neither the 
ECso values for the non pertussis toxin or the pertussis toxin pre-treated He^ ^^  mutant 
(3.0 H-/- 0.6 and 2.6 +/- 0.6pM respectively), nor the non pertussis toxin or pertussis 
toxin-pretreated Gly^^  ^ mutant (0.10 +/- 0.04 and 0.10 +!- 0.04|iM respectively), 
were statistically different from the EC50 value for the WT Cys^^  ^ 5-HTia receptor-G 
protein fusion (5.9 +/- 3 .8 |4M) due in part to the large error of the latter E C 5 0  (Table 
4.2). The E C 5 0  values for the non-pertussis toxin and pertussis toxin-pretreated 5- 
HTiA/GiiaC^^^G/I mutants were statistically different from one another (P < 0.05). As 
with the Gila fusion proteins this could indicate that the G protein with Ile^^^  has a 
higher affinity for the 5-HTia receptor, with the Cys^^  ^ having identical affinity, but 
the Gly^^  ^mutant having a lower affinity for the 5-HTia receptor.
Comparison of E C 5 0  values of GDP prevention of [^H]-8 -OH-DPAT binding 
of the pertussis toxin-treated 5-HTiA/GnaC^^^G to the 5-HTiA/GoiaC^^^G mutants did 
not show a statistically significant difference (P > 0.05). Neither were the E C 5 0  
values of the 5-HTiA/GuaC^^^I or the 5-HTiA/GoiaC^^^I mutants significantly 
different (P > 0.05). However, the trend in higher E C 5 0  values for GDP displacement 
of agonist binding for the Gna fusions compared to their Goia counterparts, could 
indicate that Gna had higher affinity for the 5-H Tia receptor than Goia-
The effect of increasing concentrations of GDP on the binding of the 5-H T ia 
selective antagonist [^H]-MPPF was investigated using the same binding protocol. 
Antagonists do not differentiate between the high and low affinity states of receptor 
binding, but bind to both with equal affinity, so it is unsurprising that neither prior 
treatment with pertussis toxin, nor increasing concentrations of GDP, had any effect 
on the binding of this radioligand (Figures 4.4, and 4.5). In figure 4.4, the binding of 
I^H]-MPPF to the 5-HTiA/Giia fusion was unaffected by either increasing 
concentrations of GDP or prior pertussis toxin treatment of the cells which ADP 
ribosylated the entire pool of endogenous Gi plus the Gna protein fused to the 5-
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HTia receptor. Again neither GDP nor pertussis toxin pretreatment had any effect of 
the binding of [^H]-MPPF to the 5-HTiA/GoiaC^^^I fusion (Figure 4.5).
The affinity of the 5-HTia receptor for the selection of G proteins was further 
investigated using the compound suramin. Suramin inhibits the formation of the 
ternary ligand-receptor-G protein complex by competing directly with the receptor 
for G protein binding (Huang et a l, 1990; Hohenegger et al., 1998; Beindl et al., 
1996). Its use can give an indication of a G protein’s affinity for an agonist-bound 
receptor (Waldhoer et al., 1999).
In figure 4.6, the effects of increasing concentrations of suramin on the 
binding of the agonist [^H]-8-OH-DPAT to the 5-HTia receptor and the 5-HTia 
receptor-Giia and Goia protein constructs was investigated following preparation of 
membranes from cells stably expressing the constructs. As in the GDP prevention 
bindings, pre-treatment of the cells prior to harvesting with pertussis toxin uncouples 
the receptor from the fused and endogenous pool of G proteins (Figure 4.6), 
preventing binding of the radioligand agonist except with low affinity. Suramin 
produced a concentration dependent decrease in binding of [^H]-8-OH-DPAT to the 
5-HTiA receptor and its WT Gua and Goia fusions presumably by uncoupling the 
receptor-G protein interaction. Statistically there was not a significant difference 
between the E C 5 0  values for the proteins, with an E C 5 0  for the 5-HTia receptor of 1.8 
+/- 0.8|iM and of 1.7 +/- 0.5 and 1.3 +/- 0.6|LiM for the WT Gna and G^a fusion 
proteins respectively (Tables 4.3 and 4.4).
As in the GDP prevention binding assays, pertussis toxin treatment of cells 
prior to harvesting and membrane production had no significant effect on the binding 
of [^H]-8-0H-DPAT to membranes expressing the 5-HTiAGüaC^^^G/I fusions 
(Figure 4.7). Suramin inhibited binding of the agonist to the receptors in a 
concentration dependent manner, with E C 5 0  values for the non- and pertussis toxin 
pre-treated Gly^^  ^ mutant of 1.2 +/- 0.2 and 0.8 +!- 0.1 jiM respectively, and 4.8 +/- 
0.8 and 5.8 +/- 0.4[xM for the Ile^^  ^ mutant, non- and pertussis toxin-treated 
respectively (Table 4.3). The E C 5 0  values for the Gly^^  ^ mutant +/- pertussis toxin 
were not significantly different from each other (P > 0.05) and neither were those of 
the Ile^ ^^  mutant +/- pertussis toxin (P > 0.05). However, the E C 5 0  values of either 
the non pertussis toxin treated Gly^^  ^ and Ile^^  ^mutants, or the pertussis toxin treated 
Gly^^  ^ and Ile^^^  mutants, were significantly different from each another (P < 0.05)(P
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= 0.0118 and 0.0002 respectively). As in previous assays the results indicate a rank 
order of affinity of suramin to prevent G protein binding of agonist bound receptor, 
with suramin having the highest affinity with Ile^ ^^  (5-6p,M approx.) mutants, 
followed by the WT Cys^^  ^ (1.7|iM approx.), and lastly by Gly^^  ^ (0.8-1.2|liM 
approx.). Therefore, the greater the concentration of suramin required to produce a 
50% reduction in agonist binding, the greater the affinity the G protein has for the 
agonist-bound receptor.
Similar results were measured in the suramin prevention bindings of the 
membranes expressing the 5-HTiA/GoiaC^^^G/I fusion proteins. Again treatment of 
the cells with pertussis toxin prior to harvesting and membrane production did not 
have a significant effect on the binding of [^H]-agonist to the receptor-G protein 
constructs (P >0.05) (Figure 4.8). Suramin produced a concentration dependent 
decrease in agonist binding, reaching a maximal effect in the 5-HTiA/GoiaC^^^G 
fusion at approximately IOijlM, but not having reached a maximal effect on the 5- 
HTia/GoIkC^^^I fusion even at lOOjiM. The EC50 values for the non-, and pertussis 
toxin-treated membranes were not significantly different for the Gly^^  ^ or the De^ ^^  
mutants. On comparison of the EC50 values for the different mutants to each other, 
the non-pertussis toxin treated values were significantly different from one another 
(P =0.0142), as were the pertussis toxin-treated values (P = 0.0003) (Table 4.4). 
Again this would indicate that in the suramin prevention binding assay, the Ile^^  ^ G 
protein had a higher affinity for the agonist bound 5-HTia receptor than the Gly and 
Cys^^  ^G proteins, that appeared to have equal affinity for the receptor.
As a control, the effect of increasing concentrations of suramin on the binding 
of the 5-HT 1A selective antagonist [^H]-MPPF was investigated. Given that 
antagonists do not distinguish between the high and low affinity binding 
conformations of a GPCR, binding to both equally, suramin had no effect on the 
binding of [^H]-MPPF to the isolated receptor (Figure 4.9) or 5-HTia receptor-G 
protein fusions (Figure 4.10). This demonstrates that suramin is not competing 
directly with [^H]-MPPF or [^H]-8-OH-DPAT at the ligand binding site.
In order to examine the proportion of a receptor that is present at rest in the 
high affinity (G protein coupled)(%Rn) and the low affinity (G protein 
uncoupled)(%RL) states, agonist displacement of [^H]-antagonist binding was 
examined for the 5-HTiA/GüaC^^^G/I fusions (Figures 4.11 and 4.12). Biphasic
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competition curves were generated with the first EC50 corresponding to the high 
affinity site for the agonist and the second EC50 corresponding to the low affinity site 
for the agonist. The antagonist [^H]-MPPF bound to these sites with equal high 
affinity, and using increasing concentrations of 8-OH-DPAT, the antagonist was 
displaced firstly from the high affinity agonist binding site and secondly from the 
low affinity site. Comparison of the results from this binding allows the calculation 
of the proportion of the receptor present in the high and low affinity states (Table 
4.5). The important data here are the pertussis toxin treated data as this allows us to 
look only at the influence of the G protein fused to the 5-HTia receptor. Although 
there is not statistical difference in the EC50 values for the Gly^ ^^  and Ile^ ^^  pertussis 
toxin treated samples, there is a significant difference between the fractions of the 
constructs in the high affinity state (P < 0.05 (0.0039)). There were over twice as 
many Ile^^  ^ receptor-G protein fusion proteins in the high affinity state (%Rh) as 
there are Gly^ ^^  fusion proteins in the high affinity state.
As a control, binding of the 5-HTia selective agonist [^H]-8-OH-DPAT to 
non-transfected HEK293 membranes was examined (Figure 4.13). Over a period of 
sixty minutes, no specific binding of the radioligand could be detected.
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Figure 4.1 Inhibition of agonist radioligand binding to
membranes prepared from HEK293 cells stably 
expressing the 5-HTia receptor and the 5-HTia 
receptor-Giia and Goia protein fusions by GDP
Percentage of specific [^H]-8 -OH-DPAT binding in the absence (100%) or presence 
o f increasing concentrations of GDP in HEK293 cells stably expressing the 5-HTia 
receptor and the WT Güa and Goia protein fusions. Pertussis toxin-treatment and 
increasing concentrations of GDP result in reduced binding o f the agonist 
radioligand. Points are mean+/-S.D. o f triplicate determinations and each curve is a 
representative experiment repeated a minimum of three times.
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Figure 4.2 Inhibition of agonist radioligand binding by GDP,
to membranes prepared from HEK293 cells stably 
expressing the pertussis toxin resistant 5- 
HTi/\/GnaC^ G/I fusion proteins
Percentage of specific [^H]-8-OH-DPAT binding in the absence (100%) or presence 
o f increasing concentrations of GDP in HEK293 cells stably expressing 5-HT ia 
receptor-G,ia protein fusions with Gly^^' and Ile^^‘ mutations. Increasing 
concentrations of GDP result in reduced binding of the agonist radioligand. Points 
are mean+/-S.D. of triplicate determinations and each curve is a representative 
experiment repeated a minimum of three times.
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Table 4.1 Mean EC50 and Hill slope values for GDP
prevention of [^H]-8-OH-DFAT binding to 
membranes prepared from HEK293 cells stably 
expressing the 5-HTia receptor and its Gua fusion 
proteins
Table showing the mean +/- SEM EC50 and Hill slope values for GDP prevention of 
specific [^H]-8-0H-DPAT binding to the 5-HT ia receptor, its WT G^a fusion protein 
and the pertussis toxin resistant GnaC^^^G/I fusion proteins. Values are means of 
results from experiments repeated a minimum of three times.
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Figure 4.3 Inhibition of agonist radioligand binding by GDP,
to membranes prepared from HEK293 cells stably 
expressing the pertussis toxin resistant 5- 
HTiA/GoiaC^^*G/I fusion proteins
Percentage of specific [^H]-8-OH-DPAT binding in the absence (100%) or presence 
of increasing concentrations o f GDP in HEK293 cells stably expressing 5-HT ia 
receptor-Goia protein fusions with Gly^^’ and Ile^^’ mutations. Increasing 
concentrations o f GDP result in reduced binding o f the agonist radioligand. Points 
are mean+/-S.D. of triplicate determinations and each curve is a representative 
experiment repeated a minimum of three times..
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Table 4.2 Mean EC50 and Hill slope values for GDP
prevention of [^HJ-S-OH-DFAT binding to 
membranes prepared from BDEK293 cells stably 
expressing the 5-HTia receptor and its Goia 
fusions proteins
Table showing the mean +/- S.E.M. EC50 and Hill slope values for GDP prevention 
of specific fH]-8-0H-DPAT to the 5-H T ia receptor, its WT Goia fusion protein and 
the pertussis toxin-resistant GoiaC^^^G/I fusion proteins. Values are means of results 
from experiments repeated a minimum of three times.
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Figure 4.4 Lack of inhibition of antagonist radioligand
binding by GDP to membranes prepared from 
HEK293 cells stably expressing the pertussis toxin 
sensitive 5-HTiA/Güa fusion protein
Percentage of specific [^H]-MPPF binding in the absence (100%) or presence o f 
increasing concentrations o f GDP in HEK293 cells stably expressing 5-HTja
receptor-G,ia protein fusion. Neither pertussis toxin-treatment, nor increasing
concentrations of GDP affect binding of the antagonist radioligand. Points are 
mean+Z-S.D. of triplicate determinations and each curve is a representative 
experiment repeated a minimum of three times.
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Figure 4.5 Lack of inhibition of antagonist radioligand
binding by GDP to membranes prepared from 
HEK293 cells stably expressing the pertussis 
toxin-resistant 5-HTiA/GoiaC I fusion protein
Percentage o f specific [^H]-MPPF binding in the absence (100%) or presence of 
increasing concentrations of GDP in HEK293 cells stably expressing 5-HTiA 
receptor-Goia protein fusion with the Ilef^' mutation. Neither pertussis toxin- 
treatment, nor increasing concentrations of GDP alter binding o f the antagonist 
radioligand. Points are mean+/-S.D. of triplicate determinations and each curve is a 
representative experiment repeated a minimum of three times.
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Figure 4.6 Inhibition of agonist radioligand binding by
suramin to membranes prepared from HEK293 
cells stably expressing the 5-HTia receptor and the 
5-HTia receptor-Giia and Goia protein fusions
Percentage of specific [^H]-8-0H-DPAT binding in the absence (100%) or presence 
of increasing concentrations o f suramin in HEK293 cells stably expressing the 5- 
HTlA receptor and the WT G,ia and Goia fusion proteins. Pre-treatment with pertussis 
toxin and increasing concentrations o f suramin result in reduced binding o f the 
agonist radioligand. Points are mean+/-S.D. o f triplicate determinations and each 
curve is a representative experiment repeated a minimum of three times.
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Figure 4.7 Inhibition of agonist radioligand binding by
suramin to membranes prepared from HEK293 
cells stably expressing the pertussis toxin resistant 
5-HTiA/GiiaC^^*G/I fusion proteins
Percentage of specific [^H]-8-0H-DPAT binding in the absence (100%) or presence 
o f increasing concentrations o f suramin in HEK293 cells stably expressing 5-HT ia 
receptor-Gjiot protein fusions with Gly^^’ and lle^^’ mutations. Increasing 
concentrations of suramin result in reduced binding o f the agonist radioligand Points 
are mean+/-S.D. of triplicate determinations and each curve is a representative 
experiment repeated a minimum of three times.
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Table 4.3 Mean EC50 and Hill slope values for suramin
prevention of [ H]-8-OH-DPAT binding to 
membranes prepared from HEK293 cells stably 
expressing the 5-HTia receptor and its Gna fusions 
proteins
Table showing the mean +/- S.E.M. EC50 and Hill slope values for suramin
prevention of specific [^H]-8-0H-DPAT binding to the 5-HT1 a  receptor, its WT Gna
fusion protein and the pertussis toxin-resistant GiiaC^^^G/I fusion proteins. Values 
are means of results from experiments repeated a minimum of three times.
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Figure 4.8 Inhibition of agonist radioligand binding by
suramin to membranes prepared from HEK293 
cells stably expressing the pertussis toxin resistant 
5-HTiA/GoiaC^**G/I fusion proteins
Percentage of specific [^H]-8-OH-DPAT binding in the absence (100%) or presence 
o f increasing concentrations o f suramin in HEK293 cells stably expressing 5-HTia 
receptor-Goia protein fusions with Gly^^' and Ile^^’ mutations. Increasing 
concentrations o f suramin result in reduced binding o f the agonist radioligand Points 
are mean+/-S.D. o f triplicate determinations and each curve is a representative 
experiment repeated a minimum of three times.
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Table 4.4 Mean EC50 and Hill slope values for suramin
displacement of [^H]-8-OH-DPAT binding to 
membranes prepared from HEK293 cells stably 
expressing the 5-HTia receptor and its Goi« fusions 
proteins
Table showing the mean +/- S.E.M. EC50 and Hill slope values for suramin affect on 
specific [^H]-8-0H-DPAT to the 5-H T ia receptor, its WT Goia fusion protein and the 
pertussis toxin-resistant GoiaC^^^G/I fusion proteins. Values are means of results 
from experiments repeated a minimum of three times.
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Figure 4.9 Lack of Inhibition of antagonist radioligand
binding by suramin to membranes prepared from 
HEK293 cells stably expressing the 5-HTia 
receptor
Percentage of specific [^H]-MPPF binding in the absence (100%) or presence of
increasing concentrations of suramin in HEK293 cells stably expressing 5-HT ia
receptor. Neither pertussis toxin-treatment, nor increasing concentrations of suramin 
alter binding of the antagonist radioligand. Points are mean+/-S.D. o f triplicate 
determinations and each curve is a representative experiment repeated a minimum of 
three times.
■  5-HT,A
^  5-HTlA ptox
i n
140-1
S= 120-
O)
12 80-
l l
60-
co
40-
Q.
20 -
1 0 ® 10 -®Zero •7 -6 1 0 ® -4
[Suramin] (M)

Figure 4.10 Lack of inhibition of antagonist radioligand 
binding by suramin to membranes prepared from 
HEK293 cells stably expressing the pertussis 
toxin-resistant 5-HTiA/GoiaC^^*I fusion protein
Percentage of specific [^H]-MPPF binding in the absence (100%) or presence of 
increasing concentrations of suramin in HEK293 cells stably expressing 5-H T ia 
receptor-GoiaC^^'l protein fusion. Neither pertussis toxin-treatment, nor increasing 
concentrations o f suramin alter binding of the antagonist radioligand Points are 
mean+/-S.D. o f triplicate determinations and each curve is a representative 
experiment repeated a minimum of three times.
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Figure 4.11 Competitive biphasic inhibition of antagonist
radioligand binding by the agonist 8-OH-DPAT to 
membranes prepared from HËK293 cells stably 
expressing the pertussis toxin resistant 5- 
HTiA/GiiaC^^*G fusion protein
Percentage of specific [^H]-MPPF binding in the absence (100%) or presence of 
increasing concentrations of 8-OH-DPAT in HEK293 cells stably expressing 5-HT ia 
receptor-G,ia protein fusion with the Gly^^' mutation. Increasing concentrations o f 8- 
OH-DPAT result in the biphasic competition for the antagonist radioligand. Points 
are mean+/-S.D. of triplicate determinations and each curve is a representative 
experiment repeated a minimum of three times.
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Figure 4.12 Competitive biphasic inhibition of antagonist
radioligand binding by the agonist 8-OH-DPAT to 
membranes prepared from HEK293 cells stably 
expressing the pertussis toxin resistant 5- 
HTiA/GiiaC^^‘l fusion protein
Percentage of specific [^H]-MPPF binding in the absence (100%) or presence of 
increasing concentrations of 8-OH-DPAT in HEK293 cells stably expressing 5-HT ia 
receptor-G,ia protein fusion with the Ile^^' mutation. Increasing concentrations of 8- 
OH-DPAT result in the biphasic competition for the antagonist radioligand. Points 
are mean+/-S.D. o f triplicate determinations and each curve is a representative 
experiment repeated a minimum of three times.
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Table 4.5 Mean high and low affinity EC50 and % Rh and
Rl values for 8-OH-DPAT displacement of [^ H]- 
MPPF binding to membranes prepared from 
HEK293 cells stably expressing the 5- 
HTiA/GiiaC^^^G/I fusion proteins
Table showing the mean +/- SEM of high and low affinity E C 5 0  and %Rh and Rl 
values for biphasic 8-OH-DPAT displacement of specific [^H]-MPPF binding to the 
5-HTiA/GiiaC^^^G/I fusion proteins. Values are means of results from experiments 
repeated a minimum of three times.
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Figure 4.13 Association binding of the agonist [^H]-8-OH- 
DPAT to membranes prepared from HEK293 
cells mock transfected with the pcDNA3 vector
Lack of specific binding of [^H]-8-0H-DAPT measured over a 60 minutes 
incubation period in HEK293 cells mock transfected with the pcDNA3 vector. 
Samples were filtered and binding halted at 5, 10, 15, 30 and 60 minutes Points are 
mean+/-S.D. of triplicate determinations and each curve is a representative 
experiment repeated a minimum of three times.
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4.3 Discussion
Receptors have at least two affinity states for agonists. The high affinity state 
occurs when the receptor is coupled to a G protein, the low affinity state when the G 
protein is uncoupled. Receptors that are not G protein coupled can often no longer be 
labelled with high affinity by agonist radioligands (Emerit et al., 1990). Antagonist 
binding is independent of affinity state, with binding equal to either G protein- 
coupled or uncoupled states (Kobilka, 1992). Activated receptor, or agonist bound 
receptor, decreases the affinity of the G« subunit of the G protein for GDP, 
promoting its release. Conversely, an excess of GDP, or non-hydrolysable analogues 
of GTP such as Gpp(NH)p, lowers the affinity of the G protein for the receptor 
(Hepler and Gilman 1992). The difference in affinity of a compound for these states 
can give an indication of its intrinsic activity (Birdsall and Lazareno, 1997).
It had been previously found using [^^S]-GTPyS binding studies that the more 
hydrophobic the amino acid at position 351 in the Güa subunit, the greater the 
affinity the a 2A-adrenoceptor had for G protein binding (Bahia et ah, 1998). 
Mutation of Cys^^  ^ to each of the other nineteen naturally occurring amino acids 
demonstrated that the Ile^^  ^ mutation produced the greatest UK-14304 stimulated 
binding of [^^S]-GTPyS to the Gna protein (Bahia et al, 1998), one and a half times 
greater than binding to the WT Cys^^  ^ protein. However, Waldhoer et al (1999), 
found that in fusion proteins between the Ai adenosine receptor and the Gna G 
protein subunit, mutation of Cys^^  ^ to either Ile^ ^^  or Gly^^  ^ decreased the affinity of 
the receptor for the G protein. Given these contrasting results, it was important to 
examine the effects of these mutations on the affinity of the 5-H T ia receptor for the 
fused Gila or Goi« G proteins.
To approach this, GDP prevention of -8-OH-DPAT binding was used to
measure the affinity of the 5-H Tia receptor for fused Gai/o subunits with WT Cys^^\ 
or Gly^^  ^ and Ile^^  ^ mutations. Following prior treatment with pertussis toxin, to 
ensure coupling of the receptor to only the fused Ga protein and not endogenous 
pools of inhibitory G proteins, cells were harvested and membranes prepared. It was 
found that higher concentrations of GDP were required to displace binding of the 
agonist radioligand to the fusion between the 5-HTia receptor and the Gna G protein 
with Ile^^  ^ (ECso 6.9 +/- 2.9jLiM), than with Gly^^  ^ ( E C 5 0  0.14 +/- O.OSjaM) (Table 
4.1). Although, pertussis toxin-treatment of cells stably expressing the WT Cys^^^
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fusion was not possible, previous data have indicated that 5-HTiA receptor-G protein 
fusions couple only to the fused Ga subunits and not endogenous G proteins. Given 
this, the EC50 of the Cys^^  ^ fusion (2.2 +/- 0.5jiM) for GDP displacement of agonist 
radioligand binding, may be a result of coupling to the fused Gna protein only. These 
results were supported by previous data published on 5-HTia receptor-Gna protein 
fusions, that showed in an intact cell adenylyl cyclase assay lower concentrations of 
5-HT were required to inhibit forskolin-stimulated adenylyl cyclase activity for the 
Ile^^  ^ fusion than for the Cys^^  ^ fusion, followed by the Gly^^  ^ fusion (Kellett et al., 
1999). These data together may indicate a rank order of affinity of G protein for 
receptor, highest to lowest, of Ile^^\ followed by Cys^^  ^ and lastly Gly^^  ^ for the 5- 
HTia receptor.
The results for the Goia fusion proteins were similar in pattern, with the Ile^^^  
mutant requiring a concentration of GDP to displace 50% of agonist radioligand 
binding of 2 , 6  +!- 0 .6 |iM ( E C 5 0 ) ,  and the Gly^^  ^ mutant requiring only 0.1 +/- 
0.04|xM ( E C 5 0 )  (Table 4.2). This follows the same order of affinity for the Goia stable 
cell lines in the intact cell adenylyl cyclase assay in chapter 3 and established for the 
Gila fusion proteins in both whole cell adenylyl cyclase and GDP prevention 
bindings. However, the E C 5 0  for GDP prevention of [^H]-8 -OH-DPAT binding 
calculated for the 5-HTiA/Goia fusion was higher than that of the Ile^^  ^ mutant (5.9 
+/- 3.8jLiM) but not significantly different. This result may be a reflection of the large 
standard error of the mean for the 5-HTia receptor - WT Goia protein fusion.
Comparison of the results for the 5-HTia receptor-Gua and Goia protein 
fusions indicates that for corresponding mutations, a higher concentration of GDP is 
required to produce 50% prevention of [^H]-8 -OH-DAPT binding to the Gna fusion 
proteins than the Goia fusion proteins (Tables 4.1 and 4.2). This is consistent with the 
results from the whole cell adenylyl cyclase assay and previously published data 
indicating a higher affinity of the 5-HTia receptor for Gna coupling than Goia 
coupling (Clawges et al., 1997; Bertin et al., 1992; Gamovskaya et al., 1997; 
Raymond et al., 1993).
A second approach used to examine the affinity of the different G proteins for 
the 5-HTiA receptor required the use of suramin. Suramin acts as a G protein 
antagonist with two distinct mechanisms of action. Firstly, at lower than |iM 
concentrations, suramin suppresses the rate of GDP release from purified G protein a
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subunits (Freissmuth et al., 1996). This effect is reversed in the presence of a GPCR 
giving an indication that the binding of suramin and an effector are mutually 
exclusive (Freissmuth et al., 1996). Secondly, suramin and its analogues disrupt the 
formation of the ternary complex, i.e. the ligand-receptor-G protein complex, by 
binding to the site of the G protein-receptor interface (Huang et al., 1990; 
Hohenegger et al., 1998; Beindl et al., 1996). The ability of suramin to disrupt the 
formation of this complex depends on the constituents involved. The higher the 
coupling affinity of the receptor and G protein, the less the ability of suramin to 
uncouple the complex formation (Waldhoer et a l, 1999). Small structural changes in 
suramin change its affinity for receptors, e.g. suramin is ten fold more potent than 
NF037 (di-demethylated suramin) at uncoupling the Ai adenosine receptor, but the 
two analogues are equipotent at uncoupling the D2 dopamine receptor (Beindl et al.,
1996). Given that these two receptors were shown to interact with identical G« 
subunits (Waldhoer et al., 1999), the contact formed between the receptor and G 
protein is diverse enough to allow selective coupling.
Suramin, ranging from lOnM up to ImM, produced concentration dependent 
decreases in [^H]-8-OH-DP AT binding to the 5-HTia receptor and its various G« 
protein constructs. Pertussis toxin treatment significantly decreased agonist binding 
to membranes expressing the 5-HTia receptor alone and the 5-HTia receptor fused to 
the WT Gila and Goia fusion proteins, but had no effect on membranes expressing 
the pertussis toxin resistant receptor-G protein fusion proteins.
As was found in the GDP displacement bindings, the results from pertussis 
toxin-treated Gna fusion expressing membranes demonstrated that the concentration 
of suramin required to produce a 50% reduction in agonist radioligand binding was 
significantly higher for the Ile^^  ^ mutant (5.8 +!- 0.4jiiM) than for the Gly^^  ^ mutant 
(0.8 +/- 0.1 |iM) (P = 0.0002). While the E C 5 0  for the WT G protein receptor fusion 
(1.7 4-/- 0.5jLiM) was not significantly different from the Gly^^  ^ mutant E C 5 0 ,  it was 
from the Ile^^^  mutant, and might indicate the same rank order of affinity of the 
receptor for G protein as in previous results, highest to lowest, Ile^^  ^> Cys^^^>Gly^^\
The same pattern is observed in the results from the Goia protein-receptor 
fusions. The E C 5 0  for suramin prevention of [^H]-8-OH-DP AT binding was 
significantly higher for the Ile^^  ^ mutant (6.1 +/- 0.7|liM) than for the Gly^^  ^ mutant 
(0.8 +!- 0.1 j^M) (P = 0.0003). This was also the case for the non pertussis toxin-
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treated results (P = 0.0142) with the EC50 for the WT Cys^^  ^ mutant falling in 
between (1.3 +/- 0.6p.M), although it was not significantly different from the results 
of the two mutants. When looked at in unison, all of these data indicate that, Güa or 
Goia proteins with the Ile^ ^^  mutation have a higher affinity for the agonist-occupied 
5-HTia receptor than the WT Cys^^  ^ receptor-G protein fusion, with both having 
greater affinity than the Gly^^  ^Ga subunits.
Another pattern that emerged throughout the binding experiments was that 
the Gila proteins appeared to have a higher affinity for the 5-HTia receptor than their 
corresponding Goia fusions did (Table 4.5). Although these differences were not 
significant (P > 0.05), this conclusion would be supported by previous findings in the 
literature (Clawges et ah, 1997; Bertin et ah, 1992; Gamovskaya et a l, 1997; 
Raymond et al., 1993), where the 5-HTia receptor preferentially coupled to Gia over 
G oa-
Although differences in Hill slope values were observed throughout the 
ligand binding assays for the various 5-HTia receptor-G protein fusions, none of 
these were significant and no firm conclusions may be drawn from the results.
The 5-HTiA selective antagonist [^H]-MPPF was also examined in GDP and 
suramin prevention bindings. As antagonists do not distinguish between G protein- 
coupled and uncoupled affinity states of a receptor, binding to both equally (Kobilka 
et al., 1992), neither pertussis toxin-treatment, nor addition of increasing 
concentrations of GDP or suramin, prevented the binding of the antagonist 
radioligand.
Two-site competitive binding is recorded in two main situations. The first is 
where there are two distinct classes of receptors to which the ligand will bind, e.g., 
the pi and P2 adrenergic receptors. The second occurs when the unlabelled ligand has 
distinct affinities for the two sites. This second situation occurs in figures 4.11 and 
4.12, where the receptors exist in two affinity states for agonist binding (Emeritt et 
al., 1990). In the G protein uncoupled form the receptors have a low affinity for 
agonist binding, but once the receptor and G protein interact, the receptor changes 
conformation and exists in the high affinity form. Activated receptor, or agonist 
bound receptor, decreases the affinity of the Ga subunit of the G protein for GDP, 
promoting its release. Conversely, an excess of GDP, or non-hydrolysable analogues 
of GTP such as Gpp(NH)p, lowers the affinity of the G protein for the receptor
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(Hepler and Gilman 1992). The difference in affinity of a compound for these states 
can give an indication of its intrinsic activity (Birdsall and Lazareno, 1997). By 
looking at agonist displacement of antagonist radioligand binding we can measure 
the fraction of the receptor existing in the two affinity states along with the EC50 of 
agonist displacement of antagonist values for these two states (Table 4.5). It was 
found that for the 5-HTia receptor GüaC^^^G fusion, only 25.1 +/- 6.1% of the 
receptor population existed in the high affinity state (%Rh). A significantly greater 
fraction of the 5-HTia receptor GnaC^^^I fusion existed in the high affinity state, 66,6 
+/- 3.2% (P = 0.0039). These data indicate that with He at position^^^ in the Güa 
protein, the 5-HTia receptor has a significantly higher affinity for the G protein than 
when Gly is present at position^^\ leading to a greater proportion of the 5-HTia 
receptor population existing in the high affinity state for agonist binding. These 
results also indicated that although the close proximity of the receptor and G protein 
in the fusion construct may favour the G protein coupled state, the construct does not 
exclusively exist in this conformation.
In order to assess more fully the possible intrinsic constitutive activity of the 
Ile^^  ^ Ga protein mutants, the differences in affinity of Gly^^\ Cys^^  ^ and Ile^^  ^ Ga 
protein mutants for the 5-HTia receptor and the differences in affinity of the 5-HTia 
receptor for Gna and Goia proteins, it was decided to conduct a number of GTPase 
assays which would measure the rate of GTP hydrolysis by the Ga protein fusions.
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Chapter 5
High Affinity GTPase Assays 
With RGSl and RGS16 Proteins
5.1 Introduction
Ligand activation of second messenger systems by the 5-HTia receptor is 
transduced via inhibitory G proteins (Boess and Martin 1994; Saudou and Hen, 1994; 
Albert et aL, 1996). Upon receptor activation the Ga subunit changes conformation, 
resulting in a decrease in affinity for GDP and an increase in affinity for GTP. 
Binding of this tri-phosphate leads to dissociation of the oc and Py subunits allowing 
stimulation of a variety of second messengers (Hamm, 1998). The period of this 
signal is determined by the intrinsic GTPase activity of the Ga protein subunit. 
Hydrolysis of GTP to GDP results in a return to the inactive conformation of the Ga 
subunit and an increased affinity for the free py dimer, re-association of these 
transducers terminates second messenger activation (Hamm, 1998; Bimbaumer and 
Bimbaumer 1995; Helmrich and Hofmann 1996).
It has not been possible to accurately measure the rate of GTP hydrolysis 
until recently, when fusions between GPCRs and G protein a  subunits demonstrated 
a number of interesting characteristics. In some constructs agonist stimulated 
signalling was transduced exclusively by the fused G protein (Kellett et a l, 1999). 
Utilising G protein a  subunits resistant to pertussis toxin catalysed ADP ribosylation 
coupled to GPCRs meant that in a GTPase assay ligand stimulated turnover of GTP 
to GDP was by the fused Ga subunit (Burt et a l, 1998). The 1:1 stoichiometry of the 
GPCR to G protein meant that ligand binding could determine not only the exact 
expression level of the GPCR but also of the G protein. Using this information the 
exact turnover of GTP to GDP by a single G protein a  subunit could be measured.
It has been previously established that addition of 5-HT to membranes 
expressing the 5-HTia receptor and its inhibitory G protein fusions results in a 
concentration-dependent increase in high affinity GTPase activity (Kellett et a l, 
1999). In constructs between the 5-HTia receptor and pertussis toxin resistant G 
protein a  subunits a lack of coupling to the endogenous pool of Gi was demonstrated 
by the lack of effect of pertussis toxin on both inhibition of adenylyl cyclase activity 
and GTP turnover in the high affinity GTPase assay. A degree of intrinsic 
constitutive activity was also measured in the 5-HTiA/GuaC^^^I fusion protein 
illustrated by the ability of spiperone to decrease basal GTPase activity in 
membranes expressing the Ile^^  ^construct (Kellett et a l, 1999).
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Another factor in determining the degree of activation of second messenger 
systems is the presence of RGS (Regulators of G protein Signalling) proteins (Hong 
et aL, 1993). This family of proteins, consisting of greater than 20 members, act as 
GAPs (GTPase activating proteins) for the Gj and Gq classes of G protein a  subunits 
(Berman et a\., 1996; Watson et aL, 1996; Ingi et aL, 1998; Kozasa et aL, 1998; 
Hepler, 1999; De Vries et aL, 2000). RGS proteins inhibit GPCR signalling in a 
number of ways. Firstly, their GAP activity decreases the length of time spent in the 
active GTP-bound confomation of the G« subunit (Saitoh et aL, 1997; Doupnik et aL,
1997). Secondly, the binding of the RGS protein to the G« subunit can hinder its 
ability to couple to second messenger generators, preventing signal generation 
(Hepler et aL, 1997). Over expression of GST fused forms of these RGS proteins 
using a bacterial expression system allows their purification and subsequent 
characterisation.
Using the high affinity GTPase assay the 5-H T ia receptor and its G,ia and 
Goia fusions were further characterised together with the effects of the two available 
recombinant RGSl and RGS 16 proteins.
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5.2 Results
GTPase assay conditions were re-established for the 5-HTia receptor-G 
protein fusions stably expressed in HEK293 cell lines following conversion to a 96 
well plate format and the use of a Packard Topcounter. Initial experiments examined 
the high affinity GTPase activity of the 5-HTiA/GüaC^^^G/I constructs at a variety of 
protein concentrations and incubation periods (Figures 5.1 and 5.2). No significant 
difference in either basal or 5-HT (lOOjiiM) stimulated GTPase activity was found 
between the incubation periods of 10, 20, 30 and 40 minutes or at four different 
protein amounts (10, 5, 2.5 and 1.25|ig) for either construct. It was concluded that 
the conditions observed represented Vo and not conditions where reactants were 
limiting. The conditions used for the subsequent GTPase assays were an incubation 
period of 20 minutes with 2.5jLig of protein.
5-HT stimulation of an endogenous receptor in HEK293 cells had shown 
stimulation of cAMP production in the intact cell adenylyl cyclase assay (Figures 
3.11 and 3.12), In order to demonstrate that 5-HT stimulated GTPase activity was 
entirely due to activation of the stably transfected 5-HTia receptor-G protein fusions, 
the 5-HTia selective agonist 8-OH-DP AT was used in parallel with 5-HT to 
stimulate high affinity GTPase activity (Figure 5.3). In both untreated and pertussis 
toxin-treated membranes expressing the 5-HTiA/GiiaC^^^G/I fusion proteins, the 
activation produced by 8-OH-DP AT was not significantly different to that of 5-HT 
(P < 0.05).
The potency of 5-HT (InM-lOOjuM) to stimulate high affinity GTPase 
activity was assessed in the seven different stable cell lines. For the 5-HTia receptor 
alone, and the WT Güa and Goia fusion proteins, treatment with pertussis toxin 
abolished agonist stimulated high affinity GTPase activity with the exception of the 
WT Gila fusion protein where concentrations above Ij^M produced a small 
stimulation of GTPase activity (Figure 5.4). The pECso values for the 5-HTia 
(7.19+/-0.06nM) receptor and the Güa and Goia (6.73+/-0.05nM and 7.51+/-0.22nM 
respectively) pertussis toxin sensitive fusion proteins were not significantly different 
from one another (P > 0.05) (Tables 5.1 and 5.2).
A concentration-dependent increase in high affinity GTPase activity was also 
seen with the pertussis toxin resistant 5-HTiA/GüaC^^^G and 5-HTiA/GüaC^^^I fusion 
proteins (Figure 5.5A). The pECso values for the 5-HTiA/GüaC^^^G protein in the
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absence or presence of pertussis toxin (6.11+/-0.07nM and 5.94+/-0.08nM 
respectively) were not significantly different from each other (P > 0.05), a result that 
may indicate that the fusion protein is not coupling to endogenous G proteins in this 
assay (Table 5.1). The same was not true for the 5-HTiA/Giiatf^^I fusion protein 
with pECso values of 7.23+/-0.09nM and 6.50+/-0.07nM for non- and pertussis 
toxin-treated membranes respectively (P < 0.05), This may indicate coupling to the 
endogenous pool of inhibitory G proteins. Comparison of the pECso values for the 
Gly^^  ^ mutant and the He^ ^^  mutant proteins established that the two non-pertussis 
toxin-treated samples were significantly different from one another (P < 0.001), as 
were the pertussis toxin-treated samples (P < 0.01). This may be a reflection of the 
higher affinity that Güa has for the 5-HTia receptor with the in the Ile^^  ^ mutation. 
The pECso values for both the Gly^^  ^ and Ile^ ^^  Gua protein mutants were 
significantly different from the WT Cys^^  ^ Gua fusion protein (P < 0.05). This result 
supports the hypothesis that the hydrophobicity of the amino acid at position 351 in 
the Gila protein is important in 5-HTia receptor-Gua protein coupling.
The results for the Goia fusion proteins were analysed and did not 
demonstrate any differences between non-treated and pertussis toxin-treated samples 
for each protein (Gly^^ ;^ 6.69+/-0.01nM and 6.88+/-0.07nM; Ile^^ :^ 7.46-i-/-0.03nM 
and 6.7l4-/-0.22nM respectively), or any differences between the Gly^^  ^ and Ile^ ^^  
mutants (P > 0.05) (Table 5.2). As with the results for the Güa fusion proteins, the 
pECgo value for the WT Goia fusion protein (7.51+/-0.22) was significantly different 
from the pECgo values for the Gly^^  ^ and He^ ^^  mutant Gua fusion proteins (P < 
0 .0 0 1 ). This result again indicates that the interaction between the 5-H T ia receptor 
and the Güa protein with the Gly^^  ^ mutation may not be as strong as the WT Güa 
protein or the Ile^^  ^mutant Güa protein interactions. Comparison of the Gua and Goia 
fusion protein results showed no differences in the EC50 values for 5-HT stimulated 
high affinity GTPase activity between the samples (P > 0.05).
RGS protein-GST fusions had previously been generated in the lab for both 
RGSl and RGS 16. cDNA encoding these fusion proteins was transformed into 
competent BL21-S1 bacteria which were grown in 500ml cultures to an 00*"°° of 
0.3-0.4 before induction with I.P.T.G. and the expressed protein subsequently 
purified following four hours growth as per section 2.3. Figure 5.6 shows a 
representative Coomassie Blue stained gel of the various samples taken during the
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purification process. Induction of the RGS-GST protein is denoted by a strong 
increase in the band present on the gel at approximately 50kDa following addition of 
IPTG and the purification was followed using Glutathione Sepharose 4B gel. 
Typically, a protein concentration of between 10 and 20|iM was purified using this 
method.
The effects of these purified RGS proteins were assessed in the high affinity 
GTPase assay (Figure 5.7, A + B). The agonists 5-HT (100p.M) and 8-OH-DAPT 
(lOOjiM) produced significant increases in GTPase activity over basal for both the 5- 
HTiA/Gila Gly^^  ^ and Ile^^  ^ pertussis toxin treated membranes (P < 0.05). These 
effects were significantly increased (P < 0.05) by the addition of either RGSl or 
RGS 16 (lp,M) to the reaction mixture when compared to agonist alone, indicating 
functional activity for the purified proteins.
A control experiment was carried out to confirm that the effect of the RGS 
proteins was due to 5-HTia receptor activity. Using mock-transfected HEK293 cells, 
the effects of 5-HT (100|4M) and RGSl (IjiiM) on GTPase activity were investigated 
(Figure 5.8). Neither 5-HT, nor RGSl alone produced any significant increase in 
GTPase activity over basal. The combination of the two did not have a significant 
effect either.
The effects of the RGSl and RGS 16 proteins on agonist-activated high 
affinity GTPase activity was examined at a range of GTP concentrations. In 
membranes expressing the 5-HTia receptor alone, over a range of nucleotide 
concentrations from 25nM to 3p.M, 5-HT produced a large increase in Vmax (15 +/- 
0.05 fold) without effecting the K,n (253 +/- 21nM and 200 +/- 13nM respectively) 
for GTP (Figure 5.9, A + B). In the presence of RGSl at lOjuM, 5-HT produced a 
much more marked increase in high affinity GTPase activity. Along with the three­
fold increase in V„tax there was also an increase in the K,n for GTP (from 256 +/- 
52nM to 616 +/- 60nM respectively). Treatment of cells with pertussis toxin prior to 
harvesting and membrane preparation produced a decrease in Vmax but no alteration 
of the K,n for GTP (Figure 5.10, A + B). It also abolished any effects of 5-HT or 
RGSl on high affinity GTPase activity.
High affinity GTPase activity in membranes stably expressing the WT 5- 
HTia receptor Güa and Goia fusion proteins was examined in the presence of RGSl 
and 5-HT (Figure 5.11, A + B). 5-HT produced over a four-fold increase in Vmax for
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the Gila fusion, and a one and a half fold increase for the Goia fusion, but did not 
have a significant effect on the K,n for GTP for either construct (P > 0.05). Addition 
of RGSl (lOjLiM) to the reaction mix produced a significant increase in V,nax in the 
presence of 5-HT over 5-HT alone (seven fold for Gua and 10 fold for Goia) (P < 
0.05) and in K„i (seven fold for both G^a and Goia) (P < 0.05). Pertussis toxin 
treatment reduced the Vmax for both Gua and Goia fusions for all treatments with the 
effects of RGSl no longer being significant (Figure 5.12, A + B).
The effects of RGSl and RGS 16 were examined in much greater detail with 
the pertussis toxin-resistant mutants of both Gna and Goia fusion proteins. The effect 
of RGS 16 was assessed at seven different concentrations (InM, 5nM, lOnM, 50nM, 
lOOnM, 500nM, and IjiiM) and those of RGSl at eight different concentrations (as 
RGS 16 plus 5|4M). The basal and 5-HT stimulated high affinity GTPase activity for 
5-HTiA/GiiaC^^^G was measured in the presence of the range of RGS protein 
concentrations. In Figure 5.13, increasing concentrations of RGSl had no effect on 
either the Vmax or Km for GTP of basal GTPase activity (P > 0.05) (Table 5.3). In the 
presence of 5-HT (IOOfxM)(Figure 5.14), an increase in both Vmax and K,n are 
measured with increasing concentrations of RGSl. Stimulation by 5-HT causes a 
significant increase in V,„ax over basal (P < 0.05), but has no effect on the K,n for GTP 
(P > 0.05). The effects of RGSl on Vmax become significant at 50nM (P = 0.0015), 
but despite clear increases, those on K,n only become significant once the 
concentration of RGSl has reached IjiiM (P = 0.0157).
In the presence of RGS 16 (Figure 5.15), as with RGSl, no increase in either 
Vmax or Km is measured for basal GTPase activity (P >0.05) (Table 5.3). 5-HT alone 
produces a significant increase in over basal (Figure 5.16) (P = 0.0015), but has 
no effect on Km (P > 0.05). Following the addition of RGS 16 at increasing 
concentrations, the effects on Vmax over 5-HT stimulation become significant at 
50nM (P = 0.0099) and the effects on Km at lOOnM (P < 0.05).
In the presence of increasing concentrations of RGSl, basal 5-HTiA/GiiaC^^^I 
GTPase activity increases in terms of Vmax and K,n (Figures 5.17 and 5.18). The 
increase in Vmax becomes significant at 5nM (P = 0.0235), but although the increase 
in Km is apparent over the eight RGS protein concentrations, increasing from 219 +/- 
36nM to 447 +/- 69nM, it is not statistically significant (P > 0.05) (Table 5.4). 
Following stimulation with 5-HT, V,„ax increases significantly over basal (P =
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0.0025) without a change in With the addition of RGSl, the V,nax and K,n become 
significant over 5-HT stimulation at lOOnM (P = 0.0083 and 0.0303 respectively).
The effects of RGS 16 are similar, although neither the increases in Vmax, 
rising from 38 +!- 10 to 81 +/- 15 (pmol/mg/min) (Table 5.4), nor in Km, rising from 
210 +/- 48nM to 411 +/- 15 InM, for basal GTPase activity become significant (P > 
0.05) (Figure 5.19). The effects on Vmax in the presence of 5-HT are significant over 
basal (P < 0.05), and in the presence of RGS 16 become significant over 5-HT 
stimulation alone at InM (P = 0.0455) (Figure 5.20). Stimulation with 5-HT alone 
has no effect on Km, but the addition of RGS 16 from concentrations of 5nM and 
above has a significant effect (P = 0.0226).
Comparison of the effects of RGSl and RGS 16 on GTPase activity of the 5- 
HTiA/GiiaC^^^G construct demonstrated no significant effect on basal GTPase 
activity for either RGS protein (Figure 5.21, A) and similar effect for both proteins 
on 5-HT stimulated high affinity GTPase activity (Figure 5.21, B). When this is 
examined in terms of fold stimulation in GTPase activity over 5-HT stimulation 
(Figure 5.22), non linear regression predicts a higher maximal increase in activity for 
RGSl (27 fold) than for RGS 16 (4 fold), although given that the curve may be either 
reaching a plateau or, the exponential phase of any RGS protein effect, these 
predictions are unlikely to be accurate. Although the curve fit for RGSl and RGS 16 
effects on basal 5-HTiA/GuaC^^^I GTP hydrolysis may not be completely accurate, it 
is apparent that the RGS proteins have a significant effect of basal turnover of GTP 
(Figure 5.21, A), The RGS protein effects on GTP turnover following 5-HT 
stimulation are almost identical (Figure 5.21, B), with neither protein having reached 
a maximal effect at the highest concentration used. When their effects are examined 
in terms of fold increase in turnover number over 5-HT stimulation, RGS 16 appears 
to have a greater effect (Figure 5.22), but given the large standard error for RGS 16 at 
l|iM , it is not surprising that this difference is not significant.
Basal GTPase activity for the 5-HTiA/GoiaC^^^G fusion protein is 
significantly modified by the addition of RGSl at IjxM in terms of Vmax (P = 0.0427), 
but the Km does not significantly change (Figure 5.23) (Table 5.5). Stimulation of 
high affinity GTPase activity with 5-HT significantly increases Vmax over basal (P = 
0.0025) but doesn’t effect Km (Figure 5.24). Increases in Vmax and K,n in the presence 
of RGSl both become significant at 50nM (P = 0.0126 and 0.019 respectively). The
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effects of RGS 16 are similar, but basal and K,n are not significantly effected 
even at IjLiM (Figure 5.24) (Table 5.5). 5-HT produces a significant increase in Vmax 
over basal (P = 0.0191) and in the presence of RGS 16, Vmax increases significantly 
over 5-HT stimulation at 5nM (P = 0.0089) (Figure 5.25). 5-HT alone has no effect 
on the Km for GTP, but in the presence of RGS 16, increases in K,n become significant 
at 50nM (P = 0.0122).
For the 5-HTiA/GoiaC^^^I fusion, RGSl produces significant increases in both 
Vmax and Km of basal GTPase activity (Figure 5.27) (Table 5.6). At lOnM the increase 
in Vmax is significant (P = 0.0012) over basal and at lOOnM the effects on Km are 
significant (P = 0.0088). 5-HT produced a significant increase in Vmax over basal (P = 
0.0015), but again did not effect the Km for GTP (Figure 5.28). In the presence of 
increasing concentrations of RGSl there was a significant increase in Vmax at InM (P 
= 0.008) and in Km at 50nM (P = 0.0019) over 5-HT stimulation. The second RGS 
protein, RGS 16 produced similar effects on basal GTPase activity (Figure 5.29) 
(Table 5.6). There was a significant increase in basal GTPase V,„ax at lOnM (P = 
0.0164), but no statistical increase in Km until lp,M (P < 0.05). 5-HT produced a 
significant increase over basal in Vmax, but not the Km for the GTPase activity of the 
5-HTiA/GoiaC^^^I fusion (Figure 5.30). For both Vmax and Km, the increasing 
concentrations of RGS 16 produced significant increases over 5-HT stimulation alone 
at 5nM (P = 0.0131 and 0.0184 respectively).
Comparison of the two RGS proteins effects shows that neither had any real 
effect on basal turnover of GTP (Figure 5.31, A), but both produced a similar 
significant effect on 5-HT stimulated GTPase activity (Figure 5.31, B). In terms of 
fold stimulation over 5-HT, RGSl and RGS 16 produce similar increases in 
stimulation, with RGS 1 appearing to produce increases at lower concentrations that 
RGS 16 (Figure 5.32). Comparison of the effects of the two RGS proteins 
demonstrated similar increases in GTP turnover for both basal and 5-HT stimulation 
(Figure 5.31, A + B). This is also reflected in the fold stimulation over 5-HT (Figure 
5.32), with no significant difference in the increases produced by either RGSl or 
RGS16(P>0.05).
In order to determine if endogenous RGS protein effects were being lost 
during membrane preparation the two fractions normally discarded during 5- 
HTiA/GoiaC^^^I membrane preparation were assayed for RGS protein activity (Figure
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5.33, A). Neither fraction produced an increase in GTPase activity, either basal or 
stimulated, but actually produced a slight decrease in activity. As a control, purified 
RGSl (lp,M) was shown to produce increases in high affinity GTPase activity 
similar to previous observations. Given these results it was decided that to assay 
these fractions at a range of GTP concentrations would not show any effects on K,n 
and Vniax'
Secondly, to investigate further the possible loss of RGS proteins during 
membrane preparation, cells were treated with 5-HT (100|xM) prior to harvesting to 
see if a stronger interaction with the membrane could be induced by interaction of 
any endogenous RGS proteins with the activated 5-HTiA/GoiaC^^^I fusion protein 
(Figure 5.33, B). There was no significant increase in basal or 5-HT stimulated 
GTPase activity in these membranes over untreated control membranes. As a control, 
purified RGSl was assayed for activity in the presence and absence of 5-HT and 
produced a response similar to previous experiments. It was decided that no 
significant effect on either Vmax or K,n would be seen in an assay of a range of GTP 
concentrations.
To examine endogenous expression of RGS proteins, quantitative reverse 
transcriptase PCR was carried out on HEK293 DNA. A list of RGS proteins 
reportedly expressed either ubiquitously or in the kidney was drawn up (Table 5.1) 
and primers and probes were designed for RGS2, RGS3, RGS4, RGS9 and GRK2. 
With the exception of RGS9, cDNA was available for the RGS proteins and was 
used to set the PCR conditions for the taqman experiments. Figure 5.34, panel A 
illustrates the successful establishment of PCR conditions for RGS2, showing that 
for the 50:50nM ratio of reverse to forward primer (yellow/green/red lines) there was 
a lower level of amplification than with the 300:300nM ratio or the 900:900nM ratio 
(group of lines to the left). From this experiment, the concentration of forward to 
reverse primer was set at 300;300nM with the concentration of the probe remaining 
constant (lOOnM final). Identical amplification for RGS3 and RGS4 was seen at the 
three different primer concentrations so the lowest concentration of 50:50nM was 
selected. For GRK2 (Figure 5.34, B), no discernible amplification was detected at 
any of the three primer concentrations, and no further experiments were performed 
on this protein. As no cDNA was available for RGS9, genomic DNA was used as a
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template for experiments to establish PCR conditions. As with GRK2, no 
amplification was detected and no further work was carried out with this protein.
With PCR conditions set, an experiment was performed to assess the 
expression of RGS proteins in HEK293 cDNA. Standard curves for RGS2, RGS3 
and RGS4 were also run using a range of cDNA concentrations (lOng -  O.lpg) and 
as a control, expression of 18S, a ribosomal DNA was assessed. Expression of 18S is 
thought to be similar throughout most cell types and is used as a reference to quantify 
the levels of unknown DNA. For RGS2, RGS3 and RGS4, replication using HEK293 
DNA as a template occurred between 30 and 35 cycles. This would normally indicate 
low levels of expression, but problems occurred with the standard curves with no 
replication being recorded below Ing of cDNA. It was speculated that this was due to 
either impurity of the cDNA samples and the overestimation of their concentration, 
or due to large amounts of secondary structure in the cDNA.
In an attempt to solve these possible problems, the DNA was isopropanol 
precipitated to remove any impurities and the concentration estimated using OD^^°. It 
was found that the concentrations were not significantly different to previous 
estimations. In an attempt to remove secondary structure, 5% DMSG was added to 
the reaction mixture and the standard curves carried out again. This did not improve 
on the results of the previous experiments. No further experiments were performed.
133

Figure 5.1 Basal and 5-HT stimulated high affinity GTPase
activity in pertussis toxin treated membranes 
expressing the 5-HTiA/G;iaC^ G fusion protein
Panel A: Basal high affinity GTPase activity in pertussis toxin pre-treated 
membranes expressing the 5-HTiA/GüaC^^'G fusion protein. Panel B: The ability of 
a previously established maximal 5-HT concentration (Kellett et al., 1999) to 
stimulate 5-HTiA/G,iaC^^'G high affinity GTPase activity.
Four different membrane amounts (10, 5, 2.5 and 1.25pg) and three different 
timepoints (20, 30 and 40min.) were examined to establish appropriate assay 
conditions. Data are mean+/-SD of triplicate determinations and are representative of 
at least three similar experiments.
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Figure 5.2 Basal and 5-HT stimulated high affinity GTPase
activity in pertussis toxin treated membranes 
expressing the 5-HTiA/GiK%C  ^ I fusion protein
Panel A: Basal high affinity GTPase activity in pertussis toxin pre-treated 
membranes expressing the 5-HTiA/GiiaC^^*I fusion protein. Panel B: The ability o f a 
previously established maximal 5-HT concentration (Kellett et a i ,  1999) to stimulate 
5-HTiA/G,iaC^^'l high affinity GTPase activity.
Four different membrane amounts (10, 5, 2.5 and 1.25pg) and three different 
timepoints (20, 30 and 40min.) were examined to establish appropriate assay 
conditions. Data are mean+/-SD of triplicate determinations and are representative of 
at least three similar experiments.
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Figure 5.3 Basal and agonist stimulated high affinity GTPase
activity in membranes expressing the 5-HTia 
receptor fused to Gly^ *^ and Ile^ *^ G^a protein 
mutants
Basal and agonist stimulated high affinity GTPase activity in non-, and pertussis 
toxin pre-treated membranes expressing either the 5-HTiA/GüaC^^’G or the 5- 
HT|A/G,iaC^^’l fusion protein. Stimulation with either 5-HT (lOOpM) or the 5-HTja 
selective agonist 8-OH-DAPT (lOOpM) was not significantly different (P > 0.05). 
Prior treatment of cells prior to harvesting with pertussis toxin did not significantly 
alter high affinity GTPase activity (P > 0.05). Data are means of triplicate 
determinations and are representative o f at least three similar experiments.
■  5-HT,A/Gi,aC” 'G
□  5-HT,A/G„aC^"G ptox
■  5-HT|A/Gii„C” 'l
■  5-HT|A/Gii„C^^'l ptox
136
40n
30-
c
O)
o 20-1 EQ.
10 - X
■
I#i;
I
I
1i
<1
!:
1 :
1 :
Basal 5-HT 8-OH-DPAT

Figure 5.4 5-HT concentration response curves for activation
of GTPase activity in the 5-HTia receptor and its 
WT Glia and Goia fusion proteins
The potency of 5-HT to stimulate high affinity GTPase activity in both untreated and 
pertussis toxin treated membranes expressing the 5-HTiA receptor and its WT Güa 
and Goia fusion proteins was examined. Data are mean+/-S.D. o f triplicate 
determinations and are representative o f at least three similar experiments.
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Figure 5.5 5-HT concentration response curves for activation
of GTPase activity in the 5-HTia receptor and its 
mutant Gna and Goi« pertussis toxin resistant 
fusion proteins
Panel A: The potency of 5-HT to stimulate high affinity GTPase activity in both 
untreated and pertussis toxin treated membranes expressing the 5-HTiA/GiiaC^^'O 
and 5-HT|A/GiiaC^^T fusion proteins was examined, 
g  5-HT,A/G.,aC''G
5-HT 1 a/G, laC^  ^’ G ptox
Y  5-HT,A/G,iaC"T 
^  5-HT,A/G,iaC^^'lptox
Panel B: 5-HT stimulation of high affinity GTPase activity in both untreated and 
)xii
HTiA/GoiaC^^'l fusion proteins were examined.
pertussis to n-treated membranes expressing the 5-HTiA/GoiaC^^‘G and 5
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Data are mean+/-S.D. o f triplicate determinations and are representative o f at least 
three similar experiments.
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Table 5.1 Mean pECso values from 5-HT stimulation of high
affinity GTPase activity for the 5-HTia receptor- 
Giia WT and mutant fusion proteins
The effects of increasing concentrations of 5-HT on high affinity GTPase activity in 
membranes expressing the WT and mutant Giia-5-HTiA receptor fusion proteins 
were measured in terms of pECso. Brackets indicate statistically significant 
comparisons. Data are mean +/- SEM from tliree similar experiments.
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Table 5.2 Mean pECso values from 5-HT stimulation of high
affinity GTPase activity for the 5-HTia receptor- 
Goia WT and mutant fusion proteins
The effects of increasing concentrations of 5-HT on high affinity GTPase activity in 
membranes expressing the WT and mutant Goia-5-HTiA receptor fusion proteins 
were measured in terms of pECso. Brackets indicate statistically significant 
comparisons. Data are mean +/- SEM from tliree similar experiments.
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Figure 5.6 Coommassie Blue staining for puriBed RGSl- and
RGS16-GST following protein purification using 
Glutathione Sepharose 4B gel
Protein was stained for with Commassie Blue following electrophoresis of purified 
protein and crude bacterial extracts using NuPAGE 4-12% Bis-Tris pre-cast gels.
Panel A: Protein of an apparent M  of approximately 50kDa was apparent, consistent 
with the calculated size of the RGSl-GST fusion protein. Lanes 1 and 12 contain 
rainbow markers, lane 2 contains bacterial sample prior to EPTG induction, lanes 3-5 
contain bacterial samples at 1, 2 and 3 hours post induction, and lanes 6-10 contain 
samples of purified RGSl6 protein. The protein at approximately 24 and 26kDa 
corresponds to degraded RGSl6 protein and GST.
Panel B: Protein of an apparent M  of approximately 50kDa was apparent, consistent 
with the calculated size of the RGSl-GST fusion protein. LaneS contains rainbow 
markers, lanes 1,2,9 and 10 contain bacterial samples 2 hours (1 + 9) and 3 hours (2 
+ 10) post IPTG induction, and lanes 3-7 and 11-15 contain samples of purified RGS 
16 protein.
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Figure 5.7 Basal and agonist stimulated high affinity GTPase
activity in membranes expressing the 5-HTia 
receptor fused to Gly^ *^ and Ile^ *^ Gii„ protein 
mutants in the presence of RGSl and RGS16 
proteins
Basal and agonist stimulated high affinity GTPase activity in pertussis toxin pre­
treated membranes expressing either the 5-HTiA/GiiaC^^*G (Panel A) or the 5-
HTiA/GiiaC^^*I (Panel B) fusion protein. Stimulation with either 5-HT (lOOpM) or 
the 5-HT IA selective agonist 8-OH-DAPT (lOOpM) was significantly (P < 0.05) 
enhanced by the presence of purified RGSl or RGS 16 proteins (IpM ). Data are 
means of triplicate determinations and are representative o f at least three similar 
experiments.
5-HT|A/G„aC^ ’‘G ptox 
5-HTia/G,i„C” 'I ptox
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Figure 5.8 Lack of effect of 5-HT and RGSl protein on mock
transfected HEK293 cells
High affinity GTPase activity was measured in un-transfected HEK293 membranes 
in the presence and absence o f 5-HT (lOOpM) and RGSl (10 |liM). Data are means of 
triplicate determinations and are representative of at least three similar experiments.
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Figure 5.9 Basal and 5-HT stimulated GTPase activity of
membranes expressing the 5-HTia receptor in the 
presence and absence of RGSl
Panel A: GTPase activity of membranes expressing the 5-HT ia receptor with 
increasing concentrations of GTP as substrate. 5-HT (lOOpM) stimulated GTPase 
activity was measured in the presence and absence of RGSl ( 1 pM). Data were 
modelled to an equation of a one-site fit hyperbola. Panel B: The data generated were 
transformed to Eadie-Hofstee plots to analyse effects on for GTP hydrolysis and
kmax-
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 5.10 Basal and 5-HT stimulated GTPase activity of
pertussis toxin-treated membranes expressing the 
5-HTia receptor in the presence and absence of 
RGSl
Panel A: GTPase activity in pertussis toxin-treated membranes expressing the 5- 
H T |a receptor with increasing concentrations of OTP as substrate. 5-HT (lOOpM) 
stimulated GTPase activity was measured in the presence and absence o f RGSl 
(IpM ). Panel B: The data generated were converted to Eadie-Hofstee plots to 
analyse effects on for GTP hydrolysis and Pmax-
Data are means o f triplicate determinations and are representative of at least three 
similar experiments.
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Figure 5.11 Basal and 5-HT stimulated GTPase activity of 
membranes expressing the 5-HTiAGüa and 5- 
HTia/GoIu receptors in the presence and absence 
of RGSl
Panel A: GTPase activity in membranes expressing the 5-HTiAGüa fusion protein 
with increasing concentrations of GTP as substrate. 5-HT (lOOpM) stimulated 
GTPase activity was measured in the presence and absence o f RGSl (IpM ). Panel B: 
GTPase activity in membranes expressing the 5-HTiAGoia fusion protein with 
increasing concentrations o f GTP as substrate. 5-HT (lOOpM) stimulated GTPase 
activity was measured in the presence and absence of RGS1 ( 1 pM).
Data are means o f triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 5.12 Basal and 5-HT stimulated GTPase activity of 
pertussis toxin-treated membranes expressing the 
5-HTiAGiia and 5-HTiA/Goia receptors in the 
presence and absence of RGSl
Panel A: GTPase activity in pertussis toxin-treated membranes expressing the 5- 
HT iaGiIo fusion protein with increasing concentrations of GTP as substrate. 5-HT 
(lOOfiM) stimulated GTPase activity was measured in the presence and absence of 
RGSl (IjLiM). Panel B: GTPase activity in pertussis toxin-treated membranes 
expressing the S-HTiaGoIq fusion protein with increasing concentrations of GTP as 
substrate. 5-HT (lOOpM) stimulated GTPase activity was measured in the presence 
and absence of RGS 1 ( 1 pM).
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 5.13 Effects of increasing concentrations of RGSl on 
the high affinity GTPase activity of pertussis toxin 
treated membranes expressing the 5- 
HTiAGiiaC^ '^G fusion protein
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HTiAG,!aC^^'0 fusion protein with increasing concentrations o f GTP as substrate. 
Basal GTPase activity was measured in the presence of various concentrations of 
RGSl. Panel B: The data generated were converted to Eadie-Hofstee plots to analyse 
effects on Km for GTP hydrolysis and Vmax-
Data are means of triplicate determinations and are representative of at least three 
similar experiments.
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Figure 5.14 Effects of increasing concentrations of RGSl on 
the 5-HT stimulated GTPase activity of pertussis 
toxin treated membranes expressing the 5- 
HTiAGiiaC  ^ G fusion protein
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HTiAGiiaC^^’O fusion protein with increasing concentrations o f GTP as substrate. 5- 
HT stimulated GTPase activity was measured in the presence of various 
concentrations o f RGSl. Panel B: The data generated were converted to Eadie- 
Hofstee plots to analyse effects on Km for GTP hydrolysis and Fmax- 
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 5.15 Effects of increasing concentrations of RGS16 on
the high affinity GTPase activity of pertussis toxin 
treated membranes expressing the 5- 
HTiAGiiaC^ *^G fusion protein
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HTiAGiiaC^^'O fusion protein with increasing concentrations of GTP as substrate. 
Basal GTPase activity was measured in the presence o f various concentrations of 
RGS 16. Panel B: The data generated were converted to Eadie-Hofstee plots to 
analyse effects on for GTP hydrolysis and Vm&\-
Data are means o f triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 5.16 Effects of increasing concentrations of RGS16 on 
the 5-HT stimulated GTPase activity of pertussis 
toxin treated membranes expressing the 5- 
HTiAGiiaC^ *^G fusion protein
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HTiAGiiaC^^'O fusion protein with increasing concentrations o f GTP as substrate. 5- 
HT stimulated GTPase activity was measured in the presence of various 
concentrations o f RGS 16. Panel B: The data generated were converted to Eadie- 
Hofstee plots to analyse effects on Km for GTP hydrolysis and Vm&x- 
Data are means o f triplicate determinations and are representative o f at least three 
similar experiments.
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Table 5.3 Mean K ,n and V,nax values for RGS protein
concentration response high affinity GTPase 
assays with the 5-HTiA/GüaC^^^G fusion protein
Panel A: Effects of a range of RGSl and RGS 16 protein concentrations on the Km 
and Vmax of basal high affinity GTPase activity in membranes expressing the 5- 
HTiA/GiiaC^^^G fusion protein.
Panel B: Effects of a range of RGSl and RGS 16 protein concentrations on the K,n 
and Vmax of 5-HT stimulated high affinity GTPase activity in membranes expressing 
the 5-HTiA/GiiaC^^^G fusion protein.
Data are mean +/- SEM from three similar experiments. An * denotes a result 
significantly different from the OnM RGS protein concentration (P < 0.05). Values 
are in nM.
152
RGSl RGS16
[RGS] Km Vmax Km Vmax
O nM  (b a s a i) 3 0 9 + /-8 8 1 1 .3 + /-0 .8 2 6 9 + /-6 1 1 1 .2 + /-1 .0
I n M 1 4 1 + /-8 6 6 .6 + /-0 .8 2 5 7 + /-5 0 1 3 .0 + /-2 .0
5 n M 1 6 0 + /-1 1 1 1 .4 + /-0 .6 588 + 7 -2 3 9 1 1 .7 + /-2 .2
lO n M 4 2 0 + /-2 2 8 1 0 .0 + /-1 .5 4 9 4 + /-2 3 9 1 6 .0 + /-2 .1
5 0 n M 2 0 8 + /-5 3 1 1 .3 + /-1 .0 3 5 8 + /-2 0 0 1 0 .0 + /-3 .0
lO O nM 2 3 2 + /-8 5 7 .6 + /-0 .3 4Ô 7 + /-5 4 1 9 .0 + /-2 .5
SOOnM 1 5 2 + /-1 4 9 .4 + /-0 .6 5 9 5 + /-1 4 3 1 4 .7 + /-2 .0
l ^ M 17 9 + /-3 9 7 .5 + /-0 .6 7 0 6 + /-4 5 3 2 2 .3 + /-7 .9
5 |iM 4 6 6 + /-2 8 1 5 .1 + /-1 .4
B
RGSl RGS16
[RGS] Km Vmax Km Vmax
O nM  (5 -H T ) 2 0 1 + /-2 5 2 9 .8 + /-2 .4 2 3 5 + /-4 3 4 0 .5 + /-4 .9
ln M + 5 - H T 4 6 5 + /-1 7 2 2 9 .3 + /-5 .2 2 2 3 + /-8 4 3 .0 + /-4 .5
5 n M + 5 -H T 1 7 5 + /-1 4 3 4 .3 + /-3 .2 1 9 8 + /-2 4 4 2 .3 + /-1 .2
lO n M + 5 -H T 2 1 6 + /-3 8 2 5 .0 + /-1 .5 3 2 1 + /-6 6 5 4 .3 + /-9 .2
5 0 n M + 5 -H T 2 5 6 + /-2 5 4 9 .7 + /-2 .7 * 2 7 4 + /-3 8 6 4 .0 + /-1 .0 *
lO O n M + 5 -H T  3 4 6 + /-2 7 3 8 .0 + /-6 .0 * 4 0 4 + /-7 8 * 6 8 .0 + /-1 8 .1 *
5 0 0 n M + 5 -H T  4 2 8 + /-6 2 8 9 .3 + /-6 .8 * 3 8 1 + /-8 3 * 1 0 1 .0 + /-1 0 .4 *
1 ( iM  + 5 -H T 4 5 1 + /-1 9 7 * 4 8 .0 + /-6 .7 * 5 6 3 + /-1 2 5 * 1 1 6 .7 + /-3 8 .2 *
5 (iM  + 5 -H T 4 4 3 + /-5 9 * 1 1 0 .7 + /-7 .6 *
p  <  0 .0 5

Figure S.17 Effects of increasing concentrations of RGSl on 
the high affinity GTPase activity of pertussis toxin 
treated membranes expressing the 5- 
HTiAGiiaC^ *^! fusion protein
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HTiAG.iaC^^'l fusion protein with increasing concentrations o f GTP as substrate. 
Basal GTPase activity was measured in the presence o f various concentrations of 
RGSl. Panel B: The data generated were converted to Eadie-Hofstee plots to analyse 
effects on Km for GTP hydrolysis and Pmax.
Data are means of triplicate determinations and are representative of at least three 
similar experiments.
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Figure 5.18 Effects of increasing concentrations of RGSl on 
the 5-HT stimulated GTPase activity of pertussis 
toxin treated membranes expressing the 5- 
HTiAGiiaC^^^I fusion protein
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HTiAGiiaC^^'l fusion protein with increasing concentrations o f GTP as substrate. 5- 
HT stimulated GTPase activity was measured in the presence of various 
concentrations of RGSl. Panel B: The data generated were converted to Eadie- 
Hofstee plots to analyse effects on for GTP hydrolysis and Fmax- 
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 5.19 Effects of increasing concentrations of RGS16 on
the high affinity GTPase activity of pertussis toxin 
treated membranes expressing the 5- 
HTiAGiiaC^ '^l fusion protein
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HTiAG.iaC^^'l fusion protein with increasing concentrations o f GTP as substrate. 
Basal GTPase activity was measured in the presence o f various concentrations of 
RG Sl6. Panel B: The data generated were converted to Eadie-Hofstee plots to 
analyse effects on for GTP hydrolysis and Pmax-
Data are means o f triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 5.20 Effects of increasing concentrations of RGS16 on 
the 5-HT stimulated GTPase activity of pertussis 
toxin treated membranes expressing the 5- 
HTiAGiiaC^ *^I fusion protein
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HTiAG.iaC^^'l fusion protein with increasing concentrations of GTP as substrate. 5- 
HT stimulated GTPase activity was measured in the presence of various 
concentrations o f R G Sl6. Panel B: The data generated were converted to Eadie- 
Hofstee plots to analyse effects on for GTP hydrolysis and Pmax- 
Data are means o f triplicate determinations and are representative o f at least three 
similar experiments.
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Table 5.4 Mean Kjn and V ^ax  values for RGS protein
concentration response high affinity GTPase 
assays with the 5-HTiA/GiiotC^^4 fusion protein
Panel A: Effects of a range of RGSl and RGS 16 protein concentrations on the K,n 
and V,nax of basal high affinity GTPase activity in membranes expressing the 5- 
HTiA/GiiaC^^^I fusion protein.
Panel B: Effects of a range of RGSl and RGS 16 protein concentrations on the Km 
and Vmax of 5-HT stimulated high affinity GTPase activity in membranes expressing 
the 5-HTiA/GiiaC^^^I fusion protein.
Data are mean +/- SEM from three similar experiments. An * denotes a result 
significantly different from the OnM RGS protein concentration (P < 0.05). Values 
are in nM.
157
RGSl RGS16
[RGS] Km Vmax Km Vmax
O nM  (b a s a i) 219+ 7-36 3 8 .7 + 7 -5 .3  210+ 7-48 3 8 .0 + 7 -9 .9
I n M 2 66 + 7 -6 2 4 1 .7 + 7 -3 .4  3 2 0 + 7 -1 0 4 58.3+7-8 .1
5 n M 2 27 + 7 -2 0 5 1 .3 + 7 -3 .8 *  170+7-22 2 4 .7 + 7 -0 .7
lO n M 325+7-61 4 2 .0 + 7 -2 .7 *  269+ 7-77 56 .0 + 7 -9 .6
5 0 n M 2 42 + 7 -3 7 5 8 .3 + 7 -7 .9 *  317+ 7-22 53 .7 + 7 -2 .0
lO O nM 2 95 + 7 -3 6 5 7 .3 + 7 -8 .9 *  250+ 7-75 56 .7 + 7 -7 .4
5 0 0 n M 520+ 7-87 9 6 .0 + 7 -1 0 .2 *  293+ 7-27 68 .0+ 7 -4 .5
l^ iM 567+ 7-82 7 9 .0 + 7 -7 .2 *  411+ 7-151 8 1 .3 + 7 -1 4 .9
5 |iM 4 4 7 + 7 -6 9 8 9 .7 + 7 -1 3 .9 *
p  <  0 .0 5
B
RGSl RGS16
[RGS] Km Vmax Km Vmax
O nM  (5 -H T ) 219+ 7-35 7 6 .0 + 7 -8 .7 277+ 7-67 5 6 .5 + 7 -1 1 .3
ln M + 5 - H T 265 + 7 -6 2 83 .7+ 7 -3 .5 639 + 7 -1 4 4 1 0 7 .0+ 7 -18 .4*
5 n M + 5 -H T 227 + 7 -2 0 6 6 .7 + 7 -8 .8 394+ 7-42* 67 .0 + 7 -2 .1 *
lO n M + 5 -H T 325+7-61 105 .3+ 7-9 .3 587+ 7-203* 1 2 0 .3+ 7-38 .4*
5 0 n M + 5 -H T 242 + 7 -3 7 130 .3+ 7-24 .1 925+ 7-231* 1 8 0 .7+ 7-23 .4*
lO O n M + 5 -H T 295+ 7-36* 182 .3+ 7-8 .8* 834+ 7-93* 1 8 9 .3+ 7 -53 .3*
5 0 0 n M + 5 -H T 520+ 7-87* 3 5 1 .0 + 7 -4 3 .0 * 1676+ 7-396* 3 8 9 .7 + 7 -7 4 .7 *
1 |iiM  + 5 -H T 567+ 7-87* 4 2 9 .7 + 7 -1 8 .5 * 1682+ 7-658* 4 6 8 .3 + 7 -2 1 9 *
5 |^ M  + 5 -H T 447 + 7 -6 9 * 6 7 2 .7 + 7 -6 9 .4 *
F  <  0 .0 5

Figure 5.21 RGSl and RGS16 régulation of basal and 5-HT 
stimulated GTPase activity in pertussis toxin 
treated membranes expressing the 5- 
HTiA/GiiaC^ '^G/1 fusion proteins
Panel A: Utilising the Pmax for GTP hydrolysis and J5max for expression levels, 
turnover numbers for basal GTPase activity in pertussis toxin treated membranes 
expressing the 5-HTiAGiiaC^^‘G/I fusion proteins in the presence o f increasing 
concentrations of purified RGSl and RGS 16 were plotted. Panel B: Turnover 
numbers were plotted for 5-HT stimulated GTPase activity in the presence of various 
concentrations of RGSl and 16.
Data are means o f triplicate determinations and are representative of at least three 
similar experiments.
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Figure 5.22 RGSl and RGS16 regulation of 5-HT stimulated 
GTPase activity in pertussis toxin treated 
membranes expressing the 5-HT,A/G;iaC^ G/I 
fusion proteins
The effects of increasing concentrations of RGSl and RGS 16 on 5-HT stimulated 
GTPase activity in membranes stably expressing the 5-HTi^/Gii«G^^  'G/I fusion 
proteins with the effects on basal GTP turnover removed.
Data are means of triplicate determinations and are representative of at least three 
similar experiments.
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Figure 5.23 Effects of increasing concentrations of RGSl on 
the high affinity GTPase activity of pertussis toxin 
treated membranes expressing the 5- 
HTiAGoiaC^ ^^ G fusion protein
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HTiAGoiaC^^'O fusion protein with increasing concentrations o f GTP as substrate. 
Basal GTPase activity was measured in the presence of various concentrations of 
RGSl. Panel B: The data generated were converted to Eadie-Hofstee plots to analyse 
effects on Km for GTP hydrolysis and Fmax-
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 5.24 Effects of increasing concentrations of RGSl on 
the 5-HT stimulated GTPase activity of pertussis 
toxin treated membranes expressing the 5- 
HT,AGoiaC  ^ G fusion protein
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HTiAGoiaC^^'O fusion protein with increasing concentrations o f GTP as substrate. 5- 
HT stimulated GTPase activity was measured in the presence o f various 
concentrations o f RGSl. Panel B: The data generated were converted to Eadie- 
Hofstee plots to analyse effects on Km for GTP hydrolysis and Tmax- 
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 5.25 Effects of increasing concentrations of RGS16 on 
the high affinity GTPase activity of pertussis toxin 
treated membranes expressing the 5- 
HTiaGoIoC^ ^^ G fusion protein
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HTiAGoiaC^^'O fusion protein with increasing concentrations o f GTP as substrate. 
Basal GTPase activity was measured in the presence o f various concentrations of 
RGS16. Panel B: The data generated were converted to Eadie-Hofstee plots to 
analyse effects on for GTP hydrolysis and Fmax-
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 5.26 Effects of increasing concentrations of RGS16 on 
the 5-HT stimulated GTPase activity of pertussis 
toxin treated membranes expressing the 5- 
HTiAGoiaC^ ^^ G fusion protein
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HTiAGoiaC^^'O fusion protein with increasing concentrations o f GTP as substrate. 5- 
HT stimulated GTPase activity was measured in the presence of various 
concentrations o f RGS16. Panel B: The data generated were converted to Eadie- 
Hofstee plots to analyse effects on Km for GTP hydrolysis and Vmax- 
Data are means of triplicate determinations and are representative of at least three 
similar experiments.
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□  5-HT + RGS16 luM
161
400n
300-
c
E
O 200-EQ.
>
100 -
0 1000 2000 3000
B [GTP] (nM)
500-1
400-
100 -
0.0 0.1 0.2 0.3 0.4 0.5 0.6
V/S

Table 5.5 Mean K,n and Vmax values for RGS protein
concentration response high affinity GTPase 
assays with the 5-HTiA/GoiaC^^^G fusion protein
Panel A: Effects of a range of RGSl and RGS 16 protein concentrations on the 
and V,nax of basal high affinity GTPase activity in membranes expressing the 5- 
HTiA/GoiaC^^^G fusion protein.
Panel B: Effects of a range of RGSl and RGS 16 protein concentrations on the Km 
and Vmax of 5-HT stimulated high affinity GTPase activity in membranes expressing 
the 5-HTiA/GoiaC^^^G fusion protein.
Data are mean +/- SEM from three similar experiments. An * denotes a result 
significantly different from the OnM RGS protein concentration (P < 0.05). Values 
are in nM.
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RGSl RGS16
[RGS] Km Vmax Km Vmax
OnM  (b a s a i) 3 5 4 + /-5 5 16.5+7-1.1 314+ 7-38 15.8+7-2 .3
I n M 3 6 5 + /-2 4 19 .3+ 7-1 .8 264+ 7-76 17.0+7-3 .8
5 n M 273 + 7 -3 9 14 .7+ 7-0 .9 321+ 7-28 13 .3+ 7-0 .9
lO n M 349+ 7-30 2 1 .0 + 7 -0 .6 42 5 + 7 -1 5 9 22 .0 + 7 -6 .7
5 0 n M 386+ 7-52 20 .0+ 7 -1 .5 345+7-71 16.0+7-0.1
lO O nM 390+ 7-2 29 .0+ 7 -2 .5 603+ 7-159 30 .0 + 7 -4 .9
SOOnM 212+ 7-10 17 .3+ 7-0 .7 394+ 7-30 21 .0 + 7 -0 .6
IjxM 329+ 7-27 3 0 .7 + 7 -3 .2 * 395+ 7-40 27 .7 + 7 -1 .2
5 p M 337+7-61 18 .3+ 7-2 .0*
P < 0 . 0 5
B
RGSl RGS16
[RGS] Km Vmax Km Vmax
OnM  (5 -H T ) 142+7-11 34 .0+ 7 -3 .5 243+ 7-67 43 .8+ 7 -6 .8
ln M + 5 - H T 279+ 7-68 6 6 .7 + 7 -1 8 .2 345+7-71 60 .0 + 7 -8 .7
5 n M + 5 -H T 3 7 0 + 7 -1 0 7 7 6 .0 + 7 -1 2 .7 185+7-8 56 .7+ 7 -2 .3*
lO n M + 5 -H T 387+ 7-56 1 58 .0+ 7 -39 .6 384+ 7-110 101 .0+ 7-14 .6*
5 0 n M + 5 -H T 539+ 7-47* 1 7 9 .0+ 7 -17 .8* 499+ 7-39* 2 2 0 .7 + 7 -7 .9 *
lO O n M + 5 -H T 7 8 4 + 7 -1 0 2 *  3 6 7 .0 + 7 -1 0 1 .6 * 833+ 7-80* 2 4 9 .0+ 7 -23 .0*
5 0 0 n M + 5 -H T 868+ 7-105* 2 9 0 .3 + 7 -4 2 .5 * 782+ 7-161* 3 7 4 .0+ 7-50 .1*
l( iM  + 5 -H T 908 + 7 -1 2 3 * 4 6 2 .7 + 7 -1 1 5 .8 * 1870+ 7-763* 5 3 2 .0 + 7 -1 2 8 *
5 |aM  + 5 -H T 9 91 + 7 -1 0 5 * 3 2 1 .0 + 7 -4 6 .7 *
p  <  0 .0 5

Figure 5.27 Effects of increasing concentrations of RGSl on
the high affinity GTPase activity of pertussis toxin 
treated membranes expressing the 5- 
HTiAGoiaC^^*! fusion protein
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HT|AGoiaC^^‘l fusion protein with increasing concentrations of GTP as substrate. 
Basal GTPase activity was measured in the presence of various concentrations of 
RGSl. Panel B: The data generated were converted to Eadie-Hofstee plots to analyse 
effects on Km for GTP hydrolysis and Vm&x-
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 5.28 Effects of increasing concentrations of RGSl on
the 5-HT stimulated GTPase activity of pertussis 
toxin treated membranes expressing the 5- 
HTiAGoiaC  ^ 1 fusion protein
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HTiAGoiaC^^‘l fusion protein with increasing concentrations o f GTP as substrate. 5- 
HT stimulated GTPase activity was measured in the presence o f various 
concentrations o f RGSl. Panel B: The data generated were converted to Eadie- 
Hofstee plots to analyse effects on for GTP hydrolysis and Fmax- 
Data are means o f triplicate determinations and are representative of at least three 
similar experiments.
■ Basal
▲ 5-HT
T 5-HT + RGSl InM
5-HT + RGSl 5nM
♦ 5-HT + RGSl lOnMV 5-HT-f RGSl 50nM
# 5-HT + RGSl lOOnMO 5-HT + RGSl 500nM
□ 5-HT + RGSl luMo 5-HT + RGSl 5uM
166
500n
400-
100 -
0 1000 2000 3000
B [GTP] (nM)
7 0 0 i
600-
^  500-
g) 400- 
~0
Q_ 300- 
>
200 -
100 -
0.0 0.1 0.2 0.3 0.4 0.5
V/S

Figure 5.29 Effects of increasing concentrations of RGS16 on
the high affinity GTPase activity of pertussis toxin 
treated membranes expressing the 5- 
HTiAGoiaC^ *^! fusion protein
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HTiAGoiaC^^'l fusion protein with increasing concentrations o f GTP as substrate. 
Basal GTPase activity was measured in the presence of various concentrations of 
RGS 16. Panel B: The data generated were converted to Eadie-Hofstee plots to 
analyse effects on ATm for GTP hydrolysis and Vmax-
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
■ Basal
▼ RGS 16 InM
RGS16 5nM
♦ RGS 16 lOnMV RGS16 50nM
• RGS 16 lOOnMo RGS16 500nM
□ RGS 16 luM
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Figure 5.30 Effects of increasing concentrations of RGS16 on 
the 5-HT stimulated GTPase activity of pertussis 
toxin treated membranes expressing the 5- 
HTiAGoiaC  ^ I fusion protein
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HTiAGoiaC^^'l fusion protein with increasing concentrations of GTP as substrate, 5- 
HT stimulated GTPase activity was measured in the presence of various 
concentrations of RGS 16. Panel B: The data generated were converted to Eadie- 
Hofstee plots to analyse effects on Km for GTP hydrolysis and Vmax.
Data are means of triplicate determinations and are representative of at least three 
similar experiments.
m  Basal
5-HT
Y  5-H T+ RGS16 InM 
5-HT + RGS16 5nM 
^  5-HT + RGS16 lOnM
y  5-HT + RGS16 50nM
0  5-HT + RGS16 lOOnM
<0 5-HT + RGS16 500nM
□  5-HT 4-RGS 16 luM
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Table 5.6 Mean K ,n and V„iax values for RGS protein
concentration response high affinity GTPase 
assays with the 5-HTiA/GoiaC^^ I^ fusion protein
Panel A: Effects of a range of RGSl and RGS 16 protein concentrations on the 
and V,nax of basal high affinity GTPase activity in membranes expressing the 5- 
HTiA/GoiaC^^*I fusion protein.
Panel B: Effects of a range of RGSl and RGS 16 protein concentrations on the K,n 
and V„iax of 5-HT stimulated high affinity GTPase activity in membranes expressing 
the 5-HTiA/GoiaC^^^I fusion protein.
Data are mean +/- SEM from three similar experiments. An denotes a result 
significantly different from the OnM RGS protein concentration (P < 0.05). Values 
aie in nM,
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R G Sl RGS16
[RGSJ Km Vmax Km Vmax
O nM  (b a s a i) 1 2 7 + /-1 3 19 .0+ 7-0 .9 289 + 7 -1 3 4 3 7 .2 + 7 -1 4 .7
I n M ■ 1 5 7 + /-1 3 2 6 .0 + 7 -2 .7  - 297+7792 46 .7 + 7 -1 2 .1
5 n M 2 1 9 + /-2 7  . 2 7 .7 + 7 -0 .9 137+7-3 2 6 .3 + 7 -1 .7
lO n M 2 2 9 + /-3 7 3 7 .3 + 7 -1 .9 * 349 + 7 -1 3 9 6 9 .3 + 7 -2 6 .6 *
5 0 n M 3 7 2 + /-4 3 54 .0 + 7 -1 .7 * 290+7-33 80 .7+ 7 -7 .1*
lO O nM 332+7-3* 78 ;7 + 7 -6 .9 * ■ 732+ 7-183 1 6 9 .0+ 7 -20 .0*
SOOnM 3 93+ 7-28* 87 .3+ 7 -3 .4* 410+ 7-62 108 .0+ 7-2 .5*
I p M 510+ 7-203* 1 2 3 .3 + 7 -1 5 .8 * 1389+ 7-181* 3 0 2 .0 + 7 -4 4 .5 *
5|J.M 3 92+ 7-15* 9 4 .3 + 7 -6 .4 *
B
R G Sl RGS16
[RGS] Km Vmax Km Vmax
O nM  (5 -H T ) 134+7-6 28 .0 + 7 -0 .8 143+7-13 4 6 .0 + 7 -1 2 .2
ln M + 5 - H T 210+ 7-11 39 .0 + 7 -1 .0 * 226+ 7-65 9 4 .7 + 7 -4 2 .8
5 n M + 5 -H T  , 236+ 7-48 53 .3 + 7 -5 .2 * 186+7-13* 4 7 .7 + 7 -3 .8 *
lO n M + 5 -H T 323+ 7-54 90 .3 + 7 -6 .5 * 549+ 7-161* 171 .7 + 7 -4 2 .3 *
5 0 n M + 5 -H T 675+ 7-25* 184 .7+ 7-9 .0* 6 10+ 7-37* 2 3 9 .0 + 7 -1 8 .0 *
lO O n M + 5 -H T  793+ 7-43* 2 9 4 .0 + 7 -9 .6 * 1191+ 7-87* 4 9 8 :7 + 7 -7 2 .6 *
5 0 0 n M + 5 -H T 1 0 9 7 + 7 - l  10* 4 0 6 .7 + 7 -3 0 .4 *  1485+ 7-116* 5 8 8 .7 + 7 -4 9 .9 *
l p M + 5 - H T 1250+ 7-265* 5 3 0 .3 + 7 -8 1 .4 *  1824+ 7-318* 1030+ 7-242*
S^iM  + 5 -H T i7 6 9 + 7 -1 6 0 * 6 3 2 .3 + 7 -1 2 .9 *

Figure 5.31 RGSl and RGS16 regulation of basal and 5-HT
stimulated GTPase activity in pertussis toxin 
treated membranes expressing the 5- 
HTiA/GoiaC^ *^G/I fusion proteins
Panel A: Utilising the V^ ax for GTP hydrolysis and B^ax for expression levels, 
turnover numbers for basal GTPase activity in pertussis toxin treated membranes 
expressing the 5-HTiAGoiaC^^‘G/I fusion proteins in the presence of increasing 
concentrations of purified RGSl and R G Sl6 were plotted. Panel B: Turnover 
numbers were plotted for 5-HT stimulated GTPase activity in the presence of various 
concentrations of RGSl and 16.
Data are means of triplicate determinations and are representative of at least three 
similar experiments.
5-HT,A/GoiaC” 'G + RGSl
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Figure 5.32 RGSl and RGS16 regulation of 5-HT stimulated
GTPase activity in pertussis toxin treated 
membranes expressing the 5-HTiA/GoiaC^^^G/I 
fusion proteins
The effects of increasing concentrations of RGSl and RGS 16 on 5-HT stimulated 
GTPase activity in membranes stably expressing the 5-HTiA/GoiaC^^^G/I fusion 
proteins with the effects on basal GTP turnover removed.
Data are means of triplicate determinations and are representative of at least three 
similar experiments.
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Figure 5.33 Assays to examine the effects of endogenous 
HEK293 RGS proteins
Panel A: Basal and 5-HT (lOOfiM) stimulated high affinity GTPase activity of 
membranes expressing the 5-HTiA/GoiaC^^‘l fusion protein with RGSl (lOpM) and 
two cytosolic fractions normally discarded during membrane preparation.
□□□
Basal
5-HT
RGSl ( IpM) 
5-HT + RGSl 
Cytosol A 
5-HT + Cytosol A 
Cytosol B 
5-HT + Cytosol B
Panel B: Basal and 5-HT (lOOpM) stimulated high affinity GTPase activity in 
membranes expressing the 5-HTiA/GoiaC^^'l fusion protein, a sample o f which had 
been pre-treated with 5-HT (lOOpM) for 10 minutes prior to cell harvesting.
I I Basal
□  5-h t
g  RGSl ( I mM)
m  5-HT + RGSl
Data are means of triplicate determinations and are representative of at least three 
similar experiments.
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Table 5.7 Table of RGS proteins reported to be expressed
either ubiquitously or in the human kidney
The table shows the RGS proteins of different classes reported in the literature as 
being expressed either ubiquitously or in the human kidney. Primers and probes for 
Taqman analysis of expression in HEK293 cells were designed for RGS2, RGS3, 
RGS4, RGS9 and GRK2.
173
2s ^ a -
CL Ou
ON

Figure 5.34 PCR amplification of RGS2 and GRK2 cDNA
using primers designed for Taqman QrtPCR
PCR conditions were established for RGS2 (Panel A) and GRK2 (Panel B) using 
cDNA samples prior to running the Taqman experiment on genomic HEIC293 DNA. 
Six concentrations of cDNA were utilised (lOng/pl, Ing/pl, lOOpg/pl, lOpg/ql, 
Ipg/pl and lOOfg/jLil) at three different primer concentrations (50:50, 300:300 and 
900:900 (nM) forward: reverse) for forty cycles. Data are plotted as increase in 
absorbance against cycle number. Data are means of triplicate determinations and are 
representative of at least three similar experiments.
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Figure 5.35 PCR âmplifîcation of RGS2 from genomic
HEK293 DNA using Taqman QrtPCR
Using previously established PCR conditions for RGS2 cDNA an experiment on 
genomic HEK293 DNA was completed. Well position 0-20 are the results of the 
standard curve using lOng/pl of RGS2 cDNA per well at a primer ratio of 
300:300nM. Well positions 36-38 are the results for the genomic HEK293 DNA. 
Data are means of triplicate determinations.
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5.3 Discussion
High affinity GTPase assays measure the rate of GTP hydrolysis to GDP in a 
sample (McKenzie and Milligan, 1990; Wise et al., 1997a,b). This is a particularly 
useful measure of the ability of ligands of GPCRs to alter the GTPase activity of the 
G protein to which they are coupled. For receptor-G protein fusion proteins 
incorporating a G,-family G protein this is best taken advantage of by introducing a 
mutation at Cys^^\ four amino acids from the end of the C terminal tail. This 
introduces an amino acid that cannot be ADP ribosylated by pertussis toxin. Pertussis 
toxin catalyses this reaction which leaves the Ga subunit incapable of GDP/GTP 
exchange in response to receptor stimulation. Mutation of Cys^^  ^ renders the Ga 
subunit resistant to ADP ribosylation and allows for pertussis toxin-treatment of the 
cells to abolish signalling through the endogenous pool of inhibitory G proteins.
Pertussis toxin-resistant fusion proteins between GPCRs and inhibitory G 
protein a  subunits were first used by (Wise et a l, 1997a) and have subsequently 
become an important tool in the characterisation of ligand binding and G protein 
activation (Carr et al., 1998; Wise et al., 1997; Wise et a l, 1999; Kellett et al., 1999; 
Dupuis et a l, 1999). The 1:1 stoichiometry that is a consequence of pertussis toxin 
abolition of endogenous G protein signalling allows for exact pharmacological 
calculation of the potency of ligands at the fused GPCR either in GTPase assays or in 
second messenger signalling assays such as the intact cell adenylyl cyclase assay 
discussed in chapter 3. This is possible by using radioligand saturation binding to 
measure the expression level of the receptor that therefore mirrors the expression 
level of the fused G protein.
The 5-HTia receptor has previously been fused to both Gi« and Goa proteins 
with some interesting results (Kellett et al., 1999; Dupuis et al., 1999). It was found 
that in fusions between the 5-HTia receptor and G^a proteins, when Cys^^  ^ was 
mutated to Ile^^\ an increase in basal GTPase activity was measured. This intrinsic 
constitutive activity could be suppressed by the inverse agonist spiperone by about 
50%. This inverse agonist had no effect on the same fusion with the Gly^^  ^mutation. 
It was also found that 5-HT produced an increase in Vmax but no change in K,„ for 
GTP in a high affinity GTPase assay using a range of GTP concentrations.
The effects of a range of 5-HT concentrations (lnM-100p,M) on the seven 
different stable cells lines were examined in terms of high affinity GTPase activity
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(Figures 5.4 and 5.5). For the 5-HTia receptor alone and the WT Güa and Goia 
fusion proteins, in the absence of pertussis toxin, 5-HT produced a concentration 
dependent increase in high affinity GTPase activity (Figure 5.4). The pECso values 
for the 5-HTiA receptor and the WT Güa and Goia fusion protein were not 
significantly different from each other (P > 0.05) (Table 5.1). Prior pertussis toxin 
treatment of membranes resulted in an abolition of agonist mediated effects with the 
exception of the WT Gua fusion protein where concentrations above IpM produced 
an increase in GTPase activity. This effect was also recorded by Kellett et ah (1999) 
and may be due to insufficient pertussis toxin treatment. It may also be a reflection of 
the ability of high concentrations of 5-HT to overcome the inhibition of receptor-G 
protein coupling caused by ADP ribosylation of the G protein due to the intrinsic 
constitutive activity of the fusion protein.
Comparison of the 5-HTia receptor-WT G protein fusion pECso values with 
the non pertussis toxin-treated Gly^^  ^ and Ile^ ^^  mutant G protein fusions 
demonstrated that for both the Güa and Goia proteins the pECso values for the Gly^^  ^
mutants were significatly lower and for the Ile^^  ^ higher than their respective WT G 
protein fusions (Tables 5.1 and 5.2). These results support the findings of Bahia et 
a l, (1998) that suggested that the more hydrophobic the amino acid at position 351 
of the Gila protein, the stronger the interaction between the receptor and G protein.
Concentration dependent increases in high affinity GTPase activity were also 
recorded for the pertussis toxin resistant fusion proteins (Figure 5.5). For each of the 
four fusion proteins, with the exception of the 5-HTiA/GüaC^^^I protein, pertussis 
toxin treatment of membranes did not result in a significant difference in pECso value 
when compared to non-pertussis toxin-treated samples (Tables 5.1 and 5.2). The 
pECso values of 5-HT stimulated high affinity GTPase activity for the 5- 
HTiA/GiiaC^^^G non and pertussis toxin-treated (6.11+/-0.07nM and 5.94+/-0.08nM 
respectively) proteins were significantly different from those of the 5-HTiA/GüaC^^^I 
fusion protein (7.23+/-0.09nM and 6.50+/-0.07nM respectively) (P < 0.001 and 0.01 
respectively). Comparison of the other EC50 values did not indicate any significant 
differences in ability to stimulate GTPase activity, a result that could indicate that the 
affinity of 5-HT for the 5-H T ia receptor is not significantly altered by the presence 
of the different G protein fusions and that the various G protein mutations may have
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altered the level of intrinsic constitutive GTPase activity, but have not altered the 
maximum level of agonist stimulated activity.
The intrinsic GTPase activity of G protein a  subunits can be altered by a 
family of proteins know as RGS proteins (Regulators of G protein Signalling) (Hong 
et a l, 1993). These act as GAPs (GTPase Activating Proteins) for the inhibitory class 
of G proteins, increasing the rate of GTP hydrolysis to GDP and thus the rate of G 
protein inactivation. These proteins vary widely in structure and have secondary 
functions, but all contain a common 120 amino acid RGS domain. It is this domain 
that interacts with the Ga subunit and increases the GTPase activity in the protein. 
Deletion of small sections of the RGS domains of RGS4, RGS 10 and RGS GAIP 
was found to abolish in vitro GAP activity (Faurobert and Hurley, 1997; Popov et a l, 
1997; Srinivasa effl/., 1998).
A number of RGS proteins have been fused to GST and transformed into 
bacterial BL21 cells. Following IPTG induction, the proteins are produced in large 
quantities and can be purified using Glutathione Sepharose 4B gel which selectively 
binds to the fused GST allowing separation from other bacterial proteins up to a final 
concentration of approximately 10-20|LiM.
Using fusions between the 5-HTia receptor and both Güa and Goia WT and 
pertussis toxin-resistant proteins the interaction between the receptor and its cognate 
G proteins was further characterised and the effects of two RGS proteins, RGSl and 
RGS 16, on these interactions examined. In fusions between the 5-HTia receptor and 
pertussis toxin resistant Güa proteins, both 5-HT and 8-OH-DPAT produced 
significant increases in high affinity GTPase activity (P < 0.05) that were not 
statistically different from each other (Figures 5.1-5.3) (P > 0.05). This effect was 
shown to be sensitive to the presence of RGSl and RGS 16 (IpM), both of which 
caused significant increases in GTPase activity at the two constructs following 
stimulation by either 5-HT or 8-OH-DPAT (Figure 5.4). As a control, it was assessed 
if RGS protein could produce any effect either in the presence or absence of 5-HT in 
mock transfected HEK293 cells (Figure 5.8). It was found that neither 5-HT 
(lOOpM) nor RGSl (l|xM) alone or combined could produce any change in the basal 
GTPase activity. To investigate this RGS protein effect further, increasing 
concentrations of GTP were used to quantitate Vmax and K,n for GTP. These assays
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were carried out in the absence and presence of RGS protein at basal and following 
5-HT (lOOpM) stimulation of GTPase activity.
In membranes expressing the 5-HTia receptor alone, 5-HT produced an 
increase in V,nax without effecting the Km for GTP (Figure 5.8). RGSl alone had no 
effect on basal activity, but in the presence of 5-HT produced a significant increase 
over 5-HT alone in both Vmax and Km for GTP (P < 0.05). The increase in K,n is not as 
a result of changes in the affinity of the Ga protein for GTP but due to the increased 
rate of GTP hydrolysis to GDP. Following pertussis toxin treatment of membranes, 
neither 5-HT nor RGSl alone or together produced any significant effects on GTPase 
activity. These effects demonstrate that in the absence of stimulation, RGSl protein 
does not effect basal GTPase activity at the 5-HTia receptor, but in the presence of 5- 
HT stimulation, it produces a large increase in Vmax and also an increase in the K,n 
which reflects the increase in GTPase activity without any actual change in the 
affinity that the G protein has for GTP. This lack of effect of RGS proteins in the 5- 
HTia receptor means that there is not a significant degree of constitutive activity in 
these membranes.
When the WT Gua and Goia proteins are fused to the 5-HTia receptor and 
stably expressed in HEK293 cells, the effects seen are slightly different to the 
receptor alone (Figure 5.9 A + B). There is an increase in basal GTPase activity that 
reflects an increase in intrinsic GTPase activity brought on by the close proximity of 
the G protein to the receptor. 5-HT alone produces a significant increase in high 
affinity GTPase activity over basal (P < 0.05), an increase that is equalled by the 
presence of RGSl alone (P < 0.05). RGS protein can cause an increase in GTPase 
activity in the absence of agonist stimulation the 5-HT ia receptor WT G protein 
fusions. This increase in GTPase activity is a reflection of the constitutive activity 
caused by increased Hkelyhood of agonist independent interaction of the receptor and 
G protein due to their close proximity . RGS protein alone also produces a significant 
increase in the K,„ for GTP which reflects the increase in hydrolysis of GTP to GDP 
and not an increase in the rate of exchange of GDP for GTP. There is a more 
dramatic increase in GTPase activity in the presence of RGSl following stimulation 
with 5-HT, producing significant increases over stimulation with either 5-HT or 
RGSl protein alone (P < 0.05). In the presence of pertussis toxin, the basal Vmax for 
both WT G protein fusions was significantly decreased over untreated basal activity.
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This reflects the inability of the receptor to stimulate GDP/GTP exchange following 
ADP ribosylation at Cys^^  ^ of the G protein. Stimulation by 5-HT, RGSl and the 
combination of the two is still seen, a reflection of the high affinity of the fused G 
protein for the 5-H T ia receptor, but these have been significantly reduced below 
untreated membranes (P < 0.05).
The results from these data give an indication of GTPase activity in the 
presence and absence of RGS proteins, but as it is not possible to show only coupling 
to the fused G protein, the value of the pertussis toxin-resistant G protein fusions 
becomes apparent. For the following experiments using the 5-HTi A / G u ^ G / I  and 
5-HTiA/GoiaC^^^G/I fusion proteins all cells were treated prior to harvest with 
pertussis toxin to prevent any signalling through the endogenous pool of inhibitory G 
proteins.
A wide range of RGS protein concentrations were examined, from InM to 
5pM for RGSl and from InM to IpM  for RGS 16. Their effects were similar on the 
two Gly^^  ^mutants and on the two Ile^^^  mutants. For both RGS proteins, incubation 
with membranes expressing the 5-HTiA/GiiaC^^^G and 5-HTiA/GoiaC^^^G in the 
absence of agonist stimulation had no effect on either Vmax or the Km for GTP with 
the exception of IpM RGSl which significantly increased the Vmax for the Goia 
Gly^^  ^ mutant without any effect on K,n (Tables 5.3 and 5.5). This reflects the low 
intrinsic constitutive GTPase activity of these two constructs and supports the 
findings of Kellett et al. (1999) where the inverse agonist spiperone had no effect on 
basal GTPase activity in membranes expressing the 5-HTiA/GiiaC^^^G fusion protein.
In the presence of lOOpM 5-HT alone, high affinity GTPase activity is 
significantly greater than basal activity for both of the Gly^^  ^ mutant fusion proteins 
(P < 0.05). Increasing levels of both RGSl and RGS 16 result in a concentration 
dependent increase in Vmax for both the Gna and Goia mutant fusions with the effects 
becoming significant at 50nM for RGSl and 5nM for RGS 16 (Tables 5.3 and 5.5). 
Km increases in response to rising concentrations of RGS protein but these effects 
only become significant for the Gna mutant at IpM for RGSl and lOOnM for 
RGS 16. Effects on the K,n for GTP for the Gda mutant fusion become significant at 
50nM for both RGS 1 and RGS 16.
In membranes expressing the 5-HTiA/GüaC^^^G fusion protein, for both 
RGSl and RGS 16 GTP does not reach saturating concentrations at the highest
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concentrations of RGS protein, reflecting the ability of the higher RGS protein 
concentrations to increase the rate of GTP hydrolysis (Figure 5.18, 5.20, 5.24, 5.28- 
30). In membranes expressing the 5-HTiA/GoiaC^^^G fusion protein, this effect is 
more pronounced, possibly indicating that the Goia protein is capable of hydrolysing 
GTP at a greater maximal rate that the Gna protein or that the RGS proteins have a 
higher affinity for Gda that Gii« protein. This may be supported by the general 
finding in the literature that the 5-HTia receptor has a greater ability to signal 
through Gia proteins that Goa proteins (Clawges et al., 1997; Berlin et al., 1992; 
Gamovskaya et al., 1997; Raymond et al., 1993). A possible explanation is that the 
greater rate of GTP hydrolysis at the Goa protein terminates signalling of second 
messenger systems before termination by the Gia protein that with a lower rate of 
GTP hydrolysis remains activated for a longer period.
When expression levels of the two receptor-G protein constructs are taken 
into account, neither RGS protein had a significant effect on basal turnover of GTP 
(molecules of GTP/G protein/minute) (Figure 5.28 and 5.29). Following the addition 
of 5-HT, RGSl and RGS 16 had similar potency at the 5-HTiA/GüaC^^^G and the 5- 
HTiA/GdaC^^^G receptor G fusion proteins. In Figures 5.30 and 5.31 the basal 
turnover of GTP for each construct at each RGS protein concentration is subtracted 
from that of the 5-HT stimulated turnover of GTP to allow accurate quantitation of 
the effects of RGS protein on 5-HT stimulated high affinity GTPase activity. From 
Figure 5.30 it appears that RGSl and RGS 16 have identical effects on 5-HT 
stimulated GTPase activity, neither having reached a concentration of RGS protein 
that produces a maximal effect. The predictions of a maximum for the effects of RGS 
protein are different however, with RGSl having a predicted 32 fold maximal effect 
on GiiaC^^^G GTPase activity and RGS 16 only a 4.4 fold effect.
The results for the 5-HTiA/GoiaC^^^G construct seemed to show that RGSl 
stimulates increases in GTPase activity at lower concentrations, but this effect was 
not however statistically significant over the effects of RGS 16. The increases in 5- 
HT stimulated GTPase activity seemed to have reached a plateau for RGSl but not 
for RGS 16, with RGSl having a predicted maximal 12.4 fold stimulation of GTP 
turnover and RGS 16 a 189 fold maximum. These figures may not be accurate, 
considering that the curves they are predicted from are only reaching the exponential 
phase in some cases. It may be realistic to assume, that as the rises in GTPase
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activity stimulated by the presence of RGSl and RGS 16 have not been statistically 
different from one another, that they will both show a similar maximal effect on GTP 
hydrolysis.
The effects of the Ile^^^  G protein -  5-HT ia receptor fusions were quite 
different. As with the Gly^^  ^ mutants, the effects of RGSl and RGS 16 over a range 
of concentrations on both basal and 5-HT stimulated GTPase activity were examined 
over a range of GTP concentrations. Unlike the Gly^^  ^ mutants, the basal GTPase 
activity of the Ile^ *^ mutants was affected by the addition of increasing 
concentrations of both RGSl and RGS 16. For the Güa fusion protein, this was 
reflected by a significant increase in V,nax at only 5nM for RGSl and a twofold, but 
not statistically significant increase in Vmax for RGS 16 (Tables 5,4 and 5.6). Both 
RGSl and RGS 16 produced statistically significant increases in Vmax for the G o ia  
fusion protein at lOnM in the absence of 5-HT stimulation. Although increases in the 
Km for GTP for both the Güa and the Goia fusion proteins were measured, only RGSl 
produced a statistically significant increase in Km for the Goia fusion protein at 
concentrations of above lOOnM. The curves generated in the presence of increasing 
concentrations of GTP did not saturate at approximately 3000nM in the presence of 
the highest concentrations of both RGSl and RGS 16 when incubated with the Güa 
and the Goia fusion proteins. This might indicate that these levels of RGS 
protein are capable, in the presence of the membranes expressing the G protein 
fusion, of increasing the hydrolysis of a greater concentration of GTP to GDP than 
was present in the assay.
In the presence of 5-HT (lOOjxM) the RGS proteins have an even more 
dramatic effect on high affinity GTPase activity at both the 5-HTiA/GüaC^^^I and 5- 
HTiA/GoiaC^^^I fusion proteins. The increase in GTPase activity stimulated by the 
presence of 5-HT alone was significantly greater than basal for the two fusion 
proteins (P < 0.05) with out affecting the K,n for GTP. For the Gna Ilef^  ^ mutant, the 
presence of RGSl produced a significant increase in Vmax and Km at lOOnM (P = 
0.0083 and 0.0303 respectively) (Tables 5.4 and 5.6). In the presence of RGS 16, 
there was a significant increase in Vmax at InM and in K,n at 5nM. This does not 
appear to reflect a difference in affinity of the RGS proteins for the Güa protein, as 
neither produce statistically different effects on the turnover of GTP once expression
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levels are taken into account either at basal levels or following 5-HT stimulation 
(Figures 5.28).
For the Goia Ile^ ^^  protein, in the presence of 5-HT, increasing concentrations 
of RGSl produced a significant elevation of V,nax and K,n at InM and 50nM 
respectively (P < 0.05) and in the presence of RGS 16 at 5nM for both Vmax and Km. 
As with the Gna Ile^^^  fusion protein the effects of neither RGS protein on turnover 
of GTP to GDP once expression level were accounted for produced statistically 
different effects from one another in the absence or presence of 5-HT stimulation 
(Figure 5.29). Once the effects on basal GTPase activity have been subtracted from 
those in the presence of 5-HT, RGSl produces a predicted 64-fold increase in 
turnover number over 5-HT stimulation for the Goia construct and RGS 16 a 1812 
fold increase (Figures 5.30 and 5.31). For the Goia fusion, RGSl has a predicted fold 
stimulation of 209 and RGS 16 a predicted 19-fold increase over 5-HT stimulated 
turnover. As with the predictions for the Gly^^  ^ mutants these figures may not be 
accurate as the concentration response curves to RGSl and RGS 16 have not 
saturated and are for the most case still in the exponential phase of effect. Again, it 
would possibly be more accurate to predict that due to the lack of statistically 
significant differences between the effects of RGSl and RGS 16 at the 5- 
HTiA/GiiaC^^^I and 5-HTiA/GoiaC^^^I fusion proteins, their affinity for both G 
proteins appears to be similar, and they will most likely have similar maximal effects 
on GTP turnover.
The effects of RGSl and RGS 16 proteins on high affinity GTPase activity 
were different for the Güa and Goia fusion proteins. Both RGS proteins produced 
greater increases in stimulated turnover for both the Gly^^  ^ and Ile^^^  Goia fusion 
proteins than for the Gly^^  ^ and Ile^^  ^ Gna fusion proteins (Figures 5.31 and 5.32). 
The effects of maximal concentrations of RGS protein on the 5-HTiA/GoiaC^^^G 
protein were significantly greater than the effects on the 5-HTiA/GüaC^^^G fusion 
protein (P < 0.05). The increase in GTP turnover for the 5-HTiA/GoiaC^^^I protein in 
the presence of 5|liM RGSl was significantly greater than for the GnaC^^^I protein (P 
< 0.05). The effects of RGS 16, which appeared to produce a larger stimulation of 
GTP turnover for the GoiaC^^^I fusion protein compared to the GuaC^^^I fusion, were 
not significantly different, a result that reflects the large error in the turnover values
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(P > 0.05). These results may be a reflection of RGSl and RGS16 having a greater 
affinity for the 5-HTiA/Goia fusion proteins than for the 5-HTiA/Giia fusion proteins.
It has been clearly demonstrated that agonist activation of GTPase activity 
has no effect on the for GTP of the stimulated G protein (Figures 5.14, 5.16, 5.18, 
5.20, 5.24, 5.26, 5.28 and 5.30). However, in the presence of high concentrations of 
RGS protein, a significant increase in K,n is measured that is due to the increase in 
the rate of GTP hydrolysis, but not any change in affinity for GTP/GDP. With this 
clear shift in in the presence of RGS protein, it could be asked why there is no 
shift in the absence of RGS protein, a shift that would represent the endogenous pool 
of RGS proteins? To investigate this lack of endogenous RGS protein effect, a 
number of simple experiments were carried out.
Firstly, using the 5-HTiA/GoiaC^^^I stable cell line, the fractions that are 
normally discarded during the preparation of cell membranes were assayed to check 
if they possessed any RGS protein activity as RGS proteins are predicted to be 
mainly cytoplasmic proteins (Burchett 2000). However, following addition of the 
cytosolic fractions normally discarded to reaction mixes already containing the 5- 
HTiA/GoiaC^^^I membranes, a decrease in basal and stimulated GTPase activity were 
measured.
Secondly, it was decided to see if pre-treatment of the cells with 5-HT 
(lOOpM) could stimulate the 5-HTia receptor and recruit the RGS protein to the 
membrane where it might then be held more securely during membrane preparation. 
It has been shown previously that receptor activation results in the recruitment of 
RGS3, RGS4 and RGS 16 to the plasma membrane from the cytoplasm (Druey et ah, 
1998; Chen et ah, 1999; Dulin et ah, 1999). However, no statistical difference was 
found between the treated and non-treated membranes in a GTPase assay.
In order to investigate the endogenous expression of RGS proteins further, it 
was decided to make use of Taqman QrtPCR, a method that allows real-time 
quantitation of specific nucleic acid sequences using a flourogenic 5’nuclease assay. 
In this assay, the probe consists of a oligonucleotide, with a reporter and quencher 
dye attached, complementary to the target sequence that is added to the PGR reaction 
mixture. During PCR, if the target of interest is present, the probe anneals 
specifically between the forward and reverse primer sites. The neucleolytic activity 
of the polymerase cleaves the probe, resulting in increased fluorescent intensity from
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the reporter dye. This occurs in every cycle of the PCR reaction and does not 
interfere with the accumulation of the PCR product.
Primers and probes were designed for a number of RGS proteins reported to 
be ubiquitously expressed, or expressed in the organ of interest, the kidney (Table 
5.7). Following problems with the standard curves run using cDNA samples for the 
RGS proteins of interest, it was only possible to conclude that RGS2, RGS3 and 
RGS4 proteins are expressed in HEK293 cells and that the expression is most 
probably at low levels. This may give some indication as to why no endogenous RGS 
protein activity is detectable in the GTPase assay, i.e. expression levels of RGS 
proteins are so low in comparison to those of the receptor and G protein of interest 
that any effect they may have is no significant enough to measure using current 
techniques.
Both RGSl and RGS 16 proteins had a significant effect on the basal GTPase 
activity for both the 5-HTiA/GüaC^^^I and 5-HTiA/GoiaC^^^I fusion proteins. It was 
decided to examine the effects of a range of ligands, including both agonists and 
inverse agonists on high affinity GTPase activity, to see if the effects of the RGS 
proteins would be of benefit in the design of a robust ligand screening assay.
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Chapter 6
High Affinity GTPase Assays 
With RGSl Protein as a Ligand Screen
6.1 Introduction
The concept of inverse agonism in GPCRs was first explored in the late 
1980’s through work done on the 8 opioid receptor (Costa and Herz, 1989). They 
demonstrated that some antagonists for the 8 opioid receptor had “negative intrinsic 
activity” in vitro, contrasting with others that lacked any intrinsic activity. An inverse 
agonist puts a receptor into a conformation that favours the G protein-uncoupled 
state, an agonist, the G protein-coupled state and an antagonist does not favour 
coupling to either form (De Lean et al., 1980).
At the human 5-HTia receptor, the ligand spiperone has been previously 
reported as acting as an inverse agonist (Barr and Manning, 1997; Newman-Tancredi 
et al., 1997; Kellett et al., 1999). A number of other ligands have also been reported 
to show inverse agonist activity at the 5-HTia receptor, including methiothepin and 
(4-)butaclamol (Newman-Tancredi et al., 1998; Stanton and Beer, 1997). The 
dopamine D% selective antagonists chlorpromazine and haloperidol bind to 5-HT 
receptors with lower affinity and have previously been shown to have inverse 
activity at 5-HTib and 5-HTid receptors (Audinot et al., 2001). Together with 5-HT, 
spiperone, and WAY100635 (Routledge, 1996), the ability of haloperidol, 
chlorpromazine, butaclamol, methiothepine and another dopamine antagonist 
thioridazine to effect GTPase activity of the 5-HTiA/GüaC^^^I and 5-HTiA/GoiaC^^^I 
fusions will be examined.
Kellett et al. (1999) showed using fusion proteins between the 5-HTia 
receptor and Gua either WT or Ile^^  ^ protein that spiperone produced a concentration 
dependent decrease in basal GTPase activity of membranes expressing this construct. 
The mutants will be used due to their increased intrinsic basal GTPase activity. This 
mutation leads to an increase in hydrophobicity at this residue and an increase in 
affinity of the receptor for the G protein (Chapter 4). This effect alone allows for 
increased ability to distinguish between antagonists at the receptor and partial 
agonists, but coupled with the increase in basal GTPase activity previously discussed 
in the presence of RGS proteins, this produces a robust assay that allows for 
screening for agonist/inverse agonist/antagonist activity under the same conditions.
Antagonists for the 5-HTia receptor enhance the antidepressant effects of 
selective serotonin uptake inhibitors (SSRIs) such as fluoxetine (Prozac) (Art!gas et 
a l, 1994; Artigas et al., 1996). This action is thought to be due to inhibition of 5-HT
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activation of presynaptic 5-HTia receptors, activation of which leads to decreased 5- 
HT release. It is therefore important to identify the exact characteristics of the co­
administered 5-HTia ligand because agonist could result in the downregulation of 
receptor expression with time whereas inverse agonists may have the opposite effect.
The ability of the high affinity GTPase assay using constitutively active 5- 
HTia receptor-G protein fusions in the presence of RGS proteins to distinguish 
between different ligand types was examined in this final section of work.
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6.2 Results
Increasing concentrations of the ligand spiperone have been previously 
shown to decrease basal GTPase activity at the 5-HTia receptor fused to either WT 
Gila protein or Ile^^  ^ mutant Gua protein (Kellett et a l, 1999). No effect was 
demonstrated at the 5-HTia receptor alone or the Gii« Gly^^  ^ fusion protein. This 
effect was completely abolished by pertussis toxin-treatment of membranes 
containing the WT fusion, but the toxin had no effect on the Ile^^^  mutant fusion, 
indicating that the effect was due to activation of Gia proteins and not another 
undescribed mechanism.
The inverse agonist properties of spiperone and a number of other ligands 
were further investigated in the 5-HTiA/GiiaC^^^I and 5-HTiA/GoiaC^^^I fusions in 
the absence and presence of RGSl. In membranes expressing these two 5-HT]a 
receptor-G protein constructs, RGS 1 produced concentration-dependent increases in 
basal GTPase activity (Figure 6.1) with the effects having EC50 values of 90nM for 
the Gila fusion protein and 52nM for the Goia fusion protein. Using a maximal 
concentration of RGSl protein produced an increase in basal GTPase activity 
providing a larger window of opportunity to assess the effects of a range of ligands. 
In parallel, competition binding curves were performed with the radioligand [^H]- 
WAY100635, allowing the pKi for each ligand to be calculated.
The effects of a range of concentrations of 5-HT (InM -  lOOjiM) were 
examined initially on the 5-HTiA/GuaC^^^I fusion protein (Figure 6.2, A). There was 
no significant difference in the EC50 for 5-HT activation of GTPase activity in the 
absence or presence of RGSl (4InM +/- 4.5 and 132 +/- 20.8nM respectively) (Table 
6.1), but from producing less than a two fold increase in GTPase activity over basal 
in the absence of RGSl, 5-HT produced a greater than five fold increase in GTPase 
activity over basal in the presence of RGSl. RGSl on its own produced less than a 
two fold increase in basal GTPase activity in membranes expressing the Gua fusion 
protein but in membranes expressing the Goia fusion protein, this elevation of basal 
GTPase activity was nearly four fold (Figure 6.3, A). The effects of 5-HT on the 5- 
HTiA/GoiaC^^^I fusion protein were similar; less than a two fold stimulation of 
GTPase activity over basal in the absence of RGSl, but a greater than ten fold 
increase in GTPase activity over basal in the presence of RGSl. The estimated pKi
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for 5-HT was 7.12 for the Gna fusion and 7.00 for the Goia fusion, figures consistent 
with those found in the literature (Newman-Tancredi et ah, 2001) (Table 6.2).
Previously, WAY100635 has been reported as a neutral antagonist at the 5- 
HTia receptor (Fletcher et al., 1996; Newman-T ancredi et al., 1997; Routledge 
1996), but in these studies using the 5-HTia receptor-G protein fusions with 
constitutive activity it acted as a partial agonist (Figures 6.4, and 6.5 A). At both the 
Gila and Goia fusions in the absence of RGSl, it showed very weak partial 
agonist activity, elevating the basal GTPase activity slightly (less than 1.5 fold), but 
in the presence of RGSl this effect was exaggerated and its partial agonist activity 
became more pronounced, particularly with the Goia fusion (Figure 6.5 A). 
Importantly, RGSl had no effect on the binding of [^H]-WAY100635 to the 
constructs, either in terms of Kd or Bmax (Figure 6 . 6  A -H B). The estimated pKi for 
WAY100635 at both the Gna and Goia fusion proteins (8.92 and 9.05 respectively) 
was consistent with those reported in the literature (Newman-Tancredi et al., 2001).
Previously published data on the 5-HTiA/Giia fusion proteins demonstrated 
that spiperone had inverse agonist activity at the 5-HTiA/Giia and 5-HTiA/GuaC^^^I 
fusion proteins (Kellett et a l, 1999), resulting in approximately 50% reduction in 
basal GTPase activity. Both of these fusions show basal constitutive activity, with 
the Ile^^^  fusion showing the greatest.
Increasing concentrations of spiperone (InM -  lOOj^M) were examined for 
effects on basal GTPase activity in membranes expressing the 5-HTiA/GiiaC^^^I 
fusion protein or the 5-HTiA/GoiaC^^^I fusion protein (Figures 6.7 and 6 .8 ). In the 
absence of RGSl, spiperone produced a clear reduction in basal GTPase activity for 
the 5-HTiA/GiiaC^^^I fusion, but this effect was less pronounced for the Goia Ile^^  ^
fusion protein (approximate 50% and 30% reductions respectively). The effects of 
RGSl are not to increase the rate of exchange of GDP for GTP on the G« subunit, 
only to increase the rate of GTP hydrolysis. Given this, it was unsurprising that the 
effects of spiperone became exaggerated in the presence of RGS protein as the basal 
rate of GTPase activity was increased over 1.5 fold for 5-HTiA/GiiaC^^^I and four­
fold for 5-HTiA/GoiaC^^^I. It was now possible to measure accurately the potency of 
spiperone at these fusion proteins, with EC50 values of 46 +/- 6 .8 nM and 32 +/- 
13nM respectively in the presence of RGSl (Table 6.1). The pKi values for spiperone 
were consistent with those found in the literature (Table 6 .2 ) (Newman-Tancredi et
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a l, 2001). It was also noted that the affinity of spiperone for the fusion proteins was 
unaffected by the presence of RGSl (Figure 6.9) with no change in the IC50 values 
for displacement of [^H]-WAY100635 binding.
To further explore the effects of the RGS protein on basal GTPase activity 
and the effects of spiperone on these, high affinity GTPase assays were carried out 
over a wide range of GTP concentrations (Figures 6.10 and 6.11) (Table 6.3). Basal 
GTPase activity was elevated in the presence of RGSl alone, again 1.5 fold in the 
case of the 5-HTiA/GüaC^^^I fusion and 4 fold for the 5-HTiA/GoiaC^^^I fusion in 
terms of Vmax> Spiperone produced a significant decrease in basal Vmax iri the absence 
of RGSl for both G^a and Goia constructs (P = 0.0308 and 0.0006 respectively) and 
a significant decrease in RGSl increased basal V,nax for both (0.0075 and 0.0005 
respectively). As a control, 5-HT also increased V,nax over basal and significantly 
increased Vmax over RGS 1 increased basal GTPase activity for both Gi and Go fusion 
proteins (P < 0.05).
The effects of a number of other ligands on basal GTPase activity in 
membranes expressing the 5-HTiA/GuaC^^^I or GoiaC^^^I fusions were examined. 
Methiothepine (Figures 6.12 and 6.13), chlorpromazine (Figures 6.14 and 6.15), (+)- 
butaclamol (Figures 6.16 and 6.17), and thioridazine (Figures 6.18 and 6.19) all 
demonstrated inverse agonist activity on basal GTPase levels. These effects were 
clearly visible in membranes expressing the 5-HTiA/GiiaC^^^I fusion protein, but as 
with spiperone it was not possible to quantitate the effects accurately. In the presence 
of RGSl though, the 1.5 fold increase in basal GTPase activity for the G^a fusion 
and the 4 fold increase for the Goia fusion, made it possible to measure the potencies 
of these inverse agonists at these constructs. These results are summarised in table 
6.1 with pECso andpK; values summarised in table 6.2.
Only in the case of haloperidol was a lack of significant inverse agonist 
activity found at both the Gna and Goia fusion proteins (Figure 6.20 and 6.21). This 
was also noted in the presence of RGS 1 indicating that this ligand has zero activity at 
the 5-HTiA receptor in these assay conditions. This was not due to a lack of receptor 
binding, illustrated by the ability of haloperidol to compete with [^H]-WAY100635 
for binding to the 5-HTia receptor (Figures 6.20B and 6.21B). Haloperidol acted as 
an antagonist at the 5-HTia receptor. The calculated pKi figure was similar to those 
found in the literature (Newman-Tancredi et aL, 2001; Millan 2000) (Table 6.2).
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Figure 6.1 The effects of increasing concentrations of RGSl
protein on high affinity GTPase activity of 
membranes stably expressing the 5-HTiA/GüaC^^ I^ 
and 5-HTiA/GoiaC^^ I^ fusion proteins
RGSl protein produced a concentration-dependent increase in high affinity GTPase 
activity in membranes expressing either the 5-HTiA/GiiaC^^^I or 5-HTiA/GoiaC^^^I 
fusion proteins. Data are means of triplicate determinations, are representative of at 
least three similar experiments and are expressed as % increase over basal GTPase 
activity.
V  5-HTiA/GoiaC” 'l
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Figure 6.2 Panel A: Effects of increasing concentrations of 5-
HT on the high affinity GTPase activity of 
membranes expressing the 5-HTiA/GüaC^^ I^ fusion 
protein in the presence and absence of RGSl. 
Panel B: Competition by 5-HT for [^ HJ-
WAY100635 binding to the 5-HT,A/GiiaC^®*I 
fusion protein.
Panel A: High affinity GTPase activity in pertussis toxin treated membranes 
expressing the 5-HTiA/GiiaC^^'l fusion protein expressed as percentage stimulation 
of basal GTPase activity in the absence of RGSl. Effects of increasing 
concentrations of 5-HT (InM  -  lOOjuM) in the absence and presence of RGSl 
(IpM ). 
g  5-HT
Y  5-HT + RGSl ( luM )
Panel B: Specific binding of [^H]-WAY100635 to the 5-HTiA/GiiaC^^'l fusion 
protein in the presence of increasing concentrations o f 5-HT expressed as a 
percentage o f radioligand binding in the absence of 5-HT.
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 6.3 Panel A: Effects of Increasing concentrations of 5-
HT on the high affinity GTPase activity of 
membranes expressing the S-HTia/GoIoC^ '^I fusion 
protein in the presence and absence of RGSl. 
Panel B: Competition by 5-HT for [^ H]-
WAY100635 binding to the 5-HT,A/GoiaC^ ‘^l 
fusion protein.
Panel A: High affinity GTPase activity in pertussis toxin treated membranes 
expressing the 5-HTiA/GoiaC^^‘l fusion protein expressed as percentage stimulation 
o f basal GTPase activity in the absence o f RGSl. Effects of increasing 
concentrations of 5-HT (InM  -  lOOjiiM) in the absence and presence of RGSl 
(IpM ). 
g  5-HT
Y  5-HT + RGS KluM)
Panel B: Specific binding o f [^H]-WAY 100635 to the 5-HTiA/GoiaC^^'l fusion 
protein in the presence of increasing concentrations o f 5-HT expressed as a 
percentage of radioligand binding in the absence o f 5-HT.
Data are means o f triplicate determinations and are representative o f at least three 
similar experiments.
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Table 6.1 Summary of EC50 values for ligand inhibition of
basal GTPase activity in the presence and absence 
of RGSl for the 5-HTia/Gh„C®*‘I and 5- 
HTia/G„i„C* '^I fusion proteins
The effects of increasing concentrations of 5-HT, WAY100635, spiperone, 
methiothepine, chlorpromazine, butaclamol, thioridazine and haloperidol on basal 
and RGSl (IpM ) stimulated GTPase activity in pertussis toxin treated membranes 
expressing the 5-HTiA/GiiaC^^^I and 5-HTiA/GoiaC^^*I fusion proteins were 
measured in terms of EC50.
Data are means of triplicate determinations and are representative of at least three 
similar experiments.
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Table 6.2 Summary of pECso values for ligand inhibition of
basal GTPase activity in the presence and absence 
of RGSl for the 5-HTiA/GüaC^^ I^ and 5- 
HTia/Goi«C^ ^^ I fusion p r o te in s .v a lu e s  are also 
show from ligand displacement of [^ H]- 
WAY100635 binding
The effects of increasing concentrations of 5-HT, WAY100635, spiperone, 
methiothepine, chlorpromazine, butaclamol, thioridazine and haloperidol on basal 
and RGSl (IpM ) stimulated GTPase activity in pertussis toxin treated membranes 
expressing the 5-HTiA/GiiaC^^^I and 5-HTiA/GoiaC^^^I fusion proteins were 
measured in terms of pECso- Ligand displacement of [^H]-WAY100635 binding to 
the 5-H T ia receptor-G protein fusions allowed calculation ofpKi figures.
Data are means of triplicate determinations and are representative of at least three 
similar experiments.
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Figure 6.4 Panel A: Effects of increasing concentrations of
WAY100635 on the high affinity GTPase activity 
of membranes expressing the 5-HTiA/GüaC^ '^l 
fusion protein in the presence and absence of 
RGSl. Panel B: Competition by WAY100635 for 
|’H1-WAY100635 binding to the 5-HT,A/GiiaC**'l 
fusion protein.
Panel A: High affinity GTPase activity in pertussis toxin treated membranes 
expressing the 5-HTiA/G,iaC^^'l fusion protein expressed as percentage stimulation 
of basal GTPase activity in the absence of RGSl. Effects of increasing 
concentrations of WAY 100635 (O.lnM -  lOpM) in the absence and presence o f 
RGSl (IpM ).
H  WAY 100635
Y  WAY 100635 + RGSl (luM )
Panel B: Specific binding o f [^H]-WAY 100635 to the 5-HTiA/GiiaC^^'l fusion 
protein in the presence of increasing concentrations of WAY 100635 expressed as a 
percentage of radioligand binding in the absence of WAY 100635.
Data are means of triplicate determinations and are representative of at least three 
similar experiments.
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Figure 6.5 Panel A: Effects of increasing concentrations of
WAY100635 on the high affinity GTPase activity 
of membranes expressing the 5-HTiA/GoiaC^ '^l 
fusion protein in the presence and absence of 
RGSl. Panel B: Competition by WAVI00635 for 
|^H1-WAY100635 binding to the 5-HT|A/G„,aC^‘l 
fusion protein.
Panel A: High affinity GTPase activity in pertussis toxin treated membranes 
expressing the 5-HTiA/GoiaC^^‘l fusion protein expressed as percentage stimulation 
of basal GTPase activity in the absence of RGSl. Effects o f increasing 
concentrations o f WAY 100635 (O.lnM -  lOpM) in the absence and presence of 
RGSl (IpM ). 
g  WAY 100635
y  WAY 100635 + RGS 1 ( 1 uM)
Panel B: Specific binding of [^H]-WAY100635 to the 5-HTiA/GoiaC^^'l fusion 
protein in the presence of increasing concentrations of WAY 100635 expressed as a 
percentage of radioligand binding in the absence of WAY100635.
Data are means o f triplicate determinations and are representative of at least three 
similar experiments.
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Figure 6.6 Saturation analysis of [^H]-WAY100635 binding
to the 5-HT,A/Gi,„C^ ‘^l and 5-HTiA/GoiaC^^I 
fusion proteins. Lack of effect of RGSl
Membranes were prepared from the cells stably expressing the 5-HTiA/GiiaC^^‘l 
(Panel A) and 5-HTiA/GoiaC^^'l (Panel B) fusion proteins and saturation binding 
assays carried out using the 5-HTia receptor selective antagonist [^H]-WAY 100635 
in the absence and presence o f RGSl (IpM ). Non-specific binding was determined 
using lOpM WAY 100635. Using the data analysis package Graphpad Prism, 
nonlinear regression analysis o f the data fitted a single site binding site, determining 
total number of binding sites {B„ax) and the equilibrium dissociation constant (Kd).
Panel A 
0  5-HT,A/G.iaC” 'l ptox
^  5-HT,a/G,i„C” 'I ptox + RGSl (IpM )
Panel B 
■  5 -HT,a/Goi<xC” 'i ptox 
5-HT|A/GoiaC” 'l ptox + RGSl (IjiM )
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Figure 6.7 Panel A: Effects of increasing concentrations of
spiperone on the high affinity GTPase activity of 
membranes expressing the 5-HTiA/GiiaC^ *^I fusion 
protein in the presence and absence of RGSl. 
Panel B: Competition by spiperone for 
WAY100635 binding to the 5-HTiA/Gi,aC^^*I 
fusion protein.
Panel A: High affinity GTPase activity in pertussis toxin treated membranes 
expressing the 5-HTiA/G,iaC’'T  fusion protein expressed as percentage stimulation 
of basal GTPase activity in the absence of RGSl. Effects o f increasing 
concentrations of spiperone (InM  -  lOOpM) in the absence and presence of RGSl 
(IpM ). 
g  Spiperone
Spiperone + RG S1 ( 1 uM)
Panel B: Specific binding o f [^H]-WAY 100635 to the 5-HTiA/GiiaC^^'l fusion 
protein in the presence of increasing concentrations of spiperone expressed as a 
percentage of radioligand binding in the absence of spiperone.
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 6.8 Panel A: Effects of increasing concentrations of
spiperone on the high affinity GTPase activity of 
membranes expressing the 5-HTiA/GoiaC^ '^l fusion 
protein in the presence and absence of RGSl. 
Panel B: Competition by spiperone for |^H|- 
WAY100635 binding to the 5-HTiA/GoiaC^ ’^l 
fusion protein.
Panel A: High affinity GTPase activity in pertussis toxin treated membranes 
expressing the 5-HTiA/GoiaC^^’l fusion protein expressed as percentage stimulation 
of basal GTPase activity in the absence of RGSl. Effects o f increasing 
concentrations of spiperone (InM  -  lOOpM) in the absence and presence of RGSl 
(IpM ).
H  Spiperone
0^  Spiperone + RGS 1 ( 1 uM)
Panel B: Specific binding of [^H]-WAY 100635 to the 5-HTiA/GoiaC^^’l fusion 
protein in the presence of increasing concentrations of spiperone expressed as a 
percentage of radioligand binding in the absence of spiperone.
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 6.9 Competition by spiperone for [^H]-WAY100635
binding to the 5-HTiA/GüaC^^*! (Panel A) and 5- 
HTiA/GoiaC^  ^ I (Panel B) fusion proteins in the 
absence and presence of RGSl
Binding of [^H]-WAY 100635 in the absence and presence of RGSl (IpM ) to the 5- 
HT|A/GiiaC^^'l and 5-HTiA/GoiaC^^‘l fusion proteins in the presence of increasing 
concentrations of spiperone (InM  -  lOOpM) expressed as a percentage of 
radioligand binding in the absence of spiperone.
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
Panel A 
g  5-HTiA/G,iaC” 'l ptox
^  5-HTiA/G„aC” 'l ptox + RGSl (IpM)
Panel B 
■  5-HTia/G„i„C” 'I ptox
5-HTia/Go,„C” ‘I ptox + RGSl (IpM)
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Figure 6.10 Enzyme kinetic analysis of the effects of 5 HT and 
spiperone on high affinity GTPase activity of 
membranes expressing the S-HTiA/GuaC^  ^ I fusion 
protein in the absence and presence of RGSl
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HTiAGiiaC^^'l fusion protein with increasing concentrations of OTP as substrate. 5- 
HT and spiperone effects on GTPase activity were measured in the presence and 
absence of RGSl (IpM ). Panel B: The data generated were converted to Eadie- 
Hofstee plots to analyse effects on for GTP hydrolysis and Fmax- 
Data are means of triplicate determinations and are representative of at least three 
similar experiments.
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Figure 6.11 Enzyme kinetic analysis of the effects of 5-HT and
spiperone on high affinity GTPase activity of 
membranes expressing the S-HTia/GoIoC^ ^^ I 
fusion protein in the absence and presence of 
RGSl
Panel A: GTPase activity in pertussis toxin treated membranes expressing the 5- 
HTiAGoiaC^^'l fusion protein with increasing concentrations o f GTP as substrate. 5- 
HT and spiperone effects on GTPase activity were measured in the presence and 
absence o f RGSl (IpM ). Panel B: The data generated were converted to Eadie- 
Hofstee plots to analyse effects on for GTP hydrolysis and Fmax- 
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
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Table 6.3 Summary of V ^ax and values from enzyme
kinetic analysis for the 5-HTiA/GuaC^  ^I and 5- 
HT)A/GoiaC  ^ I fusion proteins in the presence and 
absence of both spiperone and RGSl protein
The effects of spiperone on basal and RGSl (IpM ) stimulated GTPase activity in 
pertussis toxin treated membranes expressing the S-HTiA/GnaC^^^I and 5- 
HTlA/GoiaC^^^I fusion proteins were measured in terms of Vj„ax and K„i for GTP.
Data are means of triplicate determinations and are representative of at least three 
similar experiments.
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Figure 6.12 Panel A: Effects of increasing concentrations of
methiothepine on the high affinity GTPase activity 
of membranes expressing the 5-HTiA/GiiaC^ *^I 
fusion protein in the presence and absence of 
RGSl. Panel B: Competition by methiothepine for 
|^HI-WAY100635 binding to the 5-HT,A/Gi,„C"'l 
fusion protein.
Panel A: High affinity GTPase activity in pertussis toxin treated membranes 
expressing the 5-HTiA/GiiaC^^*I fusion protein expressed as percentage stimulation 
of basal GTPase activity in the absence of RGSl. Effects o f increasing 
concentrations of methiothepine (O.lnM -  lOjiiM) in the absence and presence o f 
RGSl (IpM).
H  Methiothepine
Methiothepine + RGS 1 ( 1 uM)
Panel B: Specific binding of [^H]-WAY 100635 to the 5-HTiA/GiiaC^^'l fusion 
protein in the presence of increasing concentrations of methiothepine expressed as a 
percentage of radioligand binding in the absence of methiothepine.
Data are means o f triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 6.13 Panel A: Effects of increasing concentrations of
methiothepine on the high affinity GTPase activity 
of membranes expressing the 5-HTiA/GoiaC^ '^l 
fusion protein in the presence and absence of 
RGSl. Panel B: Competition by methiothepine for 
|^H1-WAY100635 binding to the 5-HT,A/G.,.C^'l 
fusion protein.
Panel A: High affinity GTPase activity in pertussis toxin treated membranes 
expressing the 5-HTiA/GoiaC^^’l fusion protein expressed as percentage stimulation 
of basal GTPase activity in the absence of RGSl. Effects of increasing 
concentrations o f methiothepine (O.lnM -  lOpM) in the absence and presence of 
RGSl (IpM ). 
g  Methiothepine
^  Methiothepine + RGS 1 ( 1 uM)
Panel B: Specific binding of [^H]-WAY100635 to the 5-HTiA/GoiaC^^‘l fusion 
protein in the presence o f increasing concentrations of methiothepine expressed as a 
percentage of radioligand binding in the absence of methiothepine.
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 6.14 Panel A: Effects of increasing concentrations of 
chlorpromazine on the high affinity GTPase
activity of membranes expressing the 5- 
HTiA/GiiaC *^*I fusion protein in the presence and 
absence of RGSl. Panel B: Competition by
chlorpromazine for |^H]-WAY100635 binding to
the 5-HTiA/GiiaC^^*I fusion protein.
P a n e l  A :  H i g h  a f f i n i t y  G T P a s e  a c t i v i t y  i n  p e r t u s s i s  t o x i n  t r e a t e d  m e m b r a n e s  
e x p r e s s i n g  t h e  5- H T i A / G ü a C ^ ^ ^ I  f u s i o n  p r o t e i n  e x p r e s s e d  a s  p e r c e n t a g e  s t i m u l a t i o n
o f  b a s a l  G T P a s e  a c t i v i t y  i n  t h e  a b s e n c e  o f  R G S l .  E f f e c t s  o f  i n c r e a s i n g
c o n c e n t r a t i o n s  o f  c h l o r p r o m a z i n e  ( I n M  -  l O O p M )  i n  t h e  a b s e n c e  a n d  p r e s e n c e  o f  
R G S l  ( I p M ) .  
g  Chlorpromazine
Chlorpromazine + RGS 1 ( 1 uM)
P a n e l  B :  S p e c i f i c  b i n d i n g  o f  [ ^ H ] - W A Y 100635 t o  t h e  5-HTiA/GüaC^^'l f u s i o n  
p r o t e i n  i n  t h e  p r e s e n c e  o f  i n c r e a s i n g  c o n c e n t r a t i o n s  o f  c h l o r p r o m a z i n e  e x p r e s s e d  a s  a  
p e r c e n t a g e  o f  r a d i o l i g a n d  b i n d i n g  i n  t h e  a b s e n c e  o f  c h l o r p r o m a z i n e .
D a t a  a r e  m e a n s  o f  t r i p l i c a t e  d e t e r m i n a t i o n s  a n d  a r e  r e p r e s e n t a t i v e  o f  a t  l e a s t  t h r e e  
s i m i l a r  e x p e r i m e n t s .
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Figure 6.15 Panel A: Effects of increasing concentrations of
chlorpromazine on the high affinity GTFase 
activity of membranes expressing the 5- 
HTiA/GoiaC^ ^^ I fusion protein in the presence and 
absence of RGSl. Panel B: Competition by 
chlorpromazine for [^H]-WAY100635 binding to 
the 5-HTiA/GoiaC^^ I^ fusion protein.
Panel A: High affinity GTFase activity in pertussis toxin treated membranes 
expressing the 5-HTiA/GoiaC^^^I fusion protein expressed as percentage stimulation 
of basal GTFase activity in the absence of RGSl. Effects of increasing 
concentrations of chlorpromazine (InM  -  lOOpM) in the absence and presence of 
RGSl (IpM).
Chlorpromazine
^  Chlorpromazine +  RGS H I  uM)
Panel B; Specific binding of [^H]-WAY100635 to the 5-HTiA/GoiaC^^h fusion 
protein in the presence of increasing concentrations of chlorpromazine expressed as a 
percentage of radioligand binding in the absence of chlorpromazine.
Data are means of triplicate determinations and are representative of at least three 
similar experiments.
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Figure 6.16 Panel A: Effects of increasing concentrations of
butaclamoi on the high affinity GTFase activity of 
membranes expressing the 5-HTiA/GiiaC^  ^I fusion 
protein in the presence and absence of RGSl. 
Panel B: Competition by butaclamoi for [^ H]- 
WAY100635 binding to the 5-HTiA/GiiaC^^ I^ 
fusion protein.
Panel A: High affinity GTPase activity in pertussis toxin treated membranes 
expressing the 5-HTiA/GiiaC^^^I fusion protein expressed as percentage stimulation 
of basal GTPase activity in the absence of RGSl. Effects of increasing 
concentrations of butaclamoi (InM -  100|liM) in the absence and presence of RGSl 
(IpM).
[“ ] Butaclamoi 
^  Butaclamoi + RGS 1 (1  uM)
Panel B: Specific binding of [^H]-WAY100635 to the 5-HTiA/GiiaC^^^I fusion 
protein in the presence of increasing concentrations of butaclamoi expressed as a 
percentage of radioligand binding in the absence of butaclamoi.
Data are means of triplicate determinations and are representative of at least three 
similar experiments.
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Figure 6.17 Panel A: Effects of increasing concentrations of
butaclamoi on the high affinity GTPase activity of 
membranes expressing the 5-HTiA/GoiaC^ *^I fusion 
protein in the presence and absence of RGSl. 
Panel B: Competition by butaclamoi for |^H]- 
WAY100635 binding to the 5-HTiA/G.,aC^'l 
fusion protein.
Panel A: High affinity GTPase activity in pertussis toxin treated membranes 
expressing the 5-HT|A/GoiaC^^*I fusion protein expressed as percentage stimulation 
of basal GTPase activity in the absence of RGSl. Effects of increasing 
concentrations of butaclamoi (InM  -  lOOpM) in the absence and presence of RGSl 
(IpM ). 
g  Butaclamoi
Butaclamoi + RGS 1 ( 1 uM)
Panel B: Specific binding of [^H]-WAY 100635 to the 5-HTiA/GoiaC^^'l fusion 
protein in the presence of increasing concentrations of butaclamoi expressed as a 
percentage of radioligand binding in the absence of butaclamoi.
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 6.18 Panel A: Effects of increasing concentrations of
thioridazine on the high affinity GTPase activity 
of membranes expressing the 5-HT,A/GnaC^  ^I 
fusion protein in the presence and absence of 
RGSl. Panel B: Competition by thioridazine for 
[*H|-WAY100635 binding to the 5-HT,A/Gii„C*®'l 
fusion protein.
Panel A: High affinity GTPase activity in pertussis toxin treated membranes 
expressing the 5-HTiA/GnaC^^‘l fusion protein expressed as percentage stimulation 
o f basal GTPase activity in the absence of RGSl. Effects of increasing 
concentrations o f thioridazine (InM  -  lOOpM) in the absence and presence o f RGSl 
(IpM ). 
m  Thioridazine
Thioridazine + RGS 1 ( 1 uM)
Panel B: Specific binding o f [^H]-WAY100635 to the 5-HTiA/GiiaC^^’l fusion 
protein in the presence of increasing concentrations of thioridazine expressed as a 
percentage of radioligand binding in the absence of thioridazine.
Data are means o f triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 6.19 Panel A: Effects of increasing concentrations of
thioridazine on the high affinity GTPase activity 
of membranes expressing the S-HTia/GoIoC^ *^! 
fusion protein in the presence and absence of 
RGSl. Panel B: Competition by thioridazine for 
|^H|-WAY100635 binding to the 5-H Tia/G „, 
fusion protein.
Panel A; High affinity GTPase activity in pertussis toxin treated membranes 
expressing the 5-HTiA/GoiaC^^4 fusion protein expressed as percentage stimulation 
of basal GTPase activity in the absence o f RGSl. Effects of increasing 
concentrations of thioridazine (InM  -  lOOpM) in the absence and presence of RGSl 
(IpM ). 
g  Thioridazine
Thioridazine + RGS 1 ( 1 uM)
Panel B: Specific binding of [^H]-WAY 100635 to the 5-HTiA/GoiaC^^*I fusion 
protein in the presence of increasing concentrations of thioridazine expressed as a 
percentage of radioligand binding in the absence of thioridazine.
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
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Figure 6.20 Panel A; Effects of increasing concentrations of
haloperidol on the high affinity GTPase activity of 
membranes expressing the 5-HTiA/GuaG^  ^I fusion 
protein in the presence and absence of RGSl. 
Panel B; Competition by haloperidol for [^ H]- 
WAY100635 binding to the 5-HTiA/GiiaC^^ I^ 
fusion protein.
Panel A: High affinity GTPase activity in pertussis toxin treated membranes 
expressing the 5-HTiA/GiiaC^^^I fusion protein expressed as percentage stimulation 
of basal GTPase activity in the absence of RGSl. Effects of increasing 
concentrations of haloperidol ( I n M -  lOOpM) in the absence and presence of RGSl 
(IpM).
Haloperidol
Y  Haloperidol +  RGS H I  uM )
Panel B; Specific binding of [^H]-WAY100635 to the 5-HTiA/GiiaC^^^I fusion 
protein in the presence of increasing concentrations of haloperidol expressed as a 
percentage of radioligand binding in the absence of haloperidol.
Data are means of triplicate determinations and are representative of at least three 
similar experiments.
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Figure 6.21 Panel A: Effects of increasing concentrations of
haloperidol on the high affinity GTPase activity of 
membranes expressing the 5-HTiA/GoiaC^ ^^ I fusion 
protein in the presence and absence of RGSl. 
Panel B: Competition by haloperidol for |^H)- 
WAV100635 binding to the 5-HT,A/GoiaC^ *^I 
fusion protein.
Panel A: High affinity GTPase activity in pertussis toxin treated membranes 
expressing the 5-HTiA/GoiaC^^*I fusion protein expressed as percentage stimulation 
of basal GTPase activity in the absence of RGSl. Effects of increasing 
concentrations o f haloperidol (InM  -  lOOpM) in the absence and presence of RGSl 
(IpM ). 
g  Haloperidol
^  Haloperidol + RGS 1 ( 1 uM)
Panel B: Specific binding of [^H]-WAY100635 to the 5-HTiA/GoiaC^^^I fusion 
protein in the presence of increasing concentrations of haloperidol expressed as a 
percentage of radioligand binding in the absence of haloperidol.
Data are means of triplicate determinations and are representative o f at least three 
similar experiments.
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6.2 Discussion
From a sceptical start, inverse agonists have redefined the classification of a 
large number of drugs. Those previously classified simply as antagonists have now 
been shown in many cases to display inverse agonist activity. For example, a number 
of drugs were originally designed as antagonists for the histamine H2 receptor, 
cimetadine, ranitidine and famotidine, have been shown to be inverse agonists. Their 
use results in the up regulation of H2 receptors of up to 180% in mammalian cell 
lines (Alewijnse et a l, 1998; Smit et a l, 1996). Although a correlation between the 
level of receptor upregulation and withdrawal effects has not been found it has been 
suggested that receptor upregulation by these H2 receptor inverse agonists may lead 
to drug tolerance in ulcer treatment (Leurs et al., 1998). Distinction between inverse 
agonists and ligands acting as neutral antagonists may therefore be important in 
development of future drug therapies.
Constitutive activity was first described for a GPCR in 1989 for the Ô opioid 
receptor in NG108-15 neuroblastoma-glioma cells (Costa and Herz 1989) and later 
for overexpressed aie and P2 adrenoceptors (Lefkowitz et aL, 1993). Many ligands 
previously described as antagonists were subsequently re-classified following 
demonstration of their inverse activity (Milligan et al, 1995; Kenakin, 1996; Leff, 
1997).
The activity of a receptor can be very simple classed into two states, G 
protein uncoupled (R) and G protein coupled (R*), where in the R* form the receptor 
has increased affinity for agonists and a higher basal level of activity. Constitutive 
activity can be induced by a number of methods. Firstly and most simply, the 
receptor can be over expressed in a system. By increasing receptor number, there is 
an increase in the number of copies of R* receptors (Chidiac et al., 1994; MacEwan 
and Milligan, 1996; Smit et al., 1996). Secondly, certain mutations in the DRY 
motif, a highly conserved region at the cytosolic end of the transmembrane domain 3, 
can lead to increased G protein coupling, possibly by exposing residues in the 
intracellular domains of the GPCR that are normally only exposed following agonist 
binding (Scheer et al., 1996). Thirdly, fusion proteins between the GPCR and the G« 
subunits of inhibitory G proteins can also increase the constitutive activity of the 
receptor (Kellett et al., 1999). This increase in constitutive activity is enhanced by 
mutation of Cys^^  ^ in the C terminal region of the ot subunit to more hydrophobic
215
amino acids. Bahia et al. (1998) mutated Cys^^  ^ to every other naturally occurring 
amino acid and found a strong correlation between the hydrophobicity of the residue 
and its affinity for the 0(2A-adrenoceptor.
The data in this chapter demonstrates a clear role for both receptor-G protein 
mutant fusion proteins and the use of RGS proteins in distinguishing between neutral 
antagonists and inverse agonists. They can also help to provide useful 
pharmacological information on the potency of inverse agonists at decreasing basal 
receptor activity. Previously, data on inverse agonists has been generated from 
systems where the receptor has been overexpressed or mutated to increase 
constitutive activity. This results in a less than natural system, particularly in the case 
of the mutant GPCRs and only provides comparative data for each expression system 
and assay used. Using fusion proteins between the GPCR and G protein allows for 
the generation of much more accurate data with a WT receptor where any mutations 
used will be in the G« protein. The 1:1 stoichiometry of the receptor to G protein in 
pertussis toxin treated cells allows for exact measure of receptor and thus G protein 
expression level and so the ability of an agonist to effect GTPase activity in the fused 
G protein. These data can be used to measure the rate of hydrolysis of GTP to GDP 
as affected by an agonist.
It has been shown previously that using fusion proteins between the 5-HTia 
receptor and G^ protein subunits can lead to an increase in the intrinsic constitutive 
activity of the receptor (Kellett et al., 1999). These effects were most pronounced 
when a residue in the C terminal tail of the Ga protein involved in the coupling of 
receptor to G protein, Cys^^\ was mutated to Ile^^\ Using these properties of the 
fusion proteins provides a larger window of activity to screen for potential inverse 
agonist. However, the effect of some ligands still remains small.
The action of RGS proteins is as GAPs (GTPase activating proteins) for Gi 
and Gq subunits of G proteins (Dohlman and Thomer 1997; Koelle 1997; Berman 
and Gilman 1998). Their presence at an activated, or GTP bound G protein, results in 
an increase in GTPase activity, more rapid conversion of GTP to GDP and thus 
inactivation of the receptor generated signal. They do not affect the affinity of the G 
protein for GTP, only increase the rate at which it is converted to GDP. Taking 
advantage of this quality, RGS proteins were found to increase not only agonist 
stimulated but also the basal GTPase activity of the 5-HTia receptor fused to both
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GiiaC^^ I and GoiaC^^^I proteins (Figure 6.1). These results demonstrated that the 
maximum concentration of RGSl produced approximately a 150% increase in basal 
GTPase activity at the GüaC^^^I fusions and a 400% increase in GTPase activity at 
the GoiaC^^^I fusion protein. Having shown a small degree of inverse activity at the 
5-HTia receptor-G protein fusions in the absence of RGSl, compounds such as 
chlorpromazine, butaclamoi and thioridazine showed a much greater level of inverse 
agonist activity following the increase in basal GTPase activity stimulated by the 
RGS protein.
In the absence of RGSl, a maximal concentration of 5-HT produces less than 
a two fold increase in high affinity GTPase activity in membranes expressing either 
the 5-HTiA/GiiaC^^^I or 5-HTiA/GoiaC^^^I fusion proteins (Figures 6.2 and 6.3). 
RGSl protein produces significant increases in maximal 5-HT stimulated GTPase 
activity following activation of both constructs with over a three fold increase in 
GTPase activity for the Güa fusion protein over basal in the presence of RGS protein 
and over a two fold increase for the Goia protein. These effects occurred without 
producing a significant change in the EC50 value of 5-HT at the Güa fusion protein 
(Table 6 .1 ). There was a significant effect on the EC50 value for the Goia fusion 
protein, 158+/~13nM in the absence of RGSl protein and 429+/-37nM in the 
presence (Table 6.1). This may be due to inaccurate estimation of the EC50 value in 
the absence of RGSl protein where a shallow Hill slope was recorded (0.56). The 
pKi values from 5-HT displacement of [^H]-WAY100635 binding were similar for 
both constructs (Table 6.2).
The 5-HTiA receptor selective ligand WAY100635 has previously been 
reported as having antagonist properties at the 5-HTia receptor (Routledge, 1996). 
However, both in the absence and presence of RGS protein WAY100635 exhibited 
partial agonist activity at the 5-HTia receptor Güa and Goia Ile^^  ^ constructs (Figure 
6.4 and 6.5). In the absence of RGSl protein partial agonist effect was difficult to 
quantify with less than a 1.5 fold increase in basal GTPase activity was recorded. In 
the presence of RGSl protein WAY100635 produced a 1.5 to 2 fold increase in high 
affinity GTPase activity in membranes expressing the Güa or Gda fusion proteins. 
This compares to a 3 fold and 2 to 3 fold increase produced by 5-HT at the same 
constructs respectively. No significant differences were found between the EC50 
values in the absence or presence of RGSl protein for either construct (Table 6.1),
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with WAY100635 exhibiting the greatest affinity for the 5-HTia receptor-G protein 
fusions with predicted pKi values of 8.92 and 9.05 for the Güa and Goia fusion 
proteins respectively (Table 6.2). These results are supported by the finding that 
RGSl protein did not have any effect on the absolute ability of [^H]-WAY100635 to 
bind specifically to membranes expressing either 5-HTia receptor-G protein fusion 
(Figure 6 .6 ).
Spiperone has been previously demonstrated to exhibit inverse agonist 
properties at the 5-HTia receptor fused to either WT Gna or the mutant GnaC^^^I 
(Figure 6,7) proteins (Kellett et al., 1999). This ligand also demonstrates inverse 
agonist properties in membranes expressing 5-HTiA/GoiaC^^^I fusion protein (Figure 
6 .8 ) but these effects are difficult to quantitate. Spiperone produces a 50% reduction 
in basal GTPase activity in membranes expressing the Güa fusion protein in the 
absence of RGSl protein with an EC50 of 67+/-4.3nM. The increase in basal GTPase 
activity in the presence of RGS 1 protein makes these effects easier to quantify with 
out producing a significant change in EC50 (46+/-6.8nM). The 4 fold increase in 
basal GTPase activity produced by RGSl protein in membranes expressing the 5- 
HTiA/GoiaC^^^I fusion allows for accurate quantitation of the inverse agonist effects 
of spiperone. The difference in the EC50 for spiperone in the absence (285+/-42nM) 
and presence of RGSl protein (32+/-13nM) is most likely due to an inaccurate 
estimation in the absence of RGSl (Table 6.1). Spiperone displays similar ability to 
displace [^H]-WAY100635 binding at the 5-HTia receptor fused to either the Güa or 
Goia mutant proteins with estimated pKi values of 6.41 and 6.77 respectively (Table 
6.2). Importantly, RGSl protein does not have any effect on the ability of spiperone 
to displace the radioligand in binding studies (Figure 6.9).
The effects of spiperone on high affinity GTPase activity were further 
investigated over a range of GTP concentrations (Figures 6.10 and 6.11). In the 
absence of receptor activation RGS 1 protein produced increases in both the V,nax and 
K,n for GTP over basal (Table 6.3). Spiperone alone produced a decrease in V„tax, but 
did not effect the K,n for GTP for membranes expressing the Güa and Goia fusion 
proteins respectively. In the presence of RGS 1 spiperone reduced the V,nax and the K,n 
for GTP for membranes expressing the Güa fusion protein levels that were not 
significantly different from those in the absence of RGSl protein. For membranes 
expressing the Goia fusion protein, spiperone in the presence of RGSl protein
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reduced the Vmcvc and K,n for GTP to levels similar to the basal conditions for the 
membranes.
Of the other five compounds screened using this assay, four demonstrated 
inverse agonist activity: methiothepine (Figures 6.12 and 6.13), chlorpromazine 
(Figures 6.14 and 6.15), butaclamoi (Figures 6.16 and 6.17) and thioridazine (Figures 
6.18 and 6.19). Consistent with the results for spiperone, the inverse agonist effects 
of these compounds were difficult to quantify in the absence of RGSl protein, 
particularly for the Goi« fusion protein. In the presence of RGSl protein though, the 
elevation in basal GTPase activity for membranes expressing both the Gii« and Goia 
constructs allowed for accurate quantitation of the EC50 values for the inverse 
agonists (Table 6.2). The EC50 values at both the Gna and Gda protein fusions 
followed the same pattern with methiothepine > spiperone > butaclamoi > 
thioridazine > chlorpromazine.
The only compound that did not demonstrate inverse agonist activity at 
concentrations that were relevant to receptor occupancy levels was haloperidol 
(Figures 6.20 and 6.21). In the absence of RGSl protein haloperidol did not have any 
effect on levels of GTPase activity for membranes expressing either the Gna or Gda 
fusion proteins. In the presence of RGSl protein at concentrations above l|xM there 
appeared to be a trend for inhibition of GTPase activity, but given the ligand 
concentrations these effects are most likely to be non-specific. It was clear that the 
lack of effect on GTPase activity by haloperidol was not due to a lack of binding as it 
displaced specific [^H]-WAY100635 binding to membranes expressing the 5- 
HTiA/GiiaC^^^I and 5-HTiA/GoiaC^^^I fusion proteins (Figures 6.20 and 6.21) with 
pK( values of 6.49 and 6.33 respectively.
Comparison of the pECso values and the pKj estimates for each of the 
compounds indicates a number of discrepancies. The pEC^o values from experiments 
using membranes expressing the 5-HTiA/GiiaC^^^I fusion in the presence of RGSl 
protein, which would provide more accurate estimations, are not consistent with the 
pKi estimations from competition bindings with [^H]-WAY100635 for spiperone 
where a log order difference was recorded (pECso of 7.34 and pKi of 6.41). The 
results for the Goia fusion protein show similar inconsistencies for spiperone, 
methiothepine and butaclamoi. Further investigations could be carried out to
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determine if the differences between these results are due to inaccurate estimations 
from either the radioligand binding assays or the GTPase assays.
A further inconsistency in the data is the difference in pKi values for 
methiothepine and butaclamoi between 5-HTiA/GüaC^^^I and 5-HTiA/GoiaC^^^I 
proteins. The affinity of these ligands for 5-HTia receptor binding should not be 
effected by the G protein fused to the C terminal tail of the receptor and further 
studies would have to be undertaken to determine the accuracy of the pKi 
estimations.
These results indicate that the use of RGSl protein in the high affinity 
GTPase assay for the 5-HTiA/GiiaC^^^I and 5-HTiA/GoiaC^^^I fusion proteins, 
contributes significantly in the production of a robust and accurate screen for ligand 
characterisation.
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7 Conclusions
Following its discovery in 1947, and its subsequent implication in a variety of 
disease states, serotonin became an intensively investigated neurotransmitter. This 
lead to the discovery and characterisation of the 14 known 5-HT receptor subtypes, 
all of which are GPCRs apart from 5 -HT3 , a ligand gated cation channel. These 
receptors have be divided into seven families, 5 -HT1.7 , based on sequence homology 
and pharmacological characteristics with the GPCR members of the family generally 
coupling either negatively or positively to adenylyl cyclase through the Gia and Gsa 
family of G proteins. The 5 -HT2 receptor family signals through the Gq/na subtypes.
Probably the most studied 5-HT receptor is the 5-HTia (Pedigo et aL, 1981), 
in part due to the publication of its entire amino acid sequence by Kobilka et al. in 
1987 (modified by Chanda et aL, 1993), but also due to the wide availability of the 
selective agonist 8-OH-DPAT (Gozlan et aL, 1983; Hjorth et aL, 1982) and more 
recently the selective antagonist WAY100635 (Routledge 1996). The 5-HTiA 
receptor is negatively coupled to adenylyl cyclase via Gi/o proteins and activates 
GIRK channels through the subsequent release of the Gpy dimer. The receptor is 
found centrally at high levels in the hippocampus, lateral septum, cortical areas and 
the mesencephalic raphe nuclei (Barnes and Sharp 1999), where it is present on 
serotonergic neurons both presynaptically, functioning as a classical autoreceptor, 
and postsynaptically where activation leads to neuronal hyperpolarisation by GIRK 
channel activation. The activation of presynaptic 5-HTia receptors is thought to be 
involved in the regulation of anxiety and depression and the activation of 
postsynaptic receptors has been indicated in 5-HT stimulated increases in 
noradrenaline and ACTH release. Both pre- and postsynaptic 5-HTia receptor 
activation has been indicated in the hypothermic response in rats (Barnes and Sharp 
1999).
Despite the implicated roles of the postsynaptic 5-HTia receptor, the 
presynaptic autoreceptor has been the focus of drug research. The presynaptic 
receptor is already the target of a number of therapeutic regimens, directly with drugs 
such as buspirone and gespirone in the treatment of anxiety (Tunnicliff 1991; Barret 
and Vanover 1993), and indirectly by the SSRI fluoxetine (Prozac) in the treatment 
of depression (Artigas et aL, 1994, 1996).
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Given that the 5-HT ia receptor has also been indicated in schizophrenia, 
immune responses and neurogenesis, a complete understanding of the interaction 
between the 5-H T ia receptor, and both its ligands and cognate G proteins would be 
of great assistance in the improvement of existing and development of new therapies.
The work described in this thesis examined the interaction of the 5-HTia 
receptor with both Gia and Goa proteins using receptor-G protein fusions. First 
described by Bertin et û/.(1994), these constructs were used to investigate the 
interactions between the two fused proteins and the effects on ligand binding and 
signal generation. The actions of a class of proteins known as regulators of G protein 
signalling (RGS) proteins, that act as GTPase activating proteins (GAPs) for both the 
Gia and Goa proteins utilised in these studies, were also investigated. A number of 
different assay methods were utilised to this end, including an intact cell adenylyl 
cyclase, ligand binding, and GTPase assays. Throughout the work, pertussis toxin 
resistant G protein fusions were utilised to allow accurate measures of the G protein 
coupling and activation by using pertussis toxin to ADP ribosylate and uncouple the 
endogenous pool of inhibitory G protein. The overall findings and the implications of 
these on therapeutic approaches to disease states will be discussed in tandem with the 
future work that could be done to progress these studies further.
A number of different conclusions can be drawn from the results from the 
intact cell cyclase assay in the first chapter. Firstly, in support of the findings of 
Bahia et al. (1998) and Kellett et al. (1999), fusion proteins between the 5-HTia 
receptor and both WT and Gna proteins with Ile^^  ^ and Gly^^  ^ mutations indicated 
that the greater the hydrophobicity of the residue at position 351 in the Güa protein, 
the higher the affinity of the receptor for the G protein. This is reflected by the 
potency of 5-HT to stimulate inhibition of forskolin stimulated cAMP production via 
the 5-HTia receptor being greatest with the Cys^^4le mutation followed by the WT 
fusion and lastly by the Cys^^^Gly mutant, an order which is mirrored by a decrease 
in hydrophobicity. The results for the Goia fusion proteins in this assay were not 
statistically different from one another so do not support this hypothesis. This may be 
due to the large error in the results for these constructs, or may be a reflection of 
Cys^^  ^ not playing as significant a role for Gda binding to the intracellular loops of 
the 5-HTiA receptor as for the binding of the Güa protein. This latter suggestion 
could be supported by the inability of pertussis toxin to completely abolish agonist
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mediated inhibition of cAMP production in cells stably expressing the 5-HTiA/Goia 
WT fusion protein and might be evident in the radioligand binding results that will 
be diseussed later.
Comparison of the results of the Gii« and Goia fusion proteins demonstrated 
an obvious trend towards the Gna fusion proteins having a greater potency to inhibit 
adenylyl cyclase activity. The EC50 value for the 5-HTiA/GiiaC^^^I fusion was 
significantly less than that of the GoiaC^^^I fusion protein. This result is supported by 
numerous studies in different expression systems documented in the literature where 
the 5-HTia receptor showed a higher affinity for coupling to Gia proteins over Goa 
proteins (Clawges et ah, 1997; Bertin et ah, 1992; Gamovskaya et ah, 1997; 
Raymond et ah, 1993).
Another pattern that emerged in the intact cell cyclase assay was for steeper 
Hill slope values for inhibition of cAMP production with more hydrophobic residues 
at position 351 on the Gna proteins. These data may be a reflection of the greater 
intrinsic constitutive activity in the fusion protein with a more hydrophobic residue at 
position 351, i.e. Ile^ ^^  being more hydrophobic and having greater constitutive 
activity than WT Cys^^\ than the Gly^^  ^ mutant and suggest some form of positive 
cooperativity in the constitutively active fusion proteins.
Two final issues were addressed in Chapter 3. Firstly, inhibition of adenylyl 
cyclase activity following agonist stimulation of 5-HTiA/GoiaC^^^G was not affected 
by CO-expression of transducin a  protein. It was hypothesised that if the inhibition of 
adenylyl cyclase following Goia protein activation had been mediated by the Gpy 
dimer, co-expression of an excess of G protein a  subunits, in this case, transducin a, 
would bind to any Gpy subunits that were released following Goia activation and 
prevent inhibition of cAMP production. No firm conclusion can be drawn from these 
experiments as the expression of transducin a  was not demonstrated by Western blot 
analysis, although the expression of the 5-HTiA/GoiaC^^^G which resulted in the 
inhibition of cAMP production indicates that efficient transient transfection did 
occur. The experiments would have to be repeated and expression of both receptor 
and G protein confirmed.
Secondly, at concentrations of 5-HT greater that 1|LiM, stimulation of cAMP 
production can be measured. It was previously suggested that this effect was due to 
coupling of the 5-HTia receptor to Gs at high concentrations of 5-HT (Malmberg and
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Strange 2000). This seems unlikely because the same effect can be recorded in 
untransfected HEK293 cells where no specific binding of a 5-HTia selective 
radioligand can be measured. Malmberg and Strange (2000) found that 8 -OH-DPAT 
did not stimulate adenylyl cyclase activity. As this ligand also binds the Gs linked 5- 
HT7 receptor, this receptor can be excluded. The 5-HTsa receptor that is Gg linked 
has been shown to inhibit cAMP production in a pertussis toxin dependent manner in 
HEK293 cells (Francken et al., 1998), leaving the possible 5-HT receptors as the 5- 
HT4 or the 5-HT6 receptors. The 5 -HT4 selective antagonists GR 113808 and SB 
204070 and the S-HTe selective antagonists Ro 04-6790 and Ro 63-0563 could be 
used to determine if either of these receptors were involved. It is possible that 5-HT 
is activating some other class of receptor that is coupled to stimulation of adenylyl 
cyclase and would have to be investigated if the 5 -HT4 and S-HTe receptors were 
also excluded.
The binding of both agonist and antagonist radioligands in two different 
displacement binding assays was used to measure the affinity of the 5-HTia receptor 
for the different G protein fusions. Firstly, the ability of increasing concentrations of 
GDP or suramin to displace the binding of [^H]-8 -OH-DPAT to the 5-HTia receptor 
was examined. It is well documented that a receptor coupled to a G protein has a 
high degree of affinity for agonists and the uncoupled form a lower affinity (Emerit 
et al., 1990), with antagonists binding to both coupled and uncoupled receptors 
equally (Kobilka 1992). Both GDP and suramin have previously been demonstrated 
to uncouple a G protein fused to an adenosine receptor (Waldhoer et al., 1999) and 
produce a decrease in agonist radioligand binding. These effects are produced in 
different manners, with GDP decreasing the affinity of the receptor for the G protein 
and suramin binding to the C terminal tail of the Ga subunit and acting effectively as 
a G protein “antagonist”, competing with the receptor for G protein binding. The 
results for the 5-HTia receptor and its Gna and Goia fusion proteins gave an 
indication of the affinity of the receptor for the WT and mutant G proteins. As with 
the intact cell cyclase assay, no difference was found for the Gly^^  ^ and Ile^^  ^mutants 
either with or without pertussis toxin treatment, but binding was significantly 
reduced for the WT G protein fusions and the 5-HTia receptor alone. However, 
consistent with the intact cell cyclase results for the 5-HTiA/Goia fusion protein, a 
degree of agonist binding that could be displaced by increasing concentrations of
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GDP or suramin was retained following pertussis toxin treatment. This again may be 
an indication that although Cys^^  ^ plays a significant role in the binding of Goia to 
the 5-HTia receptor, restricting access to this site by ADP ribosylation does not 
completely abolish the receptor-G protein interaction.
It was found that higher concentrations of GDP were required to displace the 
binding of [^H]-8-0H-DPAT to both Güa and Goia with Ile^^^  than for WT G protein, 
with the Gly^^  ^ mutants requiring the lowest concentrations of GDP to produce 50% 
reduction in agonist binding. The exception to these results was the lack of difference 
between the Goia WT and Pe^^  ^ in terms of EC50. The results do indicate that the 5- 
HTia receptor has a significantly higher affinity for Gna and Goia with the Ile^ ^^  
mutation than with the Gly^^  ^ mutation. The effect of increasing concentrations of 
GDP was shown to be agonist dependent, as binding of the selective 5-H T ia 
antagonist [^H]-MPPF was not effected.
These results are supported by the second series of radioligand binding assays 
where suramin was used to uncouple the receptor-G protein interaction. As with the 
GDP displacement bindings, suramin provided an indication of the affinity of the 5- 
HTia receptor for the Gnot and Goia fusion proteins with similar results. Again, 5- 
HTia fused to G proteins with the Ile^^^  mutation required higher concentrations of 
suramin to limit the binding of [^H]-8 -OH-DPAT to the receptor than the WT, with 
the Gly^^  ^ mutants requiring the highest concentrations of suramin. The binding of 
the antagonist [^H]-MPPF was not affected by suramin.
As in the intact cell cyclase assay, these results may indicate that the Gna 
protein has a higher affinity for the 5-HTia receptor than the Goia protein. However, 
comparison of the EC50 values for displacement of [^H]-8 -OH-DPAT binding did not 
show these differences to be statistically different.
Both of these sets of agonist displacement bindings indicate that Cys^^* plays 
a significant role in the binding of the 5-HTia receptor to either Gna or Goia fusion 
proteins and that the hydrophobicity of the residue at position 351 can affect the 
affinity of this binding, with greater hyrdophobicity resulting in a higher affinity of 
the 5-HTiA receptor for the Gna or Goia proteins. The results with the WT Goia 
fusion may however indicate that although Cys^^  ^ does play a significant part in 
receptor-G protein binding, preventing binding of this site to the 5-HTia receptor 
does not completely prevent the interaction. The importance of other amino acids in
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the binding of the 5-HTia receptor and Goia proteins could be assessed by site 
directed mutatgenesis.
A third type of radioligand binding assay was used to examine the differences 
between the 5-HTiA/Giia fusions with either Ile^^^  or Gly^^  ^ mutations. These assays 
looked at the ability of a “cold” 5-HTia selective agonist to displace [^H]-MPPF 
antagonist binding from the two fusion proteins to give an indication of the 
proportion of each fusion existing in the G protein coupled state. Antagonists do not 
affect receptor-G protein coupling and are displaced by agonists in a biphasic 
manner. The first phase represents the high affinity binding of the agonist to the G 
protein coupled form of the receptor, and the second phase the low affinity binding 
of the agonist to the G protein uncoupled form of the receptor. The area under the 
curve for each of these phases is used to give an indication of the proportion of the 
receptor in either form. For the 5-HTia receptor, a larger proportion of the receptor 
was found to be in the G protein coupled form with He at position 351 than with Gly 
at the same position. This indicates again the higher affinity of the GnaC^^^I protein 
for the 5-HTiA receptor than the GiiaC^^^G protein and explains the greater degree of 
intrinsic constitutive activity measured in the GTPase assay for the former fusion 
when compared to both the Gly^^  ^mutant and the WT G protein.
The high affinity GTPase activity of the different 5-H T ia-G protein Gly^^  ^
and Ile^^^  fusions were assessed in the presence of a range of concentrations of 
purified RGSl and RGS16 at basal levels and following maximal 5-HT stimulation 
and produced some interesting results. Both RGSl and RG Sl6  produced 
concentration dependent increases in GTPase activity for each of the constructs 
following 5-HT stimulation, but also did so for both the Gua and Goia proteins with 
the Ile^ *^ mutation in the absence of agonist stimulation. This latter effect was as a 
result of the higher intrinsic level of constitutive activity following the He^ ^^  
mutation in the Goia and Gua proteins. The effect of the RGS protein could be 
measured both in terms of an increase in V,nax, the predicted maximum turnover of 
GTP to GDP, and K,n, the affinity for nucleotide. The latter effect is due to an 
increase in the rate of GTP hydrolysis (Kcad and not any effect on the exchange of 
GDP for GTP or vice versa {Kon and Ko^.
The use of pertussis toxin resistant receptor-G protein fusions has two major 
benefits. Firstly, it allows pertussis toxin treatment of the cells stably expressing the
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constructs prior to harvesting, abolishing potential coupling to the endogenous pool 
of G proteins. Secondly, radioligand saturation analysis of receptor expression 
indicates both the expression level of the receptor and due to the 1 : 1  stoichiometry of 
the receptor to G protein, also the level of G protein expression. These two 
characteristics allow for the accurate determination of GTP turnover to GDP per G 
protein per unit time and pharmacological analysis of these results.
The turnover of GTP to GDP for each construct was plotted against RGS 
protein concentration and revealed that the RGS proteins did not have a significant 
effect on basal GTPase activity for the Gly^^  ^ mutants, A significant increase in 
activity was produced for the He^ ^^  mutants, a characteristic of the intrinsic 
constitutive activity that the Ile^^^  mutation confers on the 5-H T ia-G protein fusion. 
The effects of 5-HT on GTPase turnover were also plotted against RGS 
concentration. 5-HT significantly increased the RGS protein effects on GTPase 
activity for all four constructs, with the effects of RGSl and RGS 16 not being 
significantly different from one another in terms of turnover.
In order to allow direct comparison of the effects of RGS protein on agonist 
stimulated GTPase activity, the basal turnover at each protein concentration was 
subtracted from the corresponding concentration following 5-HT stimulation. In the 
absence of agonist, both RGSl and RGS 16 proteins produced greater increases in 
GTPase activity at the Goia fusion proteins than the G^a fusion proteins. This could 
indicate either a higher level of intrinsic GTPase activity in the Goia proteins, or that 
the RGS proteins have a higher affinity for Goia proteins. In the presence of 5-HT 
(lOOjuiM), maximal concentrations of RGS protein produced greater increases in 
GTPase activity at the Goia fusions than at the Gna fusions, although due to the large 
error in the results the effects were not significant. Overall these results could 
indicate either that the Goia proteins have a greater intrinsic GTPase activity in the 
absence or presence of agonist, or that the Goia proteins have a higher affinity for 
RGS protein binding. The second possibility could be investigated using site directed 
mutagenesis of residues in the G protein a  subunit that could be important in RGS 
protein binding. Thr^^  ^is conserved in the Gi family of a  subunits and is know to be 
a site of interaction between the Ga-GTP and RGS proteins (Burchett 2000). Gly^^  ^
has also been demonstrated to be required for high affinity Ga-RGS protein
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interaction (Burchett 2000). Mutation of these and other residues may give an 
indication of the differing affinities of RGS proteins for G« subunits.
A question arose following analysis of the results from the GTPase assays: 
why was no effect of endogenous RGS protein detected? The addition of purified 
RGS protein produces an increase in the Km for GTP in the presence of agonist 
stimulation, but no equivalent increase in the K,n for GTP is recorded following 
agonist treatment alone, indicating that there is no significant endogenous RGS 
protein activity. Two approaches were used to try and reconstitute endogenous RGS 
protein effect, both of which investigated the possible presence of RGS protein only 
in the cytoplasm of HEK293 cells. A few RGS proteins are palmitoylated, e.g. 
RGS 16, but many are predicted to be cytoplasmic proteins that are recruited to the 
membrane in response to G protein activation (Hepler 1999). The first experiment 
examined this possible recruitment of RGS proteins and by treating cells with 5-HT 
prior to harvesting and membrane preparation, it was hoped that a tighter association 
with the membrane could be induced. The second experiment examined the cytosolic 
cell fractions that are normally discarded during membrane preparation for RGS 
protein activity. Neither assay produced any RGS protein effect at either basal or 
following 5-HT stimulation of GTPase activity at a single concentration of GTP so 
full saturation analysis was not carried out. It is possible that RGS protein activity 
may be lost as a result of the membrane preparation and cannot be reconstituted. To 
investigate if RGS proteins are actually expressed in HEK293 cells QrtPCR was 
carried out using Taqman analysis.
The expression of a number of RGS proteins was investigated following the 
design of primers and probes. This initial step produced problems and it was not 
actually possible to design primers for many of the RGS proteins predicted to be 
either ubiquitously expressed or found in the human kidney as the RGS proteins were 
very GC rich. Primers and probes were successfully designed for RGS2, RGS3, 
RGS4, RGS9 and GRK2. The expression of RGS2, 3 and 4 was found in HEK293 
cells at levels that would normally be predicted to be low, but this conclusion can not 
be strongly suggested due to problems with the assay. It thus appears that some RGS 
proteins are expressed, but at low levels, a finding that could explain why no 
endogenous effect could be detected in the GTPase assay.
The use of receptor-G protein fusions in screening assays for ligand activity 
has been suggested previously (Guo et al., 2001; Wurch and Pauwels, 2001) as the
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data generated, especially from high affinity GTPase assays using pertussis toxin 
resistant G proteins, gives a very accurate pharmacological comparison of activity. 
The intrinsic constitutive activity of Ile^^  ^ Güa fusion proteins allowed for the 
comparison of both agonist and inverse agonist activity under the same assay 
conditions. Coupled with radioligand binding measurements of ligand affinity, the 
effect of maximal concentrations of RGSl and RGS 16 on the basal activity of the 5- 
HTiA/GiiaC^^4 and 5-HTiA/GoiaC^^^I fusion proteins increased the window that 
would allow discrimination between agonist, antagonist and inverse agonist activity.
Using this, a number of ligands that previously showed agonist, inverse 
agonist or antagonist activity at the 5-HTia receptor were compared in the presence 
and absence of 1|LiM RGSl using the Gii« and Goia constructs over a range of 
concentrations using the high affinity GTPase assay. When accurate determination of 
an EC50 value could be made, no effect was seen on this in the presence of RGS 
protein, but a large increase in GTPase activity produced full concentration response 
curves that accurate pharmacological values could be generated from. The 5-HTia 
selective ligand WAY100635 has previously been reported to act as a neutral 
antagonist at the receptor with some studies on the structurally related WAY100135 
producing partial agonist effects under some assay conditions (Davidson et al., 1997; 
Schoeffter et al., 1997). In the high affinity GTPase assay WAY100635 was found to 
act as a weak partial agonist, producing an increase in GTPase activity in the absence 
of RGSl and a significant increase in the presence of RGSl.
The inverse agonist spiperone was also assayed at a maximum effective 
concentration (lOOpM) for effects on high affinity GTPase activity over a range of 
GTP concentrations in the absence and presence of RGSl (l^iM) at both the 5-HT ia 
Gila and Goia C^^ I^ mutants. In both cases spiperone decreases the Vmax at either basal 
or enhanced in the presence of RGS 1 protein, and prevented the increase in K,n that 
the RGS protein produced at basal activity. These data indicate that the intrinsic 
constitutive activity induced in the 5-HTiA/Goia and Gua C^^ I^ fusion proteins 
coupled with the increases in basal GTPase activity produced by the addition of 
RGSl protein produce a robust and effective assay for screening ligands for 
agonist/inverse agonist and antagonist activity under the same conditions.
The importance of knowing accurately the class of ligand that a drug falls 
into is illustrated well by the 5-HTia receptor. The SSRI fluoxetine (Prozac) is used
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in the treatment of depression, but its mechanism of action is far from clear. It does 
not produce any effects for a number of weeks following administration suggesting 
that its mechanism is not as simple of inhibition of the uptake of 5-HT (Artigas et ah, 
1996). What is clear is that it reduces the levels of 5-HT found in the synaptic clefts 
of 5-HT neurons in the dorsal raphe nucleus, and this effect is prevented by 
pretreatment with pertussis toxin which uncouples presynaptic somatodendritic 5- 
HTia autoreceptors from GIRK channels. The activation of presynaptic 5-HTia 
receptors leads to a reduced firing activity in these 5-HT neurons and thus a 
decreased release of 5-HT itself into the synaptic cleft. The time delay of weeks in 
this mechanism of action may suggest that some long term alteration of 5-HTia 
receptor expression occurs presynaptically. However in contrast to this effect, SSRIs 
cause an increase in extracellular 5-HT in the median raphe nuclei. Both of these 
areas contain high levels of 5-HT transporters, but the dorsal raphe nuclei contain a 
much higher level of presynaptic 5-HTia receptors, which by the mechanism of 
action described above would reduce the release of 5-HT.
The co-administration of 5-HTia antagonists potentiates the antidepressant 
effects of SSRIs (Artigas et al., 1994, 1996), an effect that would seem contradictory 
to the suggested mechanism of SSRI action. The co-administration leads to a larger 
increase in extracellular 5-HT in the striatum and frontal cortex, areas innervated by 
the dorsal raphe nucleus, than in the dorsal hippocampus, that is largely innervated 
by the median raphe nucleus. Differences in the pharmacology of the pre and 
postsynaptic 5-HTia receptors are well documented. For example, spiperone blocks 
the effect of microiontophoretically applied 5-HT in the raphe, but not in the 
hippocampus, and the antagonist BMY7378 is effective in the hippocampus but not 
the raphe. As yet no molecular differences between the pre and postsynaptic 5-HTia 
receptors have been shown. Another pharmacological difference is that the 5-HTia 
antagonist pindolol has been shown to be selective for the presynaptic 
somatodendritic 5-HTia autoreceptors and prevents the reduction in firing activity of 
5-HT neurons induced by SSRIs.
This again demonstrates the important role that the 5-HTia receptor plays in 
the treatment of depression, but also the importance of developing ligands that have 
well characterised effects at the 5-HTia receptor. It is known that agonists at this 
receptor lead to downregulation with time and that inverse agonists have the opposite 
effect. If the effects of co-administration of SSRIs and 5-HTia antagonists rely on
230
alterations in the level of receptor expression, as the delay of weeks in the 
effectiveness of these drugs might suggest, then it must be clearly defined if a ligand 
has either agonist/inverse agonist or antagonist activity at the 5-HTia receptor before 
its therapeutic use.
The assays utilised in the various sections of this thesis would be of great 
benefit in the future characterisation of any such drugs.
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9 Appendix
9.1 Btnax calculation
Data from saturation binding assays were analysed using Graphpad Prism™. 
Nonspecific binding of the radioligand was determined by the addition of lOOpM 5- 
HT and fitted as a straight line through the origin. This was subtracted from the total 
radioligand binding and the resulting specific binding in cpm plotted against the 
radioligand concentration. The data were fitted using a one site nonlinear regression 
binding hyperbola from which B,nax and Kd were calculated.
9.2 Ki calculation
Calculation of Kj uses a derivation of the Cheng-Prusoff equation (Cheng and 
Prusoff 1973):
Ki = IC5o/(l+L/Xd)
Where L is the ligand concentration, Kd is the equilibrium dissociation constant, and 
the IC50 is the concentration of inhibitor required to inhibit half the specific binding.
9.3 GTPase Eadie Hofstee calculation
This analysis of high affinity GTPase activity data allows the calculation of both the 
Vwiox and the K,n for the GTPase reaction. It requires the assay of GTPase activity 
over a range of GTP concentrations (25nM -  3000nM approximately). The data were 
analysed using a Microsoft Excel spreadsheet (Figure 9.1).
The treatment column defines the concentration of GTP in each triplicate reaction. 
The first triplicate reaction receives only GTP from the [^^P]-GTP in the reaction
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Figure 9.1 Example of Microsoft Excel spreadsheet used for
high affinity GTPase calculation
Data from Eadie Hofstee high affinity GTPase assays were used to calculate both the 
V,„ax for GTP hydrolysis and K„i for GTP. The spreadsheet and the calculations 
involved are explained in section 9.3.
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mixture. This varies and is defined by the half-life of of 14 days and is calculated 
for each experiment. The second treatment receives a saturating concentration of 
GTP that defines non-specific GTP hydrolysis. Further treatrrients range from the 
addition of 25nM to 3000nM “cold” GTP.
The CPM values from each reaction are meaned and the standard deviation 
calculated. The non-specific GTPase activity defined by the “High GTP” treatment 
are subtracted from the mean of each triplicate sample identifying the Specific CPM 
and the standard deviation for these mean results.
The next step corrects for the ratio between the [^^P]-GTP and the “cold” GTP:
Specific CPM x (total [GTP](nM)/[^^P-GTP](nM)) = corrected CPM
Followed by calculating the concentration of GTP hydrolysed:
Corrected CPM/CPM per pmol = pmols
The V (rate/velocity) of the reaction was calculated as follows:
(1000/2.5pg protein) x (l/20minutes) x (1000/300pl) = V
Where 2.5pg of protein was added to each reaction that was incubated for 20 
minutes, from which a final volume of 300pl was counted on the Topcount.
In order to calculate the using an Eadie Hofstee plot, V/S was calculated. This is 
simply V divided by the total GTP concentration in the reaction.
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